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Chapter 1Introduction
Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of disorders 
with a large societal and economic impact. They are defined in the Diagnostic Statisti-
cal Manual, fifth edition (DSM-5; APA, 2013) as a group of conditions that “…typically 
manifest early in development…and are characterized by deficits in personal, social, 
academic or occupational functioning” (p.31). These deficits range in severity from 
specific neurocognitive limitations to global impairments in daily functioning (DSM-5; 
APA, 2013b) with a highly heterogeneous etiology that can be based on genetic abnor-
malities, metabolic diseases, infections, environmental factors or physical trauma.
NDDs are operationalized in different categories, such as Autism Spectrum Disorder 
(ASD), speech- and language disorder, and Intellectual Disabilities (ID), based on 
their clinical characteristics. In fact, they comprise the most expensive diseases in the 
Netherlands (RIVM, 2017b). Importantly, these different classifications often overlap 
and need not be present as single entity. In this thesis, the focus is on NDDs based on 
rare genetic mutations, which in general present with ID.
ID is a condition that typically becomes apparent during early developmental years 
and includes both intellectual and adaptive functioning deficits in the conceptual, 
social and practical domains of daily life (DSM-5; APA, 2013b; Schalock et al., 2010). 
Traditionally, the level of ID was defined by IQ range. However, limitations in both IQ 
level and in adaptive functioning are nowadays crucial for diagnosis. Table 1.1 displays 
the classification of ID in the several diagnostic systems (Boat & Wu, 2015). 
In the Netherlands, it is common to use the term ‘mild ID’ for the collective group of 
people with mild ID as well as borderline ID with adaptive problems, usually referred 
to in Dutch as people with ‘Licht Verstandelijke Beperkingen, LVB’. It can be discussed 
whether this is preferable, as this group now comprises a relative high percentage of 
affected people (10%) who display a large and broad range of cognitive and adaptive 
capacities with divergent needs.
Following strict criteria, the prevalence of ID in the Netherlands is approximately 1% 
and a tenfold higher when individuals with a borderline IQ level and adaptive prob-
lems are also included (Sociaal Cultureel Planbureau (SCP), 2017). Popular media tend 
to even report higher prevalences. For instance in 2012, a national newspaper reported 
a prevalence of 1 out of 8 for people living in Amsterdam (de Telegraaf, 2012). Unfortu-
nately, the public opinion is based on the problems resulting from the vulnerability of 
this population to experience behavioral problems and social inconvenience. These 
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problems are regarded as static rather than as a dynamic result between social demands 
and individual capabilities. This is not exclusive for ID, but applies to all NDDs. The 
vulnerabilities, which make prone to develop maladaptive behaviors, can be caused by 
roughly two groups of factors: the first group comprises endogenous factors, like somatic 
and psychiatric disorders, but also neuropsychological and temperamental characteris-
tics of the person. The second group comprises exogenous factors, which are often called 
environmental factors, for example, social exclusion, overestimation of one’s capacities 
by society and use of psychotropic substances. Although the overall vulnerability often 
results from a combination of factors, there are reasons to think that the relationship 
between NDDs, ID in particular, and psychiatry is unique and hardly explored in a 
systematic and broader context (Verhoeven & Egger, 2014). 
Neurodevelopmental disorders in general health care and psychiatry
As mentioned in the previous paragraph, the different categories of NDDs show 
overlap in symptomatology, which easily leads psychiatrist to diagnose a range of 
other psychiatric disorders (Tsakanikos & McCarthy, 2014; Nieuwenhuis, Noorthoorn, 
Nijman, Naarding, & Mulder, 2017). Thus, while patients indeed come to the attention 
of psychiatrists, the NDDs may stay obscured by other psychiatric symptoms. 
With regard to the general health care prevalence in The Netherlands, NDDs have a 
prevalence comparable to that of several cancers, like skin, breast, and colon cancer 
(RIVM, 2017a). Although these prevalences are almost equal, less societal attention is 
paid to NDDs compared to these cancers. Medical doctors (including psychiatrists) 
often feel insufficient to deal with the communication and presentation of patients 
with NDDs (Wieland, Kapitein, Otter, & Baas, 2014). Also in neuroscience, NDDs 
Table 1.1 Categories of Intellectual Disabilities
Severity 
Category
Approximate Percent Distribution of 
Cases by Severity
DSM-IV Criteria (severity levels were 
based only on IQ categories)
DSM-5 Criteria (severity classified on the basis 
of daily skills)
AAIDD Criteria (severity classified on the basis 
of intensity of support needed)
Mild 85% Approximate IQ range 50-69 Can live independently with minimum level of 
support.
Intermittent support needed during transitions 
or periods of uncertainty.
Moderate 10% Approximate IQ range 36-49 Independent living may be achieved with 
moderate levels of support, such as those available 
in group homes.
Limited support needed in daily situations.
Severe 3.5% Approximate IQ range 20-35 Requires daily assistence with self-care activities 
and safety supervision.
Extensive support needed for daily activities.
Profound 1.5% IQ < 20 Requires 24-hour care. Pervasive support needed for every aspect of 
daily routines. 
Adapted from Table 9.1 Classifications of Intellectual Disability Severity in Mental Disorders and Disabilities 
Among Low-Income Children (Boat & Wu, 2015).
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comprise a group that is often under addressed in clinical studies (Feldman, Bosett, 
Collet, & Burnham-Riosa, 2014) most probably due to the complexity in both etiology 
and clinical presentation. Interestingly, NDDs seem to be unpopular among patients 
themselves as well, since NDDs are rarely simulated. As a consequence of all this, 
clinically, patients with NDD are often sent from pillar to post, and scientifically, min-
imal progress can be made in collecting evidence for diagnostic procedures or for the 
effects of treatment. 
One of the shared features between psychiatric diseases and NDD is, besides the 
social stigma, the high amount of associated health care costs. Individuals that have 
a combination of NDD and comorbid psychiatric disease(s) create by far the most 
expensive patient group that can be identified nationally. However, there is hardly any 
preventive care for this group, and only limited research efforts are made to detect the 
most vulnerable patients or to develop more specific treatment programs. This may 
be understood from the following historical perspective. 
Historical perspective on neurodevelopmental disorders 
The existence of mental disorders, including ID and psychiatric disorders, is of all 
centuries. During the middle ages, madhouses (in Dutch “dolhuysen”) were founded 
to isolate the insane, i.e., people with what we now would call ID and/ or psychiatric 
diseases, from society. Treatment was not yet available and the aim was to maintain 
safety and security in society. Highly negative explanations for having a mental disor-
der where used, like being possessed by demons, or having a contract with the devil. 
Consequently, punishment and isolation were common practice, and often regarded 
necessary to save the souls of those with mental disorders. 
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17
Chapter 1Table 1.1 Categories of Intellectual Disabilities
S
Category
Appr ximate Percent Distribution of 
Cases by Severity
DSM-IV Criteria (s verity levels were 
based only on IQ categories)
DSM-5 Criteria (severity classified on the basis 
of daily skills)
AAIDD Criteria (severity classified on the basis 
of intensity of support needed)
Mild 85% Approximate IQ range 50-69 Can live independently with minimum level of 
support.
Intermittent support needed during transitions 
or periods of uncertainty.
Moderate 10% Approx mate IQ range 36-49 Independent living may be achieved with 
moderate levels of support, such as those available 
in group homes.
Limited support needed in daily situations.
Sev re 3.5% Appr ximate IQ range 20-35 Requires daily assistence with self-care activities 
and safety supervision.
Extensive support needed for daily activities.
Profound 1.5% IQ < 20 Requires 24-hour care. Pervasive support needed for every aspect of 
daily routines. 
Adapted from Table 9.1 Classifications of Intellectual Disability Severity in Mental Disorders and Disabilities 
Among Low-Income Children (Boat & Wu, 2015).
comprise a group that is often under addressed in clinical studies (Feldman, Bosett, 
Collet, & Burnham-Riosa, 2014) most probably due to the complexity in both etiology 
and clinical presentation. Interestingly, NDDs seem to be unpopular among patients 
themselves as well, since NDDs are rarely simulated. As a consequence of all this, 
clinically, patients with NDD are often sent from pillar to post, and scientifically, min-
imal progress can be made in collecting evidence for diagnostic procedures or for the 
effects of treatment. 
One of the shared features between psychiatric diseases and NDD is, besides the 
social stigma, the high amount of associated health care costs. Individuals that have 
a combination of NDD and comorbid psychiatric disease(s) create by far the most 
expensive patient group that can be identified nationally. However, there is hardly any 
preventive care for this group, and only limited research efforts are made to detect the 
most vulnerable patients or to develop more specific treatment programs. This may 
be understood from the following historical perspective. 
Historical perspective on neurodevelopmental disorders 
The existence of mental disorders, including ID and psychiatric disorders, is of all 
centuries. During the middle ages, madhouses (in Dutch “dolhuysen”) were founded 
to isolate the insane, i.e., people with what we now would call ID and/ or psychiatric 
diseases, from society. Treatment was not yet available and the aim was to maintain 
safety and security in society. Highly negative explanations for having a mental disor-
der where used, like being possessed by demons, or having a contract with the devil. 
Consequently, punishment and isolation were common practice, and often regarded 
necessary to save the souls of those with mental disorders. 
        
Chapter 1
18
Chapter 1 At the beginning of the 19th century, a shift towards building mental institutions 
occurred, because the societal opinion about the causes of insanity gradually evolved 
from ‘works of the evil spirits’ to the existence of mental illnesses. Isolation of society 
became no longer necessary, but mental care became vital/ crucial. By the middle of 
the 19th century, social initiatives from the USA, particularly in Boston, Massachusetts, 
to create small-scale institutions for daily care of people with ID, inspired several 
European countries and within a century, here, many similar institutes were founded. 
Mental impairments were regarded to have a negative impact on society and on par-
ents’ personal life as well and for these reasons, parents were stimulated to place 
their child in these specialized institutions. (Burger, 2005; Follens, 2016; Mans, 1998; 
Vijselaar, 2010; Vos, 2011)
A perverse twisting of this general opinion took place during the Second World War, 
where Nazi-practices furthered a negative opinion by considering congenital conditions 
as life-unworthy, providing an excuse for cruel and often lethal experiments. (Tsakanikos 
& McCarthy, 2014). After the Second World War, it was therefore decided to establish rig-
orous medical-ethical criteria for scientific research, specifically for vulnerable groups, 
where obtaining informed consent is difficult and sometimes impossible. 
In the 1950’s, the care for ID and psychiatry has increasingly become separated. At this 
time, drugs were discovered that ameliorated psychiatric conditions (Tolsma, Jedeloo, 
& Kemenade van, 1954) and new insights about pedagogical approaches paid off in 
the care for persons with mental retardation(Haveman, 1981). This unfortunate split 
between psychiatry and ID has hampered the care for patients with ID ever since, espe-
cially because patients with ID are at greater risk to develop psychiatric disorders. It 
has also hindered research development, since studying psychiatric disorders in NDDs 
may provide fruitful etiological insights for a wide range of psychiatric disorders. In 
the 1970’s, maltreatment and abuse were reported in these expanding institutes and the 
focus of attention shifted towards the vulnerability of the patients. During the same 
period, de-institutionalizing care and standardization principles from Sweden were 
implemented in the Netherlands. The starting point was that participation in society 
should be allowed and stimulated, also for people with ID. This participation includes 
the right to education and basic necessities of life, like housing. De-institutionalizing 
is further translated into community care, incorporating small-scale housing facilities 
in residential areas to enable more coherence with the local population ( Tsakanikos 
& McCarthy, 2014).
In the past decades, there is an increasing focus on NDDs as a collection of entities, 
rather than separate categories, such as ID and ASD. It should be noted that in the 
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Chapter 1past, NDDs were typically diagnosed by aspecific and generalizing terminology such 
as oligophrenia (van der Horst, 1931) and insanity. This resulted from a lack of diag-
nostic tools, like the current genetic techniques, and (in extension) from the inability 
to understand the complexity of NDDs. Several cases have illustrated this complexity 
and the lack of tailor-made treatment in the recent years in the Netherlands, like 
Jolanda V., Alex O. and Brandon van I. This resulted in the foundation of the Centre 
for Consultation and Expertise (CCE(“www.cce.nl,” 2017)), funded by the Ministry of 
Health, to prevent maladministration in the future.
In 2018, however, the integration of care, treatment and guidance for people diagnosed 
with a NDD and comorbid psychiatric disease is still a very difficult. The tardiness of 
this process may reflect the complex interplay of factors that may result in ID and these 
same factors that may result in psychiatric disorders. This is sometimes referred to as 
pleiotropy and genetic components are crucially involved here (Paaby & Rockman, 
2013). 
Etiology 
The etiology of ID can be broadly divided into three groups: 1. Genetic causes (most 
frequent is Down Syndrome); 2. Perinatal factors (for example birth problems, hypoxia, 
prematurity); and 3. External factors that cause damage (intoxications, infections and 
trauma). This classification is somewhat arbitrary, because we know that there is inter-
dependence between these groups of causes. For instance, genetic processes can also 
affect birth-associated trauma and sensitivity for diseases, such as infectious diseases 
and epilepsy. 
Genetic factors are of increasing interest in research, also in the field of NDDs and 
psychiatry. Large Genome Wide Association Studies (GWAS) have been performed 
to disentangle the contribution of common variants to complex psychiatric diseases 
as well as developmental disorders, but they have rarely identified common genetic 
origins for specific developmental disorders or psychiatric symptoms (Henriksen, Nor-
dgaard, & Jansson, 2017; Kendler, 2013).
In the past few years, exome sequencing and genome sequences have provided genetic 
explanations for a wide variety of monogenic NDDs. Interestingly, such genome-wide 
analyses have also revealed the involvement of rare variants with large effect sizes 
underlying individual cases of psychiatric disorders that were previously considered 
to have a strict multifactorial etiology, for example ASD and schizophrenia. These 
genetics studies have revealed that the same molecular pathways and even the same 
genes are affected by rare and common variants across NDDs and psychiatric condi-
General Introduction
19
Chapter 1past, NDDs were typically diagnosed by aspecific and generalizing terminology such 
as oligophrenia (van der Horst, 1931) and insanity. This resulted from a lack of diag-
nostic tools, like the current genetic techniques, and (in extension) from the inability 
to understand the complexity of NDDs. Several cases have illustrated this complexity 
and the lack of tailor-made treatment in the recent years in the Netherlands, like 
Jolanda V., Alex O. and Brandon van I. This resulted in the foundation of the Centre 
for Consultation and Expertise (CCE(“www.cce.nl,” 2017)), funded by the Ministry of 
Health, to prevent maladministration in the future.
In 2018, however, the integration of care, treatment and guidance for people diagnosed 
with a NDD and comorbid psychiatric disease is still a very difficult. The tardiness of 
this process may reflect the complex interplay of factors that may result in ID and these 
same factors that may result in psychiatric disorders. This is sometimes referred to as 
pleiotropy and genetic components are crucially involved here (Paaby & Rockman, 
2013). 
Etiology 
The etiology of ID can be broadly divided into three groups: 1. Genetic causes (most 
frequent is Down Syndrome); 2. Perinatal factors (for example birth problems, hypoxia, 
prematurity); and 3. External factors that cause damage (intoxications, infections and 
trauma). This classification is somewhat arbitrary, because we know that there is inter-
dependence between these groups of causes. For instance, genetic processes can also 
affect birth-associated trauma and sensitivity for diseases, such as infectious diseases 
and epilepsy. 
Genetic factors are of increasing interest in research, also in the field of NDDs and 
psychiatry. Large Genome Wide Association Studies (GWAS) have been performed 
to disentangle the contribution of common variants to complex psychiatric diseases 
as well as developmental disorders, but they have rarely identified common genetic 
origins for specific developmental disorders or psychiatric symptoms (Henriksen, Nor-
dgaard, & Jansson, 2017; Kendler, 2013).
In the past few years, exome sequencing and genome sequences have provided genetic 
explanations for a wide variety of monogenic NDDs. Interestingly, such genome-wide 
analyses have also revealed the involvement of rare variants with large effect sizes 
underlying individual cases of psychiatric disorders that were previously considered 
to have a strict multifactorial etiology, for example ASD and schizophrenia. These 
genetics studies have revealed that the same molecular pathways and even the same 
genes are affected by rare and common variants across NDDs and psychiatric condi-
        
Chapter 1
20
Chapter 1 tions (Cukier et al., 2014; Giacopuzzi et al., 2017; Iossifov et al., 2012; Nguyen et al., 2017; 
Singh et al., 2017). This converging pattern in the genetic etiology across diagnostic 
boundaries is nicely mirroring the overlapping clinical features that are manifest in 
the same disorders. Thus, there are apparent vanishing boundaries between NDDs 
and psychiatric conditions, both at the phenotype level and at the genotype level. 
From top-down to bottom-up in the study of psychiatry and genetics
Rather than collecting large patient populations for genetic research, one can collect 
groups of patients with a similar rare genetic disorder (‘syndrome’) to have a closer 
look at the resulting intellectual, behavioral and psychiatric problems. This last 
approach, the so-called bottom-up approach (Verhoeven, Tuinier, & van der Burgt, 
2008), contributes to a detailed clinical picture as was proven for the more familiar 
syndromes as Down-, Williams-, Angelman- and Prader Willi syndromes.
Recent trends in genetic techniques enable to find a genetic cause for NDDs in the 
majority of patients ( DDD- Study, 2017; Gilissen et al., 2014; Lelieveld et al., 2016; de 
Ligt et al., 2012; Willemsen & Kleefstra, 2013). Due to the increased diagnostic capa-
bilities in genetics, the number of novel defined genetic syndromes is also rapidly 
increasing. The clinical definition of these syndromes initially focuses on the somatic 
characteristics. However, in daily life, behavioral and psychiatric problems are crucial 
barriers for daily life functioning and quality of life. Therefore, it is now urged to 
ensure phenotyping of the development, behavior, neuropsychological functioning 
and associated psychiatric disorders in these recently detected syndromes. Phenotyp-
ing is necessary to formulate starting points for symptomatic support and treatment, 
since causative repair of the genetic origin isn’t possible yet and may still not be pos-
sible in the upcoming decade(s). Only tailor-made treatment allows steering of the 
normal development in the children and adolescents and maintenance of daily func-
tioning in adults. 
Precisely by contrasting (and not combining) these unique variants, clinically relevant 
information can be obtained. Specific profiles of developmental, behavioral, neuro-
psychological and psychiatric characteristics can be defined, which allows specific 
psycho-education and care to be formulated by age group (for example in Noonan 
Syndrome, (“Zorgstandaard Noonan Syndroom”)) but can also be tailored to disease 
management. 
Behavioral phenotypes
In the literature and in daily clinical practice, associated behavioral features in genetic 
syndromes are often referred to as ‘behavioral phenotype’. The designation ‘behav-
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Chapter 1ioral phenotype’ was introduced by William Nyhan, who performed clinical research 
in the later called Lesch-Nyhan syndrome (Nyhan, 1972). He wanted to indicate the 
connection between specific behaviors and their biological substrate with this term. 
Currently, several different definitions of ‘behavioral phenotype’ circulate. There is a 
consensus definition of the Society for the Study of Behavioral Phenotypes (SSBP), 
which states that it is “a characteristic pattern of motor, cognitive, language and/or social 
abnormalities, which are consistently associated with a biological condition.” (“www.ssbp.
org.uk”). There is also a more clinical definition, formulated by Dykens et al: ”[A behav-
ioral phenotype involves..]” the heightened probability or likelihood that people with a given 
syndrome will exhibit certain behavioral and developmental sequelae relative to those without 
the syndrome” (Dykens, 1995) p. 523). Today, the latter definition is commonly used. 
Flint (Flint, 1998) indicated that this behavioral phenotype remarks the causal relation 
between the biological substrate (genetic defect) and specific behavior and not only 
to a high prevalence of specific behavior. Also, the “pathoplastic effect of IQ” should 
be taken into account, referring to the level of ID, which may influence the prevalence 
of psychiatric disorders. 
However, the empirical underpinning of that causal relationship is not easy since, 
given the rarity of the disorders, the number of available patients is very small. Trans-
lational neuroscience, enabling research that combines knowledge from molecular 
research, mutated animal models and human behavioral and neurocognitive mea-
sures, has a crucial role in this. 
From human cognition and behavior to DNA and back
Translational research in monogenic conditions has highlighted molecular path-
ways and mechanisms of action. This is nicely illustrated by studies on the Disc 
Large Homolog (DLG) family of postsynaptic scaffold proteins, which are involved 
in binding neurotransmitter receptors and enzymes into signaling complexes. These 
signaling complexes are located at the postsynaptic terminals of the brain. DLG2 and 
DLG3 mutations are associated with a variety of psychiatric disorders. Rare human 
DLG2 mutations have been associated with schizophrenia. Nithianantharajah et al 
(Nithianantharajah et al., 2013) used touchscreen based neurocognitive tests to assess 
different domains of cognitive functioning, also in a human subject who was not (yet) 
suffering of schizophrenia. DLG2-/- knock-out mice showed same deficits as human 
with a DLG2 mutation on reversal learning, extinction and attention. This added to 
knowledge about the origin and evolution of higher cognitive functions, which was the 
main focus of their study, but indirect clues were obtained for symptomatic treatment 
and training of the patients. 
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Chapter 1 Another example is Tuberous Sclerosis, which is caused by either a mutation in TSC1 
or TSC2 gene. This syndrome is characterized by benign tumors of multiple organs 
in the brain, kidney, lung, eye, skin or heart. Developmental disorders are frequently 
diagnosed, for example ASD (25-50%) and ADHD (30-55%). Ninety percent of the 
patients develop neuropsychiatric symptoms, which are not directly related to the 
location of the tumor (Curatolo, Moavero, & de Vries, 2015). Unraveling the pathway 
of action of these genes, has resulted in development of targeted treatment with mam-
malian target of rapamycin kinase (mTor) inhibitors (Leclezio & de Vries, 2015).
Rather than focusing on starting points (genetic) or end points (psychopathological 
conditions), it is highly relevant to focus on the continuum from genetics to psychia-
try. A genetic defect results in an alternative balancing of neurobiological processes 
in the body. Identifying these processes is crucial to the understanding, at various 
levels of explanation, of the mechanisms underlying complex diseases, like psychiatric 
disorders.
Aims and thesis outline
The EHMT1 gene has emerged as a crucial neurodevelopmental gene (Balemans et al., 
2014; Balemans et al., 2010; Benevento et al., 2016; Kleefstra et al., 2006; Kramer et al., 
2011). Interestingly, this gene was associated with all the overlapping categories of neu-
rodevelopmental disorders, neuropsychiatric disorders and genomic disorders (Collins 
et al., 2008; Kirov et al., 2012). This makes the EHMT1 gene and corresponding protein 
an excellent genetic factor to further study of its role in NDDs. Haploinsufficiency of 
this gene in human results in ‘Kleefstra syndrome’, KS, (OMIM 610253; Kleefstra et al., 
2006; Kleefstra et al., 2009; Stewart & Kleefstra, 2007; Willemsen, Vulto-van Silfhout, 
et al., 2012), which is characterized by the trias of ID, childhood hypotonia and distinct 
facial features. A variety of psychiatric symptoms has been described, but these could 
not yet be investigated in controlled studies. Since EHMT1 orchestrates the expression 
of other genes involved in neurodevelopment and other processes, it is highly relevant 
to carefully map the resulting psychiatric characteristics. This may provide details 
of disease processes in between the genetic starting point and the psychiatric end 
point. Systematic investigation of the clinical characteristics, associated neurocognitive 
endophenotypes and best practices in treatment, may therefore serve as a blue copy 
for application of this approach to the larger group of other rare genetic syndromes.
The overall aim of this thesis was to map the continuum from genetics to psychiatry 
through different levels of cognitive functioning, such as adaptive behavior, neuro-
cognition and psychopathology. Kleefstra Syndrome is serving as a blueprint in this 
thesis, which comprises nine chapters, divided in three parts: 
Chapter 1
22
Chapter 1 Another example is Tuberous Sclerosis, which is caused by either a mutation in TSC1 
or TSC2 gene. This syndrome is characterized by benign tumors of multiple organs 
in the brain, kidney, lung, eye, skin or heart. Developmental disorders are frequently 
diagnosed, for example ASD (25-50%) and ADHD (30-55%). Ninety percent of the 
patients develop neuropsychiatric symptoms, which are not directly related to the 
location of the tumor (Curatolo, Moavero, & de Vries, 2015). Unraveling the pathway 
of action of these genes, has resulted in development of targeted treatment with mam-
malian target of rapamycin kinase (mTor) inhibitors (Leclezio & de Vries, 2015).
Rather than focusing on starting points (genetic) or end points (psychopathological 
conditions), it is highly relevant to focus on the continuum from genetics to psychia-
try. A genetic defect results in an alternative balancing of neurobiological processes 
in the body. Identifying these processes is crucial to the understanding, at various 
levels of explanation, of the mechanisms underlying complex diseases, like psychiatric 
disorders.
Aims and thesis outline
The EHMT1 gene has emerged as a crucial neurodevelopmental gene (Balemans et al., 
2014; Balemans et al., 2010; Benevento et al., 2016; Kleefstra et al., 2006; Kramer et al., 
2011). Interestingly, this gene was associated with all the overlapping categories of neu-
rodevelopmental disorders, neuropsychiatric disorders and genomic disorders (Collins 
et al., 2008; Kirov et al., 2012). This makes the EHMT1 gene and corresponding protein 
an excellent genetic factor to further study of its role in NDDs. Haploinsufficiency of 
this gene in human results in ‘Kleefstra syndrome’, KS, (OMIM 610253; Kleefstra et al., 
2006; Kleefstra et al., 2009; Stewart & Kleefstra, 2007; Willemsen, Vulto-van Silfhout, 
et al., 2012), which is characterized by the trias of ID, childhood hypotonia and distinct 
facial features. A variety of psychiatric symptoms has been described, but these could 
not yet be investigated in controlled studies. Since EHMT1 orchestrates the expression 
of other genes involved in neurodevelopment and other processes, it is highly relevant 
to carefully map the resulting psychiatric characteristics. This may provide details 
of disease processes in between the genetic starting point and the psychiatric end 
point. Systematic investigation of the clinical characteristics, associated neurocognitive 
endophenotypes and best practices in treatment, may therefore serve as a blue copy 
for application of this approach to the larger group of other rare genetic syndromes.
The overall aim of this thesis was to map the continuum from genetics to psychiatry 
through different levels of cognitive functioning, such as adaptive behavior, neuro-
cognition and psychopathology. Kleefstra Syndrome is serving as a blueprint in this 
thesis, which comprises nine chapters, divided in three parts: 
        
General Introduction
23
Chapter 1Part 1: Clinical characteristics
In this section, the clinical characteristics in a subgroup of young patients with KS 
(chapter 2), in a larger cohort of patients with KS (chapter 3), as well as in a subgroup 
of parents with mosaicism for an EHMT1 gene defect (chapter 4), are carefully mapped 
and highlighted. Major focus is on the disentanglement of ID and psychiatric condi-
tions in all their facets. 
Part 2: Measurement and assessment
This section covers measurement and assessment in NDD particularly by using 
(neuro)psychological tests and questionnaires tapping underlying constructs of adap-
tive functioning, such as attention, memory, cognitive flexibility and components of 
communication and social reciprocity. These instruments are constructed for use in 
the general population and are also often used in ID populations, with lack of better 
alternatives. In chapters 5 and 6, we investigate aspects of validity, that is, if the instru-
ments are actually measuring what they intend to measure, and specifically study the 
role of ID as a possible moderating variable. 
Part 3: Management of both endogenous and exogenous results
Suggestions for intervention are the core of this part. First, treatment of acute psychiat-
ric episodes in KS, resulting in severe regression, is described (chapter 7). In addition, 
the consequences of the patient-related problems on their families are depicted. The 
proximity of parents is crucial to these children and the impact thereof on the parents 
has been mapped (chapter 8). 
In the ninth and final chapter of this thesis, results will be summarized and discussed 
in terms of their contribution to the theoretical advancement in the field of genetics 
and psychiatry. Strengths and limitations of the study will be reflected upon and the 
chapter is concluded with suggestions for the assessment and treatment of NDD in 
clinical practice.
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Chapter 2
Abstract
Aim: Neuropsychiatric disorders comprise a clinically heterogeneous group of conditions that 
share underlying molecular and pathological mechanisms. Knowledge about how molecular 
pathways affect cognition and emotion is highly fragmentary. The Euchromatin Histon Methyl 
Transferase 1 (EHMT1) gene encodes a protein involved in chromatin modification and is presumed 
to have an important role in the etiology of cognitive and emotional dysfunctions. While animal 
studies with EHMT mutant species showed deviations in learning, attention and social cognition, 
systematic studies investigating behavioral characteristics in humans have been hardly conducted. 
Adult case studies showed behavioral disturbances with a sudden decline in functioning together 
with sleep problems. The focus of this report is to describe symptoms and developmental aspects 
in children with EHMT1 defects and compare these to previous studies in adults and animal 
models. 
Methods: Four children with EHMT1 defects were investigated on adaptive functioning, psychi-
atric symptoms and temperament. 
Results: All subjects have a severe developmental delay and meet the criteria for autism spectrum 
disorders, irrespective of severity of their intellectual disability. Three subjects have extreme sleep 
problems, while two subjects also have anxiety and mood disorders. Temperament is character-
ized by deficits in attentional focusing and inhibition. 
Conclusions: These results show that EHMT1 defects severely affect cognitive processing, behav-
ior and emotional functioning in children. This is in agreement with previous observations in 
animal studies and adult patients. The important role of EHMT1 in cognitive processing suggests 
that disruptions in a single gene can result in a broad spectrum of psychiatric pathology in human.
Key words: Kleefstra syndrome, EHMT1 gene, Intellectual disability, Autism, Sleep, Behavior
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Chapter 2
Introduction
Twin, adoption and molecular genetic studies have produced evidence that genetic 
factors are significant contributors to the etiology of several neuropsychiatric disorders 
and related traits. Although the genetic architecture of these disorders is complex, it 
has become evident that rare, moderate risk variants such as de novo copy number 
variants (CNVs) are an important contributor to the disease risk (Burbach & van der 
Zwaag, 2009; Gershon, Alliey-Rodriguez, & Liu, 2011; Guilmatre et al., 2009; Owen, 
Craddock, & O’Donovan, 2010; Poelmans, Pauls, Buitelaar, & Franke, 2011). Identifi-
cation of harmful CNVs may be challenging, but even more difficult is defining how 
such genomic changes affect biological pathways and result in disease.
Known disruptions in a specific gene, well described in terms of biological function-
ing and associated phenotype will be of vital importance to understand the role of 
CNVs in neuropsychiatric disorders. Disruptions of EHMT1 are a clear example of a 
specific genetic abnormality that results in psychiatric symptoms. In a recent study 
using Next Generation Sequencing in humans with various cognitive dysfunctions, 
EHMT1 was identified as the only common mutated gene in an overlapping group of 
cognitive disorders: intellectual disability (ID), autism and schizophrenia (Talkowski 
et al., 2012). The EHMT1 gene is located on 9q34 at the subtelomeric end. Either 9q34 
microdeletions or intragenic EHMT1 mutations can similarly lead to impaired cogni-
tive functioning (Kleefstra et al., 2006). The gene is expressed widely in neural tissue 
strongly suggesting that the EHMT1 gene plays an important role in neurodevelop-
ment. The enzyme, for which it encodes, is capable to methylate lysine 9 of histone 
3 (K9H3 methylase). Consequently, changes in chromatin modulation occur, thereby 
influencing epigenetic processes of gene regulation (Akbarian & Huang, 2009; Jarome 
& Lubin, 2013).
Importantly, the EHMT gene is studied cross species. Behavioral studies in Drosoph-
ila melanogaster and mice with EHMT1 defects have been performed (Balemans et 
al., 2010; Kramer et al., 2011) and show strong associations between EHMT defects 
and neurocognitive abnormalities. For example, in Drosophila, neurodevelopmental 
and behavioral analyses identified EHMT as a regulator of larval locomotor behav-
ior, non-associative learning, and courtship (complex) memory. Moreover, memory 
dysfunction was repaired by EHMT re-expression during adulthood, indicating that 
cognitive defects are reversible in EHMT Drosophila mutants (Kramer et al., 2011). 
Additionally, the study of heterozygous EHMT1 knockout mice demonstrated diffi-
culties in the processing of novel stimuli, higher levels of anxiety and a deviation in 
social reaction to strangers (Balemans et al., 2010).
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In humans, mutations of EHMT1, result in a clinical syndrome, known as Kleefstra 
syndrome (KS) or chromosome 9q subtelomere deletion syndrome [OMIM 610253]. 
Worldwide about 150 cases of this syndrome are reported so far (Kleefstra et al., 2009; 
Stewart & Kleefstra, 2007; Willemsen, Vissers, et al., 2012). The clinical picture of this 
syndrome is dominated by intellectual disability, hypotonia and characteristic facial 
dysmorphisms such as micro-/brachycephaly, mid-face hypoplasia, hypertelorism, 
synophrys with/without arched eyebrows, a short nose and tongue-protrusion. These 
can be accompanied by a variety of symptoms as congenital structural heart defects, 
uro-genital defects, epilepsy and severe behavioral disturbances.
Two recent reports pay attention to the behavioral characteristics in a few adults with 
the KS (Verhoeven, Egger, Vermeulen, van de Warrenburg, & Kleefstra, 2011; Verho-
even, Kleefstra, & Egger, 2010). These patients showed clinical features like apathy 
and severe sleep problems and significant loss of functioning became apparent after 
adolescence with increasing symptoms over time. This “regressive” phenotype was 
suggested to be associated with the EHMT1 gene particularly since it was also observed 
in a patient with an intragenic EHMT1 mutation (Verhoeven et al., 2011).
To date, no studies are reported that specifically and systematically investigate symp-
toms and behavioral characteristics of children with KS. Consequently, it is as yet 
unknown which symptoms do occur due to the EHMT1 mutation and to what degree.
Therefore, the present study focuses on mapping symptoms and developmental 
aspects in childhood and compare these to the results in animal studies and in adult 
patients, thereby connecting a single gene disruption with a biological pathway and 
with behavior. In addition, this cross species comparison may be of help in future 
studies that address development of therapeutic potentials of affected chromatin 
modification. 
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Methods and Materials
Participants: 
 In this pilot study, four subjects with an EHMT1 defect participated. Three males and 
one female. The participants were referred by the department of Human Genetics, 
Radboud University Medical Center Nijmegen, the Netherlands. 
Informed consent was obtained from legal representatives (parents), because the sub-
jects aren’t competent to sign for participation. However, if a subject indicated not 
wanting to participate or wanting to quit a task, then this was immediately followed 
by termination of the task or participation. The informed consent was signed by the 
parents on a consent form, which is included in the file of the participant. The regional 
medical ethics committee (Medical Ethics Committee of the Radboud University Med-
ical Centre, Nijmegen, The Netherlands) approved the consent procedure. Their ethics 
statement is positive about the investigation file.
Patient characteristics:
Patient characteristics and developmental aspects are listed in Table 2.1. Detailed 
descriptions of the subjects are added in the appendix.
The medical and genetic characteristics of all cases have been published in short in 
previous clinical genetic studies; patient 1 was reported as patient 21 in (Willemsen, 
Vissers, et al., 2012) . Patient 2 and patient 3 were reported as patient 4 and patient 8 
respectively in (Kleefstra et al., 2006; Willemsen, Vissers, et al., 2012), patient 4 was 
reported as patient 27 in (Willemsen, Vissers, et al., 2012). Patient 1,2 and 4 had an 
intragenic EHMT1 mutation, patient 3 had a 9q34.3 microdeletion encompassing entire 
EHMT1 and other genes (3.2 Mb).
Cognitive and behavioral measures
(Mal)adaptive functioning. VABS. The Dutch adaptation of the Vineland Adaptive Behavior 
Scale (VABS; ( Sparrow, Balla, Cicchetti., 1984); This is a widely used clinical interview is 
to determine the level of adaptive functioning of people with an intellectual disability. 
The VABS consists of 3 domains: communication skills, daily living skills and social 
skills. This instrument has a good reliability and validity in this specific population 
(de Bildt, Kraijer, Sytema, & Minderaa, 2005). Primary caregivers were interviewed 
about the participants. 
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The mini Psychiatric Assessment Schedules for Adults with Developmental Disabilities 
(mini PAS-ADD); (Moss, 1997); in Dutch translation (Janssen & Maes, 2012); This is used 
to determine behavioral problems and psychiatric disease in subjects with an intel-
lectual disability by interviewing the proxy. It consists of 86 items on a 4-point scale: 
0 (symptom not present) -3 (symptom is severe). The interview is divided into seven 
subscales: Depression, Anxiety, Obsessive/Compulsive disorder, Hypomania/Mania, 
Psychosis, Unspecified disorder and Autism. All criteria are based on the International 
Classification of Diseases (ICD-10). This instrument has proven psychometric qualities 
in this specific ID adult population, but not yet in a population sample with children 
(Janssen & Maes, 2012; Prosser et al., 1998). 
Table 2.1. Patient Characteristics 
Patient 1 Patient 2 Patient 3 Patient 4
Age/ gender
Genetic defect
5 years, male
EHMT1 mutation
c.2785_2788del
(p.Ser929fs)
10, male
EHMT1 mutation
c.3409C>T
(p.R1137*)
10, male
EHMT1 deletion
3,2 Mb (137,04-140,21 MB, UCSC, NCBI build 36.1)
11, female
EHMT1 mutation
c.3072_3073del
(p.Val1026fs)
Developmental characteristics
Birth: 
Gestation (weeks + days)
Birth weight 
Abnormalities
33+4 
1750 g
Breathing problems
Incubator (1 month)
41 
3480 g
Meconium in amniotic fluid
32 
2950 g
Blood loss and minimal fetal movements during 
pregnancy.
Omphalocele and marked hypotonia at birth. After 
birth: incubator, feeding by fluid infusion
41 
3600 g
Induced labor with vacuum extraction
Respiratory problems at birth 
Infancy Floppy baby
Feeding difficulties
Floppy baby
Feeding difficulties
Poor contact with parents
Floppy baby
Feeding difficulties
Overstretching after feeding
Poor contact with parents
Easy to comfort
Feeding difficulties after switching to solid food.
Toddlerhood:
Milestones (year; months)
Laugh
Walk
Talk
Abnormalities
Delayed 
 0;8
4;3
2;6
Special interest in light, moving parts 
of objects, animals and music.
Delayed 
1;0
9;0
Not able to talk
Special interest in a specific toy 
with a sound
Delayed 
0;3
5;0
Not able to talk
Fascination with technical aspects, water and music
Delayed
0;2
2;0
5;0
Special interest in music and water.
Somatical Highlights Recurrent airway infections 
Tantrums 
Absences (decreased without 
treatment)
Dullness of hearing
Reflux in infancy
Recurrent infections: airway, bladder.
Regurgitation in infancy
Hearing and visual difficulties. 
Extreme obstipation together with mood swings 
at 10 years
Medication
Current
Past
Risperidone
Valproaat
None Pipamperon, Omeprazol
Cotrimoxazol (maintainance treatment)
Olanzapine, Valproate 
Macrogol, Bisacodyl 
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Clinical assessment: The assessment started with observation of the participant, while 
(s)he was playing/interacting with his (her) mother. Subsequently, the observer took 
over the play and tested reactions to several toys; a toy telephone, a doll with a feeding 
bottle, building blocks, a picture book, a plastic tea set and a song. The interviews 
and assessments were conducted in the same order by the first author (KV). All the 
assessments were videotaped. 
Child Behavior Checklist (CBCL/1,5-5) (Achenbach, 2000); Dutch version (Verhulst & van 
der Ende, 1992). This questionnaire measures problem behavior on a 3-point scale: 0= 
symptom is absent, 1= sometimes present, 2= often present. It is intended for children 
between 1,5 and 5 years of (developmental) age and is completed by the parent(s). It 
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consists of 100 items, which reflect problem behaviors. The psychometric properties of 
this questionnaire were proved in a population sample of Dutch normally developing 
children (Verhulst & van der Ende, 1992) as well as in a sample of children with an 
intellectual disability (Borthwick-Duffy, Lane, & Widaman, 1997).
Children’s Behavior Questionnaire (CBQ) (Rothbart, Ahadi, Hershey, & Fisher, 2001): Mea-
sures temperament on 16 subscales: activity level, anger/frustration, approach/anticipation, 
attentional focusing, attentional shifting, discomfort, falling reactivity and soothability, fear, 
high pleasure, impulsivity, inhibitory control, low pleasure, perceptual sensitivity, sadness, 
shyness and smiling and laughter. The questionnaire should be completed by parents 
on a 7-point rating scale (1= not applicable till 7= totally applicable). It is intended for 
children with a developmental age between 3 and 8 year. The psychometric properties 
are proved in a Dutch sample (Sleddens, Kremers, Candel, De Vries, & Thijs, 2011).
Social Communication Questionnaire: (SCQ); (Rutter, 2003); in Dutch: (Roeyers, 
Warreyn, & Raymakers, 2002) detects problems in social behavior and features of 
autism spectrum disorders. It is based on items of the Autism Diagnostic Interview- 
Revised(ADI-R) (Rutter, 2003). Its subcategories correspond to the three domains of 
autism in the DSM-diagnosis. It supplies a 40 item binary scale, which is completed 
by the primary caregiver(s).
The data are presented in the next section, subdivided into the following categories: 
adaptive behavior, temperament and maladaptive behavior. 
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Results
The components of adaptive behavior (VABS) are graphically represented in Figure 2.1 
as decile scores, based on the norm group of people with a severe intellectual disabil-
ity. All subjects had a severe developmental delay. A common deficit in social skills is 
shown for all subjects. The raw scores are presented in Table 2.2. 
Figure 2.1: Results on the Vineland Adaptive Behavior Scale
These scores are decile scores, which means that a decile score of 1 (Y-axis) corresponds to the 10% lowest 
scoring persons and a decile score of 10 (Y-axis) corresponds to the 10% highest scoring persons. These scores 
are standardized for people with a severe intellectual disability. 
Results on temperament (CBQ) are shown in Figure 2.2, where the mean scores of the 
children with KS are plotted against the mean of toddlers from the general population 
(Rothbart et al., 2001). CBQ scores of the children with KS were remarkably low on 
the ‘attentional focusing’ and ‘inhibitory control’ categories and relatively high on the 
categories ‘low intensity pleasure’ and ‘smiling and laughter’. 
Symptom categories of maladaptive behavior are measured by using the CBCL. All 
subjects scored in the clinical range for withdrawn behavior. Emotional reactivity 
scores and attention problems scores were also in the clinical range for patients 1, 
3 & 4. The results within the clinical range are presented in Table 2.2, together with 
the raw scores. Results on the Mini PAS-ADD and clinical assessment are presented 
in Table 2.3. They show a heterogeneous but psychiatric picture. All the children ful-
filled the mini PAS-ADD criteria for an Autism Spectrum Disorder, accompanied by 
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extreme avoidance of contact in two of them and aggressive behavior in one of them. 
The majority of the subjects fulfilled the mini PAS-ADD criteria for Anxiety Disorder, 
Sleep Disorder and Mood Disorders. Psychotic symptoms in the past are reported in 
patient 3. All subjects scored well above the cut-off (≥11) on the SCQ (Allen, Silove, 
Williams, & Hutchins, 2007). 
Table 2.2: Results on the VABS, CBCL and SCQ
Patient 1 Patient 2 Patient 3 Patient 4
Vineland score 
(developmental age in years; months) 110 (1; 7) 46 (11m) 52 (1;0) 143 (2;0)
Communication skills 41 (2;2) 10 (0;11) 15 (1;1) 49 (2;11)
Daily life skills 44 (2;0) 24 (1;4) 17 (1;1) 53 (2;6)
Social skills 25 (1;3 ) 12(<0;11) 20 (0;11) 41 (1;11)
CBCL: categories in the clinical range (t-score)
Emotionally Reactive x (80) 0 x(87,5) x(70)
Anxious-Depressed 0 0 x (75) x (75)
Somatic Complaints 0 0 x (87,5) x (75)
Withdrawn x(70) x (85) x (95) x (75)
Sleep problems 0 0 x (75) 0
Attention Problems x (85) 0 x (75) x (80)
Agressive behavior x (90) 0 x (70) 0
SCQ (total score) 24 22 23 26
Vineland: higher scores represent more abilities (comparable to developmental age in years; months)
CBCL: clinical scores: x= present, 0=absent, (t-scores)
SCQ: cut-off ≥11
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Figure 2.2: Results on temperament (CBQ)
Y-axis: 1= not applicable till 7= applicable. Normative scores of normal developing toddlers (25).
Table 2.3: Results on Mini PAS-ADD interview and clinical assessment
Patient 1 Patient 2 Patient 3 Patient 4
Mini PAS-ADD categories:
Depression 0 0 x x
Anxiety 0 0 x 0
(Hypo)mania 0 0 0 x
Psychosis 0 0 x(p) 0
Undifferented Disorder 0 0 x (p) 0
Autism Spectrum Disorder x x x x
Sleep Disorder x 0 x x
Clinical Assessment
Remarkable Details Agression Active 
avoidance of 
contact
Active 
avoidance of 
contact
Cyclic course 
of mood 
disorder
0= absent
x= present
x (p)= present in the past
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Discussion
This first study on the cognitive and neurobehavioral characteristics of children with 
KS strongly suggests that deficits in attention, cognitive processing and sleep are asso-
ciated with a severe neuropsychiatric outcome, characterized by autism spectrum 
traits and mood and anxiety problems. The combined data presented in this study 
form a unique picture of neuro-behavioral abnormalities associated with a single but 
well described genetic abnormality. While the genetic abnormality of the EHMT1 locus 
is rare, the present study may serve as a proof of principle and template. Indeed, the 
number of associated genetic abnormalities, especially copy number variants (CNVs) 
with neuropsychiatric phenotypes are rapidly growing, but only few examples exist 
where a single gene disruption is connected to a biological pathway and behavior. 
Moreover, the effects of EHMT1 mutations across species may be of help in future 
studies that may focus on identification of rescue mechanisms of the affected chro-
matin modification pathway.
Although heterogeneity is present even among the three cases with single gene dis-
ruption, interesting similarities are found. Remarkably, all subjects show deficits in 
social reciprocity and cognition. 
They all meet the criteria for autism spectrum disorder (ASD) on the mini PAS-ADD. 
However, one has to realize that these disease categories, based on the ICD and DSM 
classification, give direction to the diagnostic process and are no factual diagnoses. These 
ICD and DSM disease categories fit people with ID as a scratchy and wrong-sized coat. A 
definite classification should be the endpoint of the diagnostic process (Verhoeven et al., 
2011) and scores on instruments contribute to this. The high scores on autism traits are 
in support of recent findings from Talkowski et al (Talkowski et al., 2012), who described 
disruptions in 33 loci including EHMT1 in neuropsychiatric disorders such as ASD. 
In addition, all subjects show severe developmental delay in several respects. More 
specific, their developmental profile, scored on the VABS, shows a relative weakness 
in social skills, compared to the daily living and communication skills. On the SCQ, 
they had high scores, in particular on lack of social reciprocity, which is in line with 
the results of relative weaknesses in social functioning on the VABS. In conclusion 
the results of the interviews, questionnaires and clinical assessment all supported the 
finding of striking social deficits, and all subjects fulfill clinically the criteria for ASD.
Indeed, a diagnosis of ASD in the presence of severe developmental delays should 
only be made when impairments in social skills outweigh the expected loss of social 
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functioning due to intellectual disabilities (ID) (Towbin, 2005). The impairments of the 
patients described here, are clearly seen in social skills, especially in comparison with 
other genetic syndromes, like Down syndrome, Prader-Willi syndrome and Angelman 
syndrome (Di Nuovo & Buono, 2011). Clinically, it is relevant to distinguish between 
intellectually disability with and without autism spectrum disorder (Howlin, 2000). An 
accurate description and diagnosis of the pattern of behavioral skills and difficulties 
enables professionals to optimize treatment approaches in a personalized treatment. 
Besides ASD and developmental delay, sleep problems as well as attention problems 
are present in our cases. Sleep disturbances have been observed previously in the 
adult patients with EHMT1 mutations (Verhoeven, Kleefstra & Egger, 2010, Verhoeven 
et al., 2011). Three of the children described in our report, experience severe problems 
in falling asleep, often taking several hours. Also, they wake up several hours earlier 
than expected. While there may be some resemblance with the sleep problems in 
Smith Magenis syndrome, which are due to alterations in the melatonin metabolism 
(De Leersnyder, Claustrat, Munnich, & Verloes, 2006), no information is yet available 
on the metabolism of melatonin in Kleefstra syndrome. 
EHMT1 heterozygous knock-out mice showed hypo activity and autistic–like fea-
tures, less reaction to social cues, reduced exploration and higher levels of anxiety, 
in comparison to wildtype littermates (Balemans et al, 2010). These knockout mice 
revealed reduced activity and exploration, increased anxiety while exposed to novel 
environments and diminished social play. In our subjects we demonstrated social 
withdrawnness and high levels of emotional reactivity and anxiety/depression. The 
attentional and social problems observed during the clinical assessments have also 
been reported in adults with EHMT1 defects. A study in Drosophila identified the 
EHMT gene as a key regulator of cognition that orchestrates an epigenetic program 
featuring classic learning and memory genes (Kramer et al, 2011). The effects of this 
mutation on cognition were found to be reversible. This provides a challenge to 
develop therapeutic opportunities.
Our results should be considered in a broader perspective with genetic research 
in other conditions. In a large cohort of patients with schizophrenia de novo 9q34.3 
deletions encompassing EHMT1 were found in three patients (Kirov et al., 2012). This 
indicates that deletions of EHMT1 in humans might result in highly penetrant phe-
notypes comprising developmental disabilities and several congenital anomalies. In 
addition, the EHMT1 locus is suspected to contribute to the development of psycho-
pathology through disturbances in epigenetic mechanisms.  Our findings as well as 
the results in adults (Verhoeven, Kleefstra & Egger, 2010, Verhoeven et al., 2011) suggest 
The EHMT1 Disruption Example
39
Chapter 2
functioning due to intellectual disabilities (ID) (Towbin, 2005). The impairments of the 
patients described here, are clearly seen in social skills, especially in comparison with 
other genetic syndromes, like Down syndrome, Prader-Willi syndrome and Angelman 
syndrome (Di Nuovo & Buono, 2011). Clinically, it is relevant to distinguish between 
intellectually disability with and without autism spectrum disorder (Howlin, 2000). An 
accurate description and diagnosis of the pattern of behavioral skills and difficulties 
enables professionals to optimize treatment approaches in a personalized treatment. 
Besides ASD and developmental delay, sleep problems as well as attention problems 
are present in our cases. Sleep disturbances have been observed previously in the 
adult patients with EHMT1 mutations (Verhoeven, Kleefstra & Egger, 2010, Verhoeven 
et al., 2011). Three of the children described in our report, experience severe problems 
in falling asleep, often taking several hours. Also, they wake up several hours earlier 
than expected. While there may be some resemblance with the sleep problems in 
Smith Magenis syndrome, which are due to alterations in the melatonin metabolism 
(De Leersnyder, Claustrat, Munnich, & Verloes, 2006), no information is yet available 
on the metabolism of melatonin in Kleefstra syndrome. 
EHMT1 heterozygous knock-out mice showed hypo activity and autistic–like fea-
tures, less reaction to social cues, reduced exploration and higher levels of anxiety, 
in comparison to wildtype littermates (Balemans et al, 2010). These knockout mice 
revealed reduced activity and exploration, increased anxiety while exposed to novel 
environments and diminished social play. In our subjects we demonstrated social 
withdrawnness and high levels of emotional reactivity and anxiety/depression. The 
attentional and social problems observed during the clinical assessments have also 
been reported in adults with EHMT1 defects. A study in Drosophila identified the 
EHMT gene as a key regulator of cognition that orchestrates an epigenetic program 
featuring classic learning and memory genes (Kramer et al, 2011). The effects of this 
mutation on cognition were found to be reversible. This provides a challenge to 
develop therapeutic opportunities.
Our results should be considered in a broader perspective with genetic research 
in other conditions. In a large cohort of patients with schizophrenia de novo 9q34.3 
deletions encompassing EHMT1 were found in three patients (Kirov et al., 2012). This 
indicates that deletions of EHMT1 in humans might result in highly penetrant phe-
notypes comprising developmental disabilities and several congenital anomalies. In 
addition, the EHMT1 locus is suspected to contribute to the development of psycho-
pathology through disturbances in epigenetic mechanisms.  Our findings as well as 
the results in adults (Verhoeven, Kleefstra & Egger, 2010, Verhoeven et al., 2011) suggest 
        
Chapter 2
40
Chapter 2
that this is not only the case for schizophrenia, but also for a larger range of psycho-
pathology. This supports the hypothesis that several psychiatric syndromes such as 
schizophrenia, autism and intellectual disability have common genetic underpinning 
and share a common pathway in the pathogenesis (Burbach & van der Zwaag, 2009; 
Laumonnier et al., 2004).
A limitation of this case study is the relatively small number of participants. How-
ever, even with this small number of subjects, specific neurobehavioral abnormalities 
such as deficits in social reciprocity and cognition, sleep disturbances and attention 
problems stand out. Also, these abnormalities seem to be present in EHMT mutant 
animal models.
We have several recommendations for future research. At first, prospective continu-
ation of the present study can help to further elucidate the behavioral phenotype of 
the Kleefstra Syndrome. The question is whether these children also experience a 
loss of functioning later in life, like it was described in adult cases (Verhoeven, Kleef-
stra & Egger, 2010), and what is the course of the neurocognitive deficits? Eventually, 
prospective research may clarify the role of EHMT1 in neurodegenerative processes. 
Secondly, replication of these findings is needed in a larger cohort of participants. We 
recommend comparison of results of the animal studies with those in human subjects. 
Finally, identification of other gene disruptions that operate in the same pathway as 
EHMT may be highly relevant. Especially when these are combined with cognitive 
and social data descriptions across species. 
In conclusion, our study provides a first overview of the development and behavior in 
four children with the KS. Their behavioral and developmental profile is characterized 
by a developmental delay, autism, sleep disturbances and attention problems. Deletion 
of the EHMT1 gene increases the risk for psychopathology in childhood, followed by 
a decline in functioning in adulthood. This suggests an important role in epigenetic 
regulation in the pathophysiological pathway of several psychiatric syndromes. Fur-
ther clinical as well as fundamental research in this area may help to elucidate the 
precise role of EHMT1 and its clinical implications.
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Abstract
Detailed neurobehavioural profiles are of major value for specific clinical management, but have 
remained underexposed in the population with intellectual disabilities (ID). This was traditionally 
classified based on IQ level only. Rapid advances in genetics enable etiology-based stratification in 
the majority of patients, which reduces clinical heterogeneity. This paper illustrates that specific 
profiles can be obtained for rare syndromes with ID. Our main aim was to study (mal)adaptive 
functioning in Kleefstra Syndrome (KS) by comparing and contrasting our findings to three other 
subgroups: Koolen-de Vries Syndrome, GATAD2B-related syndrome, and a mixed control group 
of individuals with ID. In total we studied 58 individuals (28 males, 30 females) with ID; 24 were 
diagnosed with Kleefstra Syndrome, 13 with Koolen-de Vries Syndrome, 6 with the GATAD2B-re-
lated syndrome and 15 individuals with undefined neurodevelopmental disorders. All individuals 
were examined with a Vineland Adaptive Behavior Scale, mini PAS-ADD interview and an Autism 
Diagnostic Observation Schedule to obtain measures of adaptive and maladaptive functioning. 
Each of the three distinctive genetic disorders showed its own specific profile of adaptive and 
maladaptive functioning, while being contrasted mutually. However, when data of the subgroups 
altogether are contrasted to the data of KS, such differences could not be demonstrated. Based 
on our findings, specific management recommendations were dissected for each of the three 
syndromes. It is strongly suggested to consider the genetic origin in individuals with congenital 
neurodevelopmental disorders for individual based psychiatric and behavioral management.
Keywords: Adaptive functioning, GATAD2B related syndrome, Intellectual disabilities, Kleefstra 
syndrome, Koolen-de Vries syndrome, Psychopathology. 
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Introduction
Intellectual disabilities (ID) comprise a category of mental disorders with a broad clin-
ical heterogeneity, including a high variation in neurobehavioral and neurocognitive 
functioning, physical impairments and psychiatric comorbidity. The collective term ID 
is used for different conditions and is defined by several organizations. The American 
Association on Intellectual and Developmental Disabilities (AAIDD) defines ID as a 
disability, which is characterized by significant limitations in both intellectual and 
adaptive functioning, which covers many daily social and practical skills and origi-
nates before the age of 18 (Schalock et al, 2012). In previous editions, the Diagnostic 
and Statistical Manual of Mental Disorder (DSM) puts emphasis on classification 
based on IQ-level in addition to dysfunctioning in daily life. However, in its latest, fifth, 
edition (DSM-5), the IQ-test scores are removed from the diagnostic criteria to reflect 
the importance of the overall ability of daily functioning (APA, 2013a). Both definitions 
do not take etiology into account. Consequently, clinical research as well as treatment 
procedures in the ID population are still based on general characteristics like IQ levels, 
resulting in huge clinical heterogeneity. 
For clinical practice it is of great value to have specific knowledge about associated 
symptoms and the natural disease course of individual syndromes. Often, there are 
abnormalities in development and learning abilities as well as differences in the pro-
cess of aging (Coppus, 2013; Nomura & Segawa, 2005). For more established syndromes 
with higher numbers of affected patients available, specific neurobehavioural and 
cognitive profiles have been defined (Di Nuovo & Buono, 2011; Egger et al., 2013; van 
Rijn & Swaab, 2015; Wingbermühle et al., 2012). Consequently, these profiles should 
each to some extend have their own approach with respect to education, training and 
(para)medical treatment.
With the advances in genetic techniques over the recent years, there are increasing 
numbers of ID cases in which a genetic cause can be identified. At this point, in the 
majority of the ID-population, a rare genetic variant can be identified that is caus-
ative for the ID (Gilissen et al., 2014; Vissers, Gilissen, & Veltman, 2016; Willemsen 
& Kleefstra, 2013). Little is known about neuropsychiatric aspects associated with 
these rare variants, as the number of cases affected by a similar gene is mostly small 
thus making it difficult to conduct systematic studies in a homogeneous patient/
syndrome group. Sometimes characteristics of behavior and neurocognitive func-
tioning are described based on clinical observation. But even though the number 
of genes with rare variants in ID is extensive, this should not hold back the field in 
providing systematic clinical studies in single gene related syndromes as the number 
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of patients who are diagnosed with the more recently novel defined syndromes, 
steeply increases.
This study focuses on Kleefstra Syndrome (KS). KS is a rare ID syndrome, caused by 
EHMT1 haploinsufficiency (Kleefstra et al., 2006). KS patients function in the range 
from a moderate to profound ID, rarely on a mild ID to borderline ID (Bock et al., 
2016; Samango-Sprouse et al., 2016). Several KS case reports mention autistic fea-
tures, regression and sleep problems (Schmidt, Nag, Hunn, Houge, & Hoxmark, 2016; 
Verhoeven et al., 2011; Verhoeven, Kleefstra & Egger, 2010; Vermeulen et al., 2015). In 
addition, our clinical experience with these patients so far leads us to hypothesize that 
KS patients are more vulnerable to develop severe psychiatric disorders. To investi-
gate this, we studied a large cohort of KS patients at adaptive functioning and clinical 
psychiatric domains.
In this study, contrast groups are used to make a comparison. Generally, control groups 
in medical research are composed on the basis of individuals wherein the studied 
condition is lacking, but who are otherwise with similar biological characteristics. 
For research in the area of intellectual disabilities (ID), this is often done by matching 
the controls on biological as well as developmental age (DiStefano et al., 2016). As the 
cause of the ID is not taken into account in this approach, control groups are largely 
heterogeneous. Such heterogeneous groups quickly differ from homogeneous (caused 
by similar genetic defect) syndrome groups. Therefore, we believe that a control group 
should consist of several homogeneous contrast groups, in which the genetic disorders 
are all well defined. 
At the start of this study, we selected two genetic syndromes to contrast our results to, 
based on our historical experience, the well-described monogenetic causes, biological 
age range and level of functioning: Koolen-deVries Syndrome (KdVS) (Koolen et al., 
2006; Sharp et al., 2006; Shaw-Smith et al., 2006) and GATAD2B related Syndrome (GS) 
(Willemsen et al., 2013). Systematic neurobehavioral research in these rare syndromes 
was not previously performed. KdVS is associated with a mild to moderate ID, rarely 
a more severe ID. Subsequently, problems in expressive language and in about half of 
the patients, there is a variety of behavioral problems, including features of autism, 
anxiety, psychosis and ADHD (Koolen et al., 2015). A report on GS cases mentions 
behavioral characteristics, like tics, hyperactivity and sleep problems (Willemsen et al., 
2013). Finally, a mixed group (MG) was composed of other rare (un)defined neurode-
velopmental disorders. All together, the KdVS, GS and MG groups form a cumulative 
control group (CC), which meets the more “traditional” format of contrasting a specific 
syndrome to a clinical heterogeneous control group. 
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To summarize, in this first report on adaptive and maladaptive behavioral function-
ing in KS, we systematically contrast monogenetic syndromes to identify syndrome 
specific profiles. We hypothesize that KS patients are more vulnerable to develop 
severe psychiatric disorders, especially autism spectrum disorders, mood disorders 
and psychosis. Our second hypothesis is that results emerge more clearly, when data 
of KS patients are contrasted to the data of patients with other well-defined genetic 
syndromes. 
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Materials and methods
Participants
Included were 58 patients (28 males, 30 females) subdivided into 4 groups: Kleefstra 
Syndrome (KS, n=24), Koolen-de Vries Syndrome (KdVS, n=13), GATAD2B syndrome 
(GS, n=6) and a mixed group (MG, n=15). The participants in the KS, KdVS and GS 
cover all the identified subjects with these syndromes in the Netherlands and Bel-
gium. Due to the rarity of individual genetic syndromes this number was maximum 
to achieve. In addition, the KdVS, GS and MG-groups are taken together for statistical 
analyses and then referred to as cumulated control group (CC) (Figure 3.1). 
Patient characteristics are summarized in Table 3.1. Patients with KS, KdVS and GS 
were invited to participate from the department of Human Genetics, Radboud Uni-
versity Medical Centre, the Netherlands. The MG subjects have very rare genetic 
variants (Table 3.1) or an undefined condition underlying their neurodevelopmen-
tal disorder and are recruited both from the department of Human Genetics (HG), 
Radboud university medical center, the Netherlands and from the department of 
Child- and Adolescent Psychiatry (CP), Karakter Horst, the Netherlands. Informed 
consent was obtained by legal representatives and included in the participant file. The 
regional medical ethical committee (medical research ethics committee CMO/METC 
Arnhem-Nijmegen, the Netherlands) approved the study (NL43187.091.13), which was 
performed in full accordance with the Declaration of Helsinki. 
Table 3.1: Patient characteristics
Groups Subgroups N Genetic specification (N) Male:Female (N) Biological age range 
(min-max in years)
Biological age
Mean ±SD
Kleefstra Syndrome (KS) 24 EHMT1 gene mutation (n= 8)
/ microdeletion (n=16)
9:15 3-37 15,42±10,42
Cumulated control group (CC) 34 19: 15 3-40 14,29±10,13 
Koolen-de Vries Syndrome (KdVS) 13 KANSL gene mutation (n=1)/ 
microdeletion (n=12)
6:7 5-34 18,31±10,70
GATAD2B-related Syndrome (GS) 6 GATAD2B gene microdeletion (n=6) 2:4 3-40 16,50±13,64
Mixed Group (MG) 15 * 11:4 3-30 9,93± 6,33
Total 58 28: 30 3-40 14,76±10,18
*Genetic variants identified in the mixed group (MG)
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Instruments 
In this study, we aimed to focus solely on clinical parameters, obtained through clin-
ical interviews (VABS, mini PAS-ADD), or by direct testing of the subject (ADOS-2), 
in order to obtain measurements.
Figure 3.1: Composition of Groups
Vineland Adaptive Behavior Scale (VABS). 
The Dutch adaptation of the Vineland Adaptive Behavior Scale ( Sparrow, Balla, Cic-
chetti, 1984) is a widely used clinical interview, which determines the level of adaptive 
functioning of people with an intellectual disability. The VABS consists of 3 domains: 
communication skills, daily living skills and social skills. This instrument has a good 
reliability and validity in this specific population (de Bildt et al., 2005). Primary care-
givers were interviewed about the participants.
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Genetic variant N=
ANKRD11mutation 3
SIN3A mutation 3
PACS1mutation 2
FOXP2 mutation 1
2p16.3 microdeletion
FBOX17 gene
1
7q11.22 microdeletion
AUTS2 gene
1
7q36.1 microdeletion 1
17p13.3 microduplication 
YWHAE gene
1
Unknown result 1
Refused the advice to perform whole exome sequencing 1
Total 15
Autism Diagnostic Observation Schedule (ADOS)
ADOS is a semi-structured play to assess autism features (Lord, Rutter, DiLavore, & 
Risi, 1999; Lord et al., 1989). It is performed by a certified psychologist or psychiatrist 
(in this cohort, the first author, K.V.) and consists of 4 modules, based on the (develop-
mental) age and language capacity of the participant. Module 1 is preverbal to minimal 
verbal capacity, module 2 is used by the capacity to use short sentences and module 3 
is used by a normal verbal capacity, but still includes play elements. Module 4 can be 
used in normal functioning adults. In this studies module 1,2 and 3 are performed. For 
each of these modules is a comparison score available, which corrects for biological 
age and language capacity. The cut-off for clinical suspicion of an autism spectrum 
disorder is from 5 and above (moderate to severe suspicion).
The mini Psychiatric Assessment Schedules for Adults with Developmental Dis-
abilities (mini PAS-ADD) 
The mini PAS-ADD (Moss, 1997) in Dutch translation (Janssen & Maes, 2012); is used to 
determine behavioral problems and psychiatric disease in subjects with an intellectual 
disability by interviewing the proxy. It consists of 86 items on a 4-point scale: 0 (symp-
tom not present) -3 (symptom is severe). The interview is divided into seven subscales: 
Depression, Anxiety, Obsessive/Compulsive disorder, Hypomania/Mania, Psychosis, 
Unspecified disorder and Autism. All criteria are based on the International Classifi-
cation of Diseases (ICD-10). This instrument has proven psychometric qualities in this 
specific ID adult population, but not yet in a population sample with children (Janssen 
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& Maes, 2012; Prosser et al., 1998). To our opinion, however, we believe that it is also 
applicable to adolescents/ children with ID, because many adjusted criteria for people 
with ID overlap with the criteria for children. For example, an irritable mood is more 
often seen in children as well as people with ID as an expression of a depressive disorder. 
The mini PAS-ADD was completed for all participants, except the ones who were 
referred from the CP outpatient clinic. They had a regular anamnestic interview at 
intake.
Procedure
All participants were visited at home, except seven cases from the control group who 
were referred by the Child Psychiatric department. Those were examined at the out-
patient clinic for Intellectual Disabilities & Child Psychiatry (Horst, the Netherlands) 
as a part of a normal diagnostic procedure. 
All home visits and intakes were performed by the same investigator (K.V.) in the pres-
ence of a research assistant. 
The home visit started by interviewing the parents with the VABS and the mini PAS-
ADD. The participant was mostly present in the same room and was able to get used 
to the presence of the investigator. After this, one of the modules of the ADOS-2 
was chosen and made ready in a quiet and familiar room of the house (living room, 
kitchen). During the ADOS-2 one of the parents was present in the same or an open 
adjacent room, filling in questionnaires. The ADOS-2 was videotaped and scored con-
form the manual of the ADOS-2. 
For the controls, which were already seen for clinical intake, the VABS and the ADOS 
were performed after a normal intake procedure, including history taking and obser-
vation. These tests were performed in the same room setting as the intake and (one of ) 
the parents were also present, filling in questionnaires. Because of time and capacity 
of the participants, the mini PAS-ADD was not carried out. 
Statistical analyses
Analyses were performed using SPSS 22.
Adaptive functioning 
The scores of the VABS subdomains were first plotted against normative data (decile 
scores) and subsequently standardized (into Z-scores). In addition a covariate analysis 
was performed to test the influence of biological age.
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Maladaptive functioning
For the means of prevalence rates, the cut-off scores were used conform the manuals of 
the ADOS and mini PAS-ADD. A Fisher’s exact test was performed to compare point 
prevalences (current episodes) as well as lifetime prevalences between the several 
groups. Scores of each syndrome (n>5) were first plotted against all other participants 
to systematically test for syndrome specific psychopathology, followed by a Fisher’s 
exact test between the several subgroups. 
After this, the ADOS comparison scores and subscales scores on the mini PAS-ADD 
were also compared to complete tendencies within the clinical picture. For this pur-
pose non parametric tests for independent samples were used: the Mann-Whitney test 
for comparing KS against CC, a Kolmogorov-Smirnov for the smaller samples of as 
well KdVS as well as GS against all other participants. Finally, the Kruskal-Wallis test 
to screen for overall tendencies between the several contrast groups.
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Results
Adaptive functioning
The first step was to calculate and contrast adaptive functioning in KS and CC, based 
on the deciles for the Dutch population of people with ID (decile scores, Figure 3.2). 
The adaptive functioning of the participants was slightly lower compared to the mean 
of the total ID population in the Netherlands (Figure 3.2a, KS versus CC, a decile score 
of 5 reflects the mean of the total Dutch ID population). There is a clear difference 
in level of adaptive functioning with CC subjects performing better at all domains in 
comparison to KS. 
Because of the large variability within the CC group, a statistical mean was calculated. 
The scores of the several groups were also separated from each other and again pre-
sented as deciles (Figure 3.2b: KS, KdVS, GS and MG). This shows more specific profiles 
for each of the syndromes. However, in the calculation of the Dutch decile scores the 
patients with severe to profound ID are slightly underrepresented. So to draw clear 
conclusions, also for the syndromes with lower levels of adaptive functioning, we con-
trasted them to each other by calculating Z-scores. This resulted in syndrome even 
more specific profiles, which are displayed in Figure 3.2c.
Finally, an analysis of the VABS scores with biological age as a covariate was performed 
to assess this component in the different groups. We expected a positive correlation 
between the biological age and the developmental age in the age category of our 
patients (3-40 years, Table 3.1). A significant result was only seen in the CC group and 
the MG subgroup (Kendall’s tau, correlation coefficient in CC= 0.272, p=0.027 and in 
MG=0.518, p= 0.009). This means that in the syndrome groups (KS, KdVS and GS), no 
linear association was demonstrated between biological age and the level of adaptive 
functioning. 
Maladaptive functioning
After assessment of adaptive functioning, maladaptive functioning was determined 
based on the ADOS and mini PAS-ADD scores. Prevalence rates for major psychiatric 
disorders and symptoms are shown in Table 3.2 for each of the groups. 
To measure whether these prevalence rates are significantly different for each of the 
syndromes, several analyses were performed. Initially, KS and CC were contrasted 
against each other at several domains of the mini PAS-ADD (measuring episodic psy-
chopathology) and the ADOS (comparison) scores. Prevalence rates were tested with 
a Fishers exact test and symptom scores with a Mann-Whitney test.
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Figure 3.2: Profiles of Adaptive Functioning
Adaptive Functioning on the VABS: at the X-axis: Comm= Communication, Day= Daily living skills, 
Soc= Socialization and Tot= Total performance. The scores in 2a and 2b are based on the norm deciles 
for the total population with an ID in the Netherlands, conform the manual. A decile score of 5 reflects 
the mean of the total Dutch ID population. 
Figure 3.2a shows a difference in adaptive functioning, although both groups are matched on bio-
logical age. 
Figure 3.2b illustrates the importance of separating the genetic syndromes in the Cumulated Control 
group (CC) in order to obtain specific profiles.
Figure 3.2c shows the Z-scores of the several syndromes.
The results are displayed in Table 3.2 and Table 3.3. Significant higher prevalences of 
autism spectrum disorders (p=0.001), current major depressive disorder (p=0.043) and 
current OCD (p=0.033) were demonstrated in KS. The prevalence of psychosis was not 
significantly higher (p=0.066 for past episode), but a Mann-Whitney test of the psy-
chotic subscale showed significantly severe symptom scores for KS as well for current 
psychosis (p= 0.015) as well as in the past (p=0.005). Most strikingly, all KS-participants 
with a biological age above 15 years have (had) a psychosis. 
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psychosis (p= 0.015) as well as in the past (p=0.005). Most strikingly, all KS-participants 
with a biological age above 15 years have (had) a psychosis. 
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Secondly, results of the KdVS group were compared against all other participants, using 
a Fisher’s exact test for prevalence rates and a Kolmogorov-Smirnov test for the sever-
ity of symptoms. This resulted in significantly lower prevalence of lifetime depression 
(p=0.041) and current OCD (p=0.048). Severe levels of anxiety symptoms in the past 
(p=0.022) were demonstrated KdVS. For GS, exact the same procedure was followed, 
resulting in a significantly lower prevalence of ASD (p=0.005). After this, the same was 
done for MG, but no significant results were demonstrated for prevalence rates neither 
for symptom scores. This confirms our second hypothesis that mixing blurs the outcome.
Subsequently, all separate groups (KS, KdVS, GS and MG) were contrasted against 
each other. Prevalence rates were again compared by Fisher’s exact tests and resulted 
in discriminating prevalences for ASD (p=0.00) and current OCD (p=0.042). An overall 
Kruskal-Wallis test for symptom scores showed significant differences at the ADOS 
comparison scale (p=0.01) and at the psychotic symptoms (past) scale (p=0.033).
Our results enabled differentiation between the syndromes, which is visualized for 
psychiatric comorbidity in Figure 3.3 and further outlined hereafter.
Kleefstra Syndrome:
Participants with KS have a low level of adaptive functioning with a fairly uniform pat-
tern of functioning, except for socialization skills. This is in line with the autism scores, 
measured with the ADOS. All KS participants fit the diagnostic criteria for ASD and 
there is a significant difference in the prevalence of ASD in contrast to the control group 
as well as to the specific syndromes. KS-participants also show significant higher prev-
alence of current depressive episodes and OCD. Symptom scores for OCD (present and 
past) and psychosis (past) are significantly severe, resulting in a discriminating clinical 
picture: all KS subjects in this cohort suffer from ASD, are vulnerable to severe forms of 
OCD, depression and psychosis. In addition to this 100% of the patients above the age of 
18 show a decline in functioning, which was not reversible. This was preceded by severe 
sleep problems. The decline in functioning results in the absence of a linear relationship 
between biological age and adaptive functioning. Our hypothesis is that this regression is 
due to suffering from a(n) (unrecognized) psychotic episode. The prevalence of psychosis 
is about 10 times higher compared to the general ID population, where the prevalence 
is around 3% ( Tsakanikos & McCarthy, 2014) and also significantly higher compared to 
the contrast groups, with a prevalence of 4% in CC. It is important to highlight that none 
of the participants received an optimal treatment for this. So conclusively, we confirmed 
our first hypothesis: KS patients are extremely vulnerable to develop severe psychiatric 
disorders and should be carefully monitored for this. 
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Koolen-de Vries Syndrome (KdVS):
Patients with KdVS have a moderate level of functioning compared to the general 
population with an ID in the Netherlands. Obvious is the strength on socialization 
in the patients without autism (6/13). This was also observed by clinical observation. 
The KdVS cohort showed low prevalence of depressive disorders as well as OCD. 
The subscale scores of present anxiety symptoms were more severe, but not resulting 
in a higher prevalence of anxiety disorder. Based on clinical observation there is a 
suspicion of AD(H)D in the participants with this syndrome; they had a surplus of 
defocused attention, which made it difficult to focus attention and complete tasks. 
Table 3.2: Psychopathology prevalences
Autism 
Spectrum 
Disorder1
Major 
depressive 
Disorder2
Anxiety 
Disorder2 
(Hypo)mania2 Obsessive 
Compulsive 
Disorder 2
Psychosis2 Onspecified 
disorder2
Regression2a Sleep 
problems2a
 Kleefstra Syndrome (KS, n=24)
•	 present (%)
•	 past (%)
•	 22/23 (95,7%)* •	 4/24 (16,6%)*
•	 10/24(41,6%)*
•	 6/24(25%)
•	 11/24(45,8%)
•	 3/24(12,5%)
•	 7/24(29,2%)
•	 4/24 (16,6%)*
•	 8/24 (33,3%)*
•	 5/24 (20,8%)*
•	 7/24 (29,2%)*
•	 2/24 (8,3%)*
•	 9/24 (37,5%)*
•	 4/24 (16,6%)
•	 12/24 (50%)
•	 10/24 (41,6%)
•	 19/24 (79,2%)
Cumulative Control Group
(CC, n=34)
•	 present (%)
•	 past (%)
 
•	 17/34 (50%) •	 0/27 (0%)
•	 6/27 (22%)
•	 7/27 ( 26%)
•	 14/27 (52%)
•	 4/27 (15%)
•	 7/27 ( 26%)
•	 2/27 (7,5%)
•	 3/27 (11%)
•	 1/27 (4%)
•	 1/27 (4%)
•	 0/27 (0%)
•	 4/27 (15%)
•	 1/27 (4%)
•	 8/27 (30%)
•	 15/27 (56%)
•	 23/27 (85%)
KoolendeVries Syndrome (KdVS, 
n=13)
•	 present (%)
•	 past (%)
•	 7/13 (53,8%) •	 0/13 (0%)
•	 1/13 (7,7%)
•	 4/13 (30,8%)
•	 9/13 (69,2%)
•	 2/13 (15,3%)
•	 4/13 (30,8%)
•	 0/13 (0%)*
•	 1/13 (7,7%)*
•	 1/13 (7,7%)
•	 1/13 (7,7%)
•	 0/13 (0%)
•	 1/13 (7,7%)
•	 1/13(7,7%)
•	 4/13 (30,8%)
•	 7/13 (53,8%)
•	 9/13 (69,2%)
GATAD2B Syndrome (GS, n=6)
•	 present (%)
•	 past (%)
•	 1/6 (16,5%)* •	 0/6 (0%)
•	 3/6 (50%)
•	 2/6 (33,3%)
•	 3/6 (50%)
•	 0/6 (0%)
•	 1/6 (16,7%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 4/6 (66,7%)
•	 3/6 (50%)
•	 6/6 (100%)
Mixed Control Group (MG, n=15)
•	 present (%)
•	 past (%)
•	 9/15 (60%) •	 0/8 (0%)
•	 2/8 (25%)
•	 1/8 (12,5%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 0/8 (0%)
•	 0/8 (0%)
•	 0/8 (0%)
•	 3/8 (37,5%)
•	 0/8 (0%)
•	 0/8 (0%)
•	 5/8 (62,5%)
•	 8/8 (100%)
Total (n=58)
•	 present (%)
•	 past (%)
•	 39/57 (68,5%) •	 4/51 (7,8%)
•	 16/51 (31,3%)
•	 13/51 (25,5%)
•	 25/51 (49%)
•	 7/51 (13,7%)
•	 14/51 (27,4%)
•	 6/51 (11,8%)
•	 11/51 (21,6%)
•	 6/51 (11,8%)
•	 8/51 (15,7%)
•	 2/51 (3,9%)
•	 13/51 (25,5%)
•	 5/51 (9,8%)
•	 20/51 (39,2%)
•	 25/51 (49%)
•	 42/51 (82,4%)
1 Measured with the ADOS and presented as a life time prevalence, because ASD is a developmental disor-
der. A diagnosis was made, based on the comparison scores on the ADOS-2 with a cut-off of 5 and above. 
In the KS group, 1 of the participants was not able to complete the ADOS-2 module 1, due to aggression.
2 Measured with the mini PAS-ADD
2asymptom scales: Regression is measured in subdomain A of the mini PAS-ADD. A score of ≥2 is indicative 
for loss of functions (minimum score=0;maximum score=6) and is seen as regression in this cohort. Sleep 
problems are measured in the subdomains D (stopped sleeping in the night), E (problems falling a sleep) 
and F (early awaking <1 hour to normal or disturbed sleep in the night; question 11 and 12 of section F). A 
score of ≥1 is indicative for at least one of these. The scores are corrected for anhedonia (question 13), which 
is also measured in section F.
*Significant different prevalence (p<0.05).
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and F (early awaking <1 hour to normal or disturbed sleep in the night; question 11 and 12 of section F). A 
score of ≥1 is indicative for at least one of these. The scores are corrected for anhedonia (question 13), which 
is also measured in section F.
*Significant different prevalence (p<0.05).
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Table 3.2: Psychopathology prevalences
Autism 
Spectrum 
Disorder1
Major 
depressive 
Disorder2
Anxiety 
Disorder2 
(Hypo)mania2 Obsessive 
Compulsive 
Disorder 2
Psychosis2 Onspecified 
disorder2
Regression2a Sleep 
problems2a
 Kleefstra Syndrome (KS, n=24)
•	 present (%)
•	 past (%)
•	 22/23 (95,7%)* •	 4/24 (16,6%)*
•	 10/24(41,6%)*
•	 6/24(25%)
•	 11/24(45,8%)
•	 3/24(12,5%)
•	 7/24(29,2%)
•	 4/24 (16,6%)*
•	 8/24 (33,3%)*
•	 5/24 (20,8%)*
•	 7/24 (29,2%)*
•	 2/24 (8,3%)*
•	 9/24 (37,5%)*
•	 4/24 (16,6%)
•	 12/24 (50%)
•	 10/24 (41,6%)
•	 19/24 (79,2%)
Cumulative Control Group
(CC, n=34)
•	 present (%)
•	 past (%)
 
•	 17/34 (50%) •	 0/27 (0%)
•	 6/27 (22%)
•	 7/27 ( 26%)
•	 14/27 (52%)
•	 4/27 (15%)
•	 7/27 ( 26%)
•	 2/27 (7,5%)
•	 3/27 (11%)
•	 1/27 (4%)
•	 1/27 (4%)
•	 0/27 (0%)
•	 4/27 (15%)
•	 1/27 (4%)
•	 8/27 (30%)
•	 15/27 (56%)
•	 23/27 (85%)
KoolendeVries Syndrome (KdVS, 
n=13)
•	 present (%)
•	 past (%)
•	 7/13 (53,8%) •	 0/13 (0%)
•	 1/13 (7,7%)
•	 4/13 (30,8%)
•	 9/13 (69,2%)
•	 2/13 (15,3%)
•	 4/13 (30,8%)
•	 0/13 (0%)*
•	 1/13 (7,7%)*
•	 1/13 (7,7%)
•	 1/13 (7,7%)
•	 0/13 (0%)
•	 1/13 (7,7%)
•	 1/13(7,7%)
•	 4/13 (30,8%)
•	 7/13 (53,8%)
•	 9/13 (69,2%)
GATAD2B Syndrome (GS, n=6)
•	 present (%)
•	 past (%)
•	 1/6 (16,5%)* •	 0/6 (0%)
•	 3/6 (50%)
•	 2/6 (33,3%)
•	 3/6 (50%)
•	 0/6 (0%)
•	 1/6 (16,7%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 0/6 (0%)
•	 4/6 (66,7%)
•	 3/6 (50%)
•	 6/6 (100%)
Mixed Control Group (MG, n=15)
•	 present (%)
•	 past (%)
•	 9/15 (60%) •	 0/8 (0%)
•	 2/8 (25%)
•	 1/8 (12,5%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 2/8 (25%)
•	 0/8 (0%)
•	 0/8 (0%)
•	 0/8 (0%)
•	 3/8 (37,5%)
•	 0/8 (0%)
•	 0/8 (0%)
•	 5/8 (62,5%)
•	 8/8 (100%)
Total (n=58)
•	 present (%)
•	 past (%)
•	 39/57 (68,5%) •	 4/51 (7,8%)
•	 16/51 (31,3%)
•	 13/51 (25,5%)
•	 25/51 (49%)
•	 7/51 (13,7%)
•	 14/51 (27,4%)
•	 6/51 (11,8%)
•	 11/51 (21,6%)
•	 6/51 (11,8%)
•	 8/51 (15,7%)
•	 2/51 (3,9%)
•	 13/51 (25,5%)
•	 5/51 (9,8%)
•	 20/51 (39,2%)
•	 25/51 (49%)
•	 42/51 (82,4%)
1 Measured with the ADOS and presented as a life time prevalence, because ASD is a developmental disor-
der. A diagnosis was made, based on the comparison scores on the ADOS-2 with a cut-off of 5 and above. 
In the KS group, 1 of the participants was not able to complete the ADOS-2 module 1, due to aggression.
2 Measured with the mini PAS-ADD
2asymptom scales: Regression is measured in subdomain A of the mini PAS-ADD. A score of ≥2 is indicative 
for loss of functions (minimum score=0;maximum score=6) and is seen as regression in this cohort. Sleep 
problems are measured in the subdomains D (stopped sleeping in the night), E (problems falling a sleep) 
and F (early awaking <1 hour to normal or disturbed sleep in the night; question 11 and 12 of section F). A 
score of ≥1 is indicative for at least one of these. The scores are corrected for anhedonia (question 13), which 
is also measured in section F.
*Significant different prevalence (p<0.05).
GATAD2B-related Syndrome (GS):
Patients with GS have low levels of adaptive functioning with strength on social func-
tioning and weaknesses in communication skills. Problems with expressive language 
skills are evident, whereas the non-verbal communication is comparable to their 
overall level of functioning. This deficit in verbal capacity is sometimes mistaken as 
a symptom of autism. However, our cohort shows that ASD occurs significantly less 
often in GS. Sleep problems, mood and anxiety disorders are common in this syn-
drome, however, these prevalence rates were not significantly discriminating in this 
small group. Regression was also reported in 2/3 of the group and was temporary. How-
ever in some cases this regression stopped after psychiatric diagnosis and treatment. 
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drome, however, these prevalence rates were not significantly discriminating in this 
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Table 3.3: ADOS scores between groups
Group (n) ADOS2 
Comparison 
Score
range (min-max)
ADOS2 
Comparison 
Score
mean±SD
Clinical 
diagnosis *
(% of patients)
Kleefstra Syndrome 
(n=23)1
42-10 6,74 ± 1,60 22/23 (95,7%)2
Cumulated Control 
Group (n=34)
1-10 4,76 ± 2,38 17/34 (50%)
KoolendeVries 
Syndrome (n=13)
1-10 5,08 ± 2,53 7/13 (53,8%)
GATAD2B 
mutation (n=6)
1-8 3,17 ± 2,58 1/6 (16,7%)
Mixed Group (n=15) 1-8 5,13 ± 2,07 9/15 (60%)
Total (n=58) 1-10 5,56 ± 2,30 39/58 (67,2%)
•	 Clinical diagnosis is based on a ADOSscore of 5 and above together with an expert opinion. 
1 One drop-out because of severe aggression during ADOS. 
2 The participant with a comparison score of 4 was severely sedated and in the isolation room 
Mixed Control Group (MG):
The level of adaptive functioning in MG subjects was averaged and compared to the 
total population with an ID. Statistical analysis did not show differences in any of 
the domains. This confirms our hypothesis that mixing genetic subgroups blurs the 
clinical picture. 
The prevalence of ASD is comparable to prevalence rates mentioned in literature for 
people with an ID ( Tsakanikos & McCarthy, 2014). The prevalence rates for the remain-
ing categories can be overshadowed by the bisection of the participants, because half 
of them completed the mini PAS-ADD interview. The prevalence of psychosis deviates 
from the literature, even when taken into account that the prevalence for psychosis is 
already higher in patients with ID. 
Following our results, we propose clinical guidelines for management of psychiatric 
comorbidity of KS, KdVS and GS as summarized in table IV. These guidelines are 
based on current clinical guidelines, enhanced with our specific experiences.
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Figure 3.3: Comorbidity rates per syndrome 
At the Y-axis are the cumulative lifetime prevalences (expressed in percentages) for each of the psycho-
pathology categories. 
Adaptive and Maladaptive Functioning
59
Chapter 3
Figure 3.3: Comorbidity rates per syndrome 
At the Y-axis are the cumulative lifetime prevalences (expressed in percentages) for each of the psycho-
pathology categories. 
        
Chapter 3
60
Chapter 3
Discussion
In this paper we provide an overview of the profiles of adaptive and maladaptive 
functioning of the largest KS cohort studied so far, showing that these are markedly 
different from several other rare genetic disorders with ID. 
KS patients showed low levels of functioning and an abnormal course, characterized 
by sudden regression of functioning during adolescence. Adult patients suffered with-
out exception from severe and persistent regression. Interestingly, all patients who 
suffered from regression showed high symptom scores of psychosis, but this was not 
recognized in most of them and none of the patients received optimal antipsychotic 
treatment. In addition to this, there is a high prevalence of psychosis in KS. We hypoth-
esize that the sudden and persistent regression is an expression of a psychotic episode 
and needs to be treated likewise. In our KS-cohort, optimal treatment with antipsy-
chotic drugs was achieved at normal to high dosages of atypical antipsychotic drugs. 
Besides, an extremely high prevalence of ASD was found in KS as well as an extra 
vulnerability to develop OCD and increased levels of depressive episodes. The ques-
tion rises whether the depressive symptoms can be attributed to a comorbid mood 
disorder or are an expression of a psychosis as well (also known as ‘negative’ symp-
toms). Disentangling this can be complicated in patients with low levels of adaptive 
functioning. It can be questioned whether the observed OCD symptoms are related 
to an OCD sensu strictu or (at least partially) to the diagnosis of autism (stereotypies 
and restricted behaviors), depression, and/or psychosis. 
The analyses based on contrast groups enabled us to discuss associated features for 
both KdVS as well as GS. Participants with KdVS showed low rates of associated psy-
chopathology. They sometimes experience (severe) symptoms of anxiety, although 
this is usually not leading to a formal diagnosis of anxiety disorder. Perhaps, these 
symptoms might be a result of underlying problems with executive functioning. Fur-
ther neuropsychological testing is recommended for this. They may also be related to 
their level of adaptive functioning, since anxiety is a common phenomenon in infants/
preschoolers. 
Participants with GS in our sample were more vulnerable to mood and anxiety symp-
toms, when contrasting their profiles to those of the other disorders. However, this 
should be interpreted with caution, since the GS cohort represents only six partici-
pants and analysis of additional patients is required to confirm this observation. 
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Interestingly, the adaptive functioning of the CC group does not provide insight into 
the strengths and weaknesses of the different gene-related subgroups. This may imply 
that it may be more fruitful to classify the ID population into categories based on 
underlying genetic defect instead of IQ level. 
Additionally, the developmental pattern of adaptive functioning also varied between 
the different syndromes. This suggests that during life the level of adaptive function-
ing should be assessed periodically and in relation to maladaptive functioning. In 
the three syndromes, there was no linear relationship between aging and the level 
of adaptive functioning. Regression towards lower levels of functioning commonly 
occurs as well as stagnation of learning abilities. This regression may be due to 
lack of diagnosis and treatment of major psychiatric illness in people with ID, a 
phenomena that has been described for patients with mild intellectual disability 
(Kok, van der Waa, Klip, & Staal, 2016). It is important for (health) care, social goals 
and school functioning to figure out how these learning curves run for each of the 
syndromes. We suspect that prevention of over- and under stimulation results in 
lower rates of (secondary) psychopathology, less stress, a higher quality of life and 
also less health care costs. 
The prevalence of psychopathology in the total group matches the prevalence of psy-
chopathology in ID reported previously in literature (Borthwick-Duffy, 1994; Cooper, 
Smiley, Morrison, Williamson, & Allan, 2007; Dykens, 2000; Horovitz et al., 2011). 
Nevertheless, each syndrome shows its own pattern of adaptive as well as maladap-
tive functioning. We suggest specific target symptoms for diagnostic and treatment 
procedures for each syndrome in Table 3.4. The ADOS is discriminating in assessing 
autism features, even in the syndromes with the lowest levels of adaptive functioning 
and preverbal capacities. The ability of using comparison scores between the specific 
modules fits the need for personalized diagnostics within a research design. It is not 
always regarded as valuable to diagnose ASD in moderate to profound ID, because the 
approach and guidance for these patients already include some characteristics of the 
ASD methods: visualization with pictograms and a lot of daily routine for example. 
However, the approach and guidance are essentially different in ID with and without 
ASD regarding socialization (ASD patients need more stimulation and training in this) 
and limiting perseveration and stereotype interests and behavior. And last but not 
least, the range of comorbid psychopathology differs between these groups, further 
emphasizing syndrome specific guidance. 
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The strength of this study is the detailed measuring of psychopathology in the largest 
cohort of KS patients so far, and contrasting these to profiles of other rare genetic 
disorders with ID. Psychopathology and consequent maladaptive functioning have 
a direct impact on adaptive functioning. Knowledge about associated psychopathol-
ogy adds a specific focus to the existing literature about these genetic syndromes. In 
general behavioral problems are rarely specified in literature on genetic syndromes 
with ID, although they are one of the major problems for parents and caregivers to 
deal with in daily life. On the other hand, studies on psychopathology in ID focus 
on IQ-related groups, which are clinical heterogeneous. Stratification based on the 
genetic origin provides specific profiles for as well adaptive as well as maladaptive 
functioning compared to the ‘old fashioned ’classification by IQ level. This is urgently 
needed to personalize the treatment of psychopathology as well as the counseling for 
people with ID.
Table 3.4: Syndrome specific guidelines for treatment of psychopathology
Syndrome Target symptoms to be especially aware of in diagnostic procedures General guidelines for treatment of the target 
symptom*
Medication advise for severe cases**
KS •	 Autism
•	 Psychosis &Regression (preceded by sleep problems)
•	 Depressive Mood disorder
•	 Reduce stimuli, 
•	 Reduce stress, restore a normal sleep pattern 
(day-night rhythm) and immediate treatment 
with medication.
•	 Activation and in severe cases antidepressive 
medication.
•	 Low dosage of antipsychotics to reduce 
hypersensitivity.
•	 Antidepressive agents to reduce severe 
obsessive compulsive symptomsNormal 
to high dosages of atypical antipsychotics 
(preference for Olanzapine to restore sleep or 
Aripiprazole)
•	 antidepressive agents conform clinical 
guidelines for depressive episodes. 
KdVS •	 Anxiety
•	 ADHD
•	 Psychotherapeutic treatment procedures, 
including psychomotor therapy (social 
anxiety), EMDR (specific traumata) and 
musical therapy (generalized anxiety).
•	 Daily structure and routine. Reduction of 
stimuli during daytime.
•	 Not observed. Procedures conform clinical 
guidelines for anxiety disorders is advised .
•	 Stimulant agents conform clinical guidelines 
for ADHD.
GS •	 Problems with expressive language
•	 Sleep problems
•	 Anxiety and Mood disorders
•	 Regression
•	 Speech therapy to optimize non-verbal skills.
•	 Day night rhythm, routine going to bed.
Reduction of stimuli during daytime; 
including rest moments.
•	 Activation and psychotherapeutic 
intervention, including psychomotor therapy 
(social anxiety), EMDR (specific traumata) and 
musical therapy (generalized anxiety).
•	 Psychiatric consultation for further 
diagnostics. 
•	 none
•	 Low dosage of antipsychotics to reduce 
perceptual hypersensitivity. 
•	 Antidepressive agents conform clinical 
guidelines. 
•	 Dependent on underlying disorder.
*Observed, advised and effective in our patient population
** Observed, advised and effective in our patient population, always together with psychiatric consultation.
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One of the restrictions of this and any similar study on rare syndromes is that the sta-
tistical power is limited. Despite this, we were able to show significant differences at 
several domains, using proper statistical test. As such, the differences in neurocognitive 
profiles are not likely attributed to false positive results. Secondly, it remains difficult to 
use proper diagnostic procedures, which fit both the special needs of the total ID pop-
ulation as well as the specific individual symptoms and specific syndromes. However, 
the ID population pre-eminently needs personalized diagnostic procedures. A last 
limitation is the composition of the subscale (hypo)mania within the mini PAS-ADD, 
which includes several features overlapping the DSM-V classification of ADHD. We 
recommend an additional instrument for measuring ADHD (symptoms) in future 
studies. Furthermore, we recommend the use of the ADOS to discriminate autism 
features, even in the extremes of adaptive functioning. Future studies should include 
adapted neuropsychological tests in order to obtain a detailed neurocognitive profile 
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for each of the genetic syndromes, which relate cognitive measures to adaptive as well 
as maladaptive functioning. Other recommendations for future research include fol-
low-up of the participants over several years to examine the natural course of adaptive 
and maladaptive functioning and anticipate on proper intervention in case of evolving 
psychopathology. 
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Abstract
Background: Genetic mosaicism is only detected occasionally when there are no obvious health 
or developmental issues. Most cases concern healthy parents in whom mosaicism is identified 
upon targeted testing of a genetic defect that was initially detected in their children. A germline 
genetic defect affecting the EHMT1 gene causes Kleefstra syndrome, which is associated with the 
typical triad of distinct facial appearance, (childhood) hypotonia, and intellectual disability. A high 
degree of psychopathology is associated with this syndrome. A few parents with a mosaic EHMT1 
mutation have been detected upon testing after a child was diagnosed with a germline EHMT1 
defect. At first glance, carriers of a mosaic EHMT1 mutation appeared to function normally. How-
ever, recent studies have shown that de novo, postzygotic mutations in important developmental 
genes significantly contribute to autism spectrum disorder (ASD). Therefore, we hypothesized 
that EHMT1 mosaicism could cause neuropsychiatric defects. To investigate this, we performed a 
detailed investigation of cognitive neuropsychiatric parameters in parents identified with EHMT1 
mosaicism.
Methods: Three adults (two males, one female) with a genetically confirmed diagnosis of EHMT1 
mosaicism were examined by means of a battery of tests and observational instruments covering 
both neurocognitive and psychiatric features. The battery included the following instruments: the 
Autism Diagnostic Observation Schedule (ADOS), the mini Psychiatric Assessment Schedules 
for Adults with Developmental Disabilities (mini PAS-ADD), the Vineland Adaptive Behavior 
Scale (VABS) and the Cambridge Neuropsychological Test Automated Battery (CANTAB). These 
measures were compared with our previously reported data from Kleefstra syndrome patients 
with confirmed (germline) EHMT1 defects.
Results: All three subjects achieved maximum total scores on the VABS, indicative of adequate 
(adaptive) functioning. In all, scores above cut-off were found on the ADOS for ASD and on the 
mini PAS-ADD for major depressive disorder (lifetime). Finally, results on the CANTAB showed 
impaired cognitive flexibility in all subjects.
Conclusion: Individuals with EHMT1 mosaicism seem to have increased vulnerability for devel-
oping severe psychopathology, especially ASD and mood disorders. Although at first glance they 
appear to be well-adapted in their daily functioning, they may experience significant psychiatric 
symptoms and show reduced cognitive flexibility in comparison to the general population. 
Key words: Kleefstra syndrome, EHTM1, Mosaicism, Cognition, Autism spectrum disorder, Major 
depressive disorder
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Background
Kleefstra syndrome (KS; OMIM #610253) is caused by haploinsufficiency of the euchro-
matin histone methyltransferase 1 (EHMT1) gene located at chromosome 9q34.3. Almost 
all cases of KS are due to de novo microdeletions or intragenic loss-of-function muta-
tions in this gene(Kleefstra et al., 2006; Willemsen, Vulto-van Silfhout, et al., 2012). 
So far, no inherited cases have been reported, except for a few cases on the basis of 
parental mosaicism. Mosaicism for EHMT1 defects appears to be rare. At present, only 
four cases have been reported: three with a 9q34.3 microdeletion (Herve et al., 2015; 
Willemsen et al., 2011) and one with a splice-site mutation in EHMT1 (Rump et al., 2013). 
These carriers of a genetic EHMT1 mosaicism were reported to function normally in 
daily life. However, the focus of these reports was on the genetic and somatic features 
of the subjects. No data was presented on the possible psychopathology, which is the 
most pronounced comorbidity in patients with KS caused by a germline EHMT1 defect 
(Schmidt et al., 2016; Verhoeven et al., 2011; Vermeulen, de Boer, et al., 2017a; Vermeulen 
et al., 2015). 
The full KS phenotype is characterized by the core triad of intellectual disability (ID), 
(childhood) hypotonia, and distinct facial features. Additional clinical features include 
specific behavioral characteristics, heart and urogenital defects, epilepsy and over-
weight (Kleefstra et al., 2006; Kleefstra et al., 2009; Willemsen, Vulto-van Silfhout, et 
al., 2012). Recently, we studied the specific profile of behavioral characteristics in KS, 
which led us to conclude that KS patients are extremely vulnerable to developing 
severe psychiatric disorders. In our cohort, the prevalence of autism spectrum disorder 
(ASD) is nearly 100% (Vermeulen, de Boer, et al., 2017a). In addition, we found high 
prevalence of mood disorders and psychotic disorders. Moreover, patients above the 
age of 18 years in our cohort showed severe regression with a loss of at least 30-50% of 
their initial functioning (Kleefstra, Nillesen, & Yntema, 1993; Verhoeven et al., 2011; K. 
Vermeulen, de Boer, et al., 2017a). Interestingly, recent studies have shown that de novo 
postzygotic mutations (PZM) in important developmental genes contribute to ASD 
(Krupp et al., 2017; Lim et al, 2017). Based on this evidence, we set out to investigate the 
presence of psychopathology in the parents with an EHMT1 mosaicism. 
In this study, we examined three subjects with EHMT1 mosaicism for the presence 
of psychopathology. All three subjects are seemingly unaffected parents of children 
diagnosed with KS caused by a germline EHMT1 defect. We hypothesized that indi-
viduals with EHMT1 mosaicism are vulnerable to psychopathology, which may have 
significant clinical consequences.
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Methods
Participants
Subjects with EHMT1 mosaicism were invited by the department of Human Genet-
ics, Radboud university medical center, Nijmegen, the Netherlands, to participate in 
this study. Informed consent was obtained. The regional medical ethical committee 
(medical research ethics committee CMO/METC Arnhem-Nijmegen, the Nether-
lands) approved the study (NL43187.091.13), which was performed in full accordance 
with the Declaration of Helsinki.
Subject characteristics are summarized in Table 4.I. 
Mosaic pattern detection
In all three subjects the presence of mosaicism was detected upon carrier testing after 
the initial finding of a deletion in 9q34 by genome wide arrays in their respective 
children. Subsequent confirmation by fluorescent in situ hybridization (FISH) and/or 
multiplex ligation-dependent probe amplification (MLPA) in blood or in additional 
tissue was performed in all three subjects.
Instruments
The instruments that were used in this case study are briefly described below. More 
extensive details can be found in the study of Vermeulen et al. (Vermeulen, de Boer, 
et al., 2017a) where the instruments have been applied previously in a large cohort of 
patients with the full KS-phenotype.
The Autism Diagnostic Observation Schedule (ADOS) is a semi-structured observational 
method to assess autism features (Lord, Rutter, DiLavore, & Risi, 1999; Lord et al., 1989). 
It is performed by a certified psychologist or psychiatrist (in this cohort, the first author, 
K.V.) and consists of four modules, based on the (developmental) age and language 
capacity of the participant. Module 4 is designed for normal functioning adults and 
was used in the current study. A total cut-off score of 7 and above is suspect for an ASD. 
The Dutch version of the mini Psychiatric Assessment Schedules for Adults with Develop-
mental Disabilities (mini PAS-ADD) is a psychometrically adequate interview for the 
detection of psychiatric symptoms and disease in persons with developmental disabili-
ties (Janssen & Maes, 2013; Prosser et al., 1998). It consists of 86 items on a 4-point scale: 
0 (symptom not present) to 3 (symptom is severe). The interview is divided into seven 
subscales: Major depressive disorder (MDD), Anxiety, Obsessive-Compulsive disorder, 
Hypomania/Mania, Psychosis, Unspecified disorder and Autism. All criteria are based 
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on the International Classification of Diseases (ICD-10). In this study subjects were 
interviewed about themselves. 
The Dutch adaptation of the VABS ( Sparrow, Balla, & Cicchetti, 1984) is a widely used 
clinical interview, which determines the level of adaptive functioning. The age-equiv-
alent scores aid in classifying intellectual and developmental disabilities. The VABS 
consists of three domains: communication skills, daily living skills, and social skills. 
This instrument has good reliability and validity (de Bildt et al., 2005). In this study, 
the subjects were interviewed about themselves.
The Cambridge Neuropsychological Test Automated Battery (CANTAB) is a tablet-based 
neuropsychological test set comprising all major cognitive domains. Four subtests of 
the CANTAB were performed in the following sequence:
1. The Motor Screening Test (MOT) is a training procedure designed to introduce 
the subject to the tablet touchscreen. In our cohort, it is also an estimate to reac-
tivity, which could not be tested with an official reaction time test because of the 
complexity of the latter (pushing a button instead of the touchscreen during the 
task).
2. The Pattern Recognition Memory (PRM) is a test of visual pattern recognition 
memory in a two-alternative forced choice discrimination paradigm. These pat-
terns are designed in such a way so that they cannot easily be given verbal labels. 
This study presents the number of correct responses.
3. The Intra-Extra Dimensional Test Shift (IED) is a test of rule acquisition and 
reversal. Visual discrimination, cognitive flexibility and sustained attention are 
tested. This study presents: (1) total errors, a measure of the subject’s efficiency in 
attempting the test, and (2) the number of completed stages. 
4. Paired Associate Learning (PAL) assesses visual memory and new learning. It 
consists of eight stages. Each stage is composed of several trials, consisting of the 
first presentation of the shape(s) and followed by representation when the subject 
makes an error. The clinical mode terminates after ten repeat presentations. This 
study presents the total number of errors.
Procedure
Subjects were visited at home. After obtaining informed consent, the study procedure 
consisted of two clinical interviews with the subjects (VABS and, mini PAS-ADD), fol-
lowed by a semi-structured observation (ADOS) and the tablet-based neurocognitive 
tests (CANTAB). These procedures were performed by a certified psychiatrist (KV).
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Clinical reports
Subject 1 is a 44-year-old married male. He is a father of two children; the youngest 
son was diagnosed with KS. After finishing a higher professional education, he started 
working as a data engineer. He does not report social or communicative problems him-
self; meaningful social contacts are limited, even with family members and colleagues.
He had a normal development. His medical history includes an inguinal hernia and 
hydrocele in childhood, both of which were surgically corrected. The family history 
does not mention any medical or developmental problems. At physical examination 
no typical facial characteristics were observed.
Subject 2 is a 43-year old female, mother of two children, and her youngest daughter 
was diagnosed with KS. The somatic characteristics of subject 2 and her youngest 
daughter have been previously described, represented as family 2 (Willemsen et al., 
2011). At the age of 13 years, the subject emigrated from Morocco to the Netherlands. 
She experienced learning difficulties and did not finish high school. Besides running 
the household, she started working as a care assistant for elderly people. She was not 
able to take care of her own financial administration, because of learning difficulties. 
Her psychiatric history reported a MDD during pregnancy for which fluoxetin was 
prescribed. Further medical history mentioned three spontaneous abortions, psoriasis 
and nephritis. Additionally, she experiences sleep disturbances comprising apneas 
and frequent awakenings during the night. 
Her social network was limited to her family. She had no friends and experienced 
problems in initiating and maintaining contacts and conversations. Small talk was 
difficult for her. At the time of examination, she was divorced and not able to work 
due to mental health problems, consisting of problems in social reciprocity, reactive 
depressive complaints as well as overstimulation and burnout. 
At the time of our investigations, she experienced a second major depressive episode 
with psychotic features (imperative hallucinations and delusions). The imperative 
hallucinations had led to a suicide attempt. Her general practitioner was informed 
after our examination and intensive outreaching care was suggested based on our 
observation. Physical examination of this subject at the age of 43 years showed obesity 
and minor dysmorphic features as previously described, including a hypoplastic mid-
face, small upslanting palpebral fissures, a depressed nasal root and anteverted nares. 
Subject 3 is a 39-year-old male with three children: the second child was diagnosed 
with KS. There is no further family history of somatic or neuropsychiatric disorders. 
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After finishing primary school, he struggled to finish high school (practical education 
level) because of learning disabilities. He went through different jobs, but at the time 
of the current evaluation he was not able to work due to his impaired somatic and 
mental health. He lives an isolated life, together with his wife and children. Despite 
his social isolation, the patient did not experience any problems in social behavior.
His birth was complicated by a forceps delivery. The remaining medical history 
revealed atrial fibrillation, knee surgery, tonsillectomy, tympanostomy, mild audi-
tory and visual impairment. Pharmacotherapy started after the atrial fibrillation was 
diagnosed and comprised the following: metoprolol, acenocoumarol, simvastatin and 
perindopril. Physical examination at the age of 39 years showed obesity, an occipi-
to-frontal circumference of 59 cm (nearly +1 SD) and minor dysmorphic features 
including a hypoplastic midface and synophrys. 
Genetic analysis
Subject 1: After the detection of an intragenic EHMT1 deletion in the son by routine 
array analysis, we performed an MLPA (kit P340-A1, MRC-Holland, Amsterdam, The 
Netherlands) analysis to confirm the deletion in subject 1. We detected an intragenic 
deletion of exons 5-17 of EHMT1 in DNA from both blood lymphocytes and a buccal 
swab sample, with a mosaicism of 40%. In cultured fibroblasts the level of mosaicism 
was 15-20-% of cells carrying the deletion.
Subject 2: Results were presented in more detail in a previous study (Willemsen et al., 
2011). In summary, genome-wide array analysis on DNA from the daughter revealed 
an interstitial deletion of ∼200 kb in 9q34.3 encompassing at least the first five exons of 
the EHMT1 gene. Carrier testing by array in both parents showed that this deletion was 
inherited from subject 2 (the mother), but her array results showed a less pronounced 
loss, suggestive of mosaicism.
Interphase FISH analysis with two different FISH probes on a buccal swab sample 
from subject 2 showed the deletion in 80% of her cells (50-55 cells analyzed), indi-
cating that she is a mosaic carrier of the 9q34.3 deletion: .nuc ish del(9)(q34.3q34.3)
(RP11_417A4-)[37/55],(RP13_467E5-)[45/50].
Subject 3: After the detection of a 9q34.3 deletion in the son (arr [hg 19] 9q34.3(140350924 
140551108)x1), the array analysis on DNA from subject 3 suggested the presence of a 
mosaic deletion in 9q34.3. Subsequent FISH analyses on blood lymphocytes showed 
an abnormal signal pattern in 29 of 50 cells analyzed, suggesting 60% mosaicism: ish 
del(9)(q34.3q34.3)(RP11-48C7-)[29/50].
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Table 4.1: Genetic, psychopathological and neurocognitive subject characteristics of the subjects
Subject 1 Subject 2 Subject 3
Sex/age (years) Male/44 Female/43 Male/39
Genetic defect 
[EHMT1 mosaicism]
∼60 kb deletion exons 5-17 EHMT1
40% mosaicism in blood lymphocytes and buccal swab
∼200 kb deletion exons 1-5 EHMT1
80% mosaicism buccal swab
∼200 kb deletion exon 1 EHMT1
60% mosaicism blood lymphocytes 
VABS (maximum score)
Communication (134) 134 121 132
Daily living skills (184) 184 176 177
Socialization (132) 132 118 132
Raw score (450) 450 415 441
Mean developmental age in years >12 >12 >12
ADOS Module 4 (cut-off score)
Communication (2) 4 2 2
Social interaction (4) 7 10 9
Total score (7) 11 12 11
Classification Autism spectrum disorder Autism spectrum disorder Autism spectrum disorder
Mini PAS-ADD
Major depressive disorder Past Present and Past Present and Past
Anxiety disorder - Present and Past -
(Hypo)mania - - -
Obsessive compulsive disorder - Present and Past -
Psychosis - Present and Past -
Unspecified disorder - - -
Autism spectrum disorder - - -
CANTAB *
MOT mean latency 85-90% 40-45% 80-85%
MOT error 70-75% 95-100% 40-45% 
PRM 20-25% 0-5% 70-75%
IED error 30-35% 10-15% 10-15%
IED completed stages 15-20% 5-10% 10-15%
PAL 55-60% 0-5% 75-80%
* The percentages represent the subjects’ performance compared to the normative group.
E.g. a subject score of 10% means that 90% of the normative group has better scores on this item. 
Abbreviations: VABS Vineland Adaptive Behavior Scale, mini PAS-ADD Psychiatric Assessment 
Schedules for Adults with Developmental Disabilities, CANTAB, Cambridge Neuropsychological Test 
Automated Battery, MOT Motor Screening Test, PRM Pattern Recognition Memory, IED Intra-Extra 
Dimensional, PAL Paired Associate Learning
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Table 4.1: Genetic, psychopathological and neurocognitive subject characteristics of the subjects
Subject 1 Subject 2 Subject 3
Sex/age (years) Male/44 Female/43 Male/39
Genetic defect 
[EHMT1 mosaicism]
∼60 kb deletion exons 5-17 EHMT1
40% mosaicism in blood lymphocytes and buccal swab
∼200 kb deletion exons 1-5 EHMT1
80% mosaicism buccal swab
∼200 kb deletion exon 1 EHMT1
60% mosaicism blood lymphocytes 
VABS (maximum score)
Communication (134) 134 121 132
Daily living skills (184) 184 176 177
Socialization (132) 132 118 132
Raw score (450) 450 415 441
Mean developmental age in years >12 >12 >12
ADOS Module 4 (cut-off score)
Communication (2) 4 2 2
Social interaction (4) 7 10 9
Total score (7) 11 12 11
Classification Autism spectrum disorder Autism spectrum disorder Autism spectrum disorder
Mini PAS-ADD
Major depressive disorder Past Present and Past Present and Past
Anxiety disorder - Present and Past -
(Hypo)mania - - -
Obsessive compulsive disorder - Present and Past -
Psychosis - Present and Past -
Unspecified disorder - - -
Autism spectrum disorder - - -
CANTAB *
MOT mean latency 85-90% 40-45% 80-85%
MOT error 70-75% 95-100% 40-45% 
PRM 20-25% 0-5% 70-75%
IED error 30-35% 10-15% 10-15%
IED completed stages 15-20% 5-10% 10-15%
PAL 55-60% 0-5% 75-80%
* The percentages represent the subjects’ performance compared to the normative group.
E.g. a subject score of 10% means that 90% of the normative group has better scores on this item. 
Abbreviations: VABS Vineland Adaptive Behavior Scale, mini PAS-ADD Psychiatric Assessment 
Schedules for Adults with Developmental Disabilities, CANTAB, Cambridge Neuropsychological Test 
Automated Battery, MOT Motor Screening Test, PRM Pattern Recognition Memory, IED Intra-Extra 
Dimensional, PAL Paired Associate Learning
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Results
The genetic, psychopathological and neurocognitive characteristics are presented in 
Table 4.1.
Psychopathological and neurocognitive studies
The developmental age of all three mosaic carriers was twelve years or older. This 
maximum score on the clinical interview VABS is in line with the developmental age 
of the general population. Additionally, all subjects fulfilled the diagnostic criteria 
for ASD and MDD either currently and/or in the past. In contrast to the ADOS-2, the 
mini PAS-ADD did not formally determine ASD as the total subscale scores were just 
below the cut-off score. Notwithstanding, ASD items scored in the mini PAS-ADD 
were similar to the clinical observations of the ADOS. During the clinical observa-
tion, all participants scored on limited eye contact and minimum use of emotional 
gestures, when testing was focused on the communication. For social interaction, all 
three showed impaired social reciprocity, a limited range of facial expressed emotions, 
and an inadequate description of their role in social relations.
In addition to estimating the degree of psychopathology, we used the CANTAB to 
measure several cognitive functions of our subjects. The percentages represent the 
subjects’ performance compared to the normative group with the same sex and age. 
Subject 1 had low scores on the PRM and IED. Subject 2 had overall low scores on the 
tests. Subject 3 experienced problems with the IED. Detailed results are presented in 
Table 4.1; all IED scores were lower than 35% of the peer group, indicating an impaired 
mental flexibility in all three subjects. 
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Discussion
In this report we describe the consequences of EHMT1 mosaicism on psychopathology 
in three adult subjects. The three seemingly unaffected parents included in this study 
had been referred to the clinical genetics department only because of the diagnostic 
trajectory of each parent’s respective child. The discovery of EHMT1 mosaicism in 
these subjects was unexpected (Herve et al., 2015; Rump et al., 2013; Willemsen et al., 
2011). The degree of mosaicism that was measured in different tissues varied from 
15-40% (subject 1) to 80% (subject 2). It is difficult to predict the clinical consequences of 
mosaicism, as the patterns and distribution of abnormal cells can vary widely between 
different tissues, depending on the timing of the mutation events (De, 2011). Despite 
this predicted variation, all three subjects had an ASD, a (prior) MDD, and other asso-
ciated neurocognitive dysfunctions. Some symptoms that can be seen in patients with 
a germline EHMT1 mutation had a variable occurrence in the mosaic individuals. 
The results are indicative of a vulnerability to develop severe psychiatric disorders 
that carriers of an EHMT1 mosaic mutation possess. This correlates with the high 
prevalence of psychopathology, which has been reported for individuals with the full 
KS phenotype due to a germline EHMT1 mutation (Mitra, Dodge, Van Ness, Sokeye, & 
Van Ness, 2017; Verhoeven et al., 2011; Vermeulen, de Boer, et al., 2017a). Based on the 
ADOS test, all mosaic subjects met the criteria for ASD and all had a (prior) MDD. 
This is further corroborated by our findings on the CANTAB. All subjects showed 
weaknesses in performance on the IED, which is suggestive of cognitive inflexibility. 
This might be related to the set-shifting problems often seen in subjects with ASD, 
although findings on executive function deficits in adults with ASD were inconsistent 
(Chen et al., 2016). These deficiencies on the IED are on the continuum compared with 
a significant high dropout on the IED in our previous research on subjects with the full 
KS phenotype (unpublished data). Subject 3 had no other deviating scores compared 
to his norm group. Subject 1 showed performance problems on the PRM but we could 
not clearly link this to his clinical profile. Subject 2 had low scores on all tasks, most 
likely due to (a combination of ) her learning and mood problems. 
Psychopathology has a direct impact on adaptive functioning. The adaptive behavior 
measured with the VABS implies a developmental age above 12 years, consistent with 
adult functioning, for all of our subjects. Nevertheless, all three of them struggle to 
fulfill their role in society, most likely as a direct consequence of their neurodevel-
opmental problems. They became socially isolated and experienced difficulties in 
finding the right type of education and employment that would suit their strengths 
and weaknesses. Therefore, the clinical relevance for diagnosing these subjects with 
EHMT1 mosaicism and consequent neuropsychiatric assessment is significant. Opti-
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mal treatment of the psychopathology may improve daily functioning and positively 
influence the well-being of the individuals treated, their families, including the child 
with KS, as well as their participation in society. Based on our findings, personalized 
psychiatric evaluation and treatment should be considered for subjects diagnosed 
with EHMT1 mosaicism. The diagnostic procedure should include a special atten-
tion to ASD and mood disorders. Furthermore, these cases illustrate that presence 
of mosaic deletions could potentially be missed, since the genetic defects were only 
discovered during the diagnostic phase of the children with the full KS phenotype. 
None of the subjects had been referred to a medical specialist for their own psychiatric 
problems prior to our studies. These subjects tend to have a more subtle presentation 
but this can nevertheless cause impaired (social) functioning. Therefore, our study also 
demonstrates that genetic analysis should be considered in patients with a psychiatric 
disorder and other characteristics of KS without the classic appearance. 
Despite the similarities in psychopathology between our subjects, the consequences 
of mosaicism in general are widespread and unique for each individual (Cohen, 
Wilson, Trinh, & Ye, 2015). The phenotypic expression of somatic mosaicism has 
been investigated and reported in several studies including mosaic trisomy 21 (Down 
syndrome) and mosaic fragile X syndrome (Papavassiliou, Charalsawadi, Rafferty, & 
Jackson-Cook, 2015; Pretto et al., 2014). These studies show severe phenotypic expres-
sion, as well as somatic mosaicism without clinical consequences. The expression of 
the behavioral phenotype is also variable. In mosaic trisomy 21, for example, the social 
adaptive skills were significantly better in the subjects with a mosaicism compared to 
non-mosaic subjects with Down syndrome. However, the intellectual performance 
did not relate to the level of mosaicism (Papavassiliou et al., 2015). This necessitates 
interpretative caution, especially since we assessed the psychopathology of only three 
subjects with an EHMT1 mosaicism and each had different levels of mosaic expression. 
Interestingly, in recent studies it was shown that rare postzygotic mutations in import-
ant developmental genes contribute significantly to ASD (Krupp et al., 2017; Lim et 
al, 2017). Our present results obtained for three ASD subjects with such a rare mosaic 
defect in EHMT1 are in line with these reports. EHMT1 is an important developmental 
gene that is extremely intolerant to loss of function mutations (http://exac.broadin-
stitute.org )(Tachibana et al., 2005). Further clinical studies are warranted to provide 
more insight into the wide spectrum of the EHMT1 mosaicism, although the extremely 
low prevalence of such mosaic defects hampers the careful collection of symptoms 
in larger cohorts. For future research, we recommend to include more specific mea-
sures on IQ, ASD and mood disorders in subjects with an EHMT1 mosaicism. These 
measures should be in addition to a (semi)structured clinical observation as people 
with neurodevelopmental disorders, like ASD, are more likely to have deviating scores 
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on questionnaires (Havdahl et al., 2016; Vermeulen, Egger, et al., 2017). Thus, clinical 
interviews and observations should always be performed to gain a more comprehen-
sive and objective insight into the psychopathology.
Conclusion
Subjects with EHMT1 mosaicism seem vulnerable to developing psychiatric disor-
ders, especially ASD and mood disorders. However, since the behavioral outcome of 
mosaicism is unpredictable, these results should be interpreted with caution. Based 
on our findings in this small but unique cohort, we recommend screening subjects 
with an EHMT1 mosaicism for psychopathology. In our experience, multidisciplinary 
care, combining expertise in psychiatry, clinical genetics and clinical neuropsychology, 
is of additional value in these complex cases where a broad perspective is required. 
Ideally, a careful diagnostic assessment of psychopathology, cognition and physical 
health should be performed to provide an integrative diagnosis. Deficits in daily func-
tioning and behavioral problems may well be a result of an underlying genetic or 
otherwise somatic cause, which is often not clearly present. Clinical considerations 
should therefore include the possibility of a genetic mosaicism in parents who have 
one or more children with a neurodevelopmental disorder of genetic origin and a 
typical combination of complaints, as illustrated in this study.
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The context of symptom measures: 
interpretation and clinical diagnosis 
of autism spectrum disorders in 
intellectual disabilities
This chapter has been published as a letter to the editor:
Vermeulen K., Egger J.I.M., Janzing J.G.E., van Dongen L., van Bokhoven H. Kleefstra T., Staal W. 
(2017) The context of Symptom Measures: Interpretation and Clinical Diagnosis of Autism Spec-
trum Disorders in Intellectual Disabilities. [Journal of the American Academy of Child and Adolescent 
Psychiatry, vol. 56, (7) pp 618-619].
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To the Editor:
Last December, Havdahl et al. (Havdahl et al., 2016) highlighted the use of autism 
spectrum disorder (ASD) symptom measures in specific groups in their article enti-
tled “Multidimensional influences on autism symptom measures: implications for etiological 
research”. This is an important and timely topic, since public attention is generated for 
the increasing prevalence of ASD. Dr. Havdahl et al. carefully mapped which of the 
tested instruments is most sensitive to detect actual ASD symptoms and to distinguish 
these from other typical comorbid neurodevelopmental disorders, such as intellec-
tual disability (ID) and attention-deficit/hyperactivity disorder (ADHD). The Autism 
Diagnostic Observation Schedule – Second Edition (ADOS-2), proved most useful 
in this context. However, they argued that this instrument and others with similar 
measurement claims can not simply (our emphasis) be used in children with ID. In 
our experience, it is certainly possible to apply the ADOS-2 in intellectually disabled 
children and to differentiate the presence versus absence of ASD, provided the process 
of diagnostic decision making can be performed in an interdisciplinary way and with 
high levels of expertise in ID and ASD. We present data to support this notion. We 
systematically investigated 58 patients with ID and an etiologically involved monoge-
netic disorder for comorbid features of ASD. To measure ASD symptom scores, we 
used instruments comparable to those used by Havdahl et al., namely the ADOS-2 
(clinician observational assessment), in particular modules 1 to 3, the Child Behavior 
Checklist (CBCL; parent-based questionnaire), and the social communication ques-
tionnaire (SCQ; parent-based questionnaire). The ADOS-2 offers the opportunity to 
select a module based on the level of language skills and includes calibrated severity 
scores for different biological ages. In line with the study by Dr. Havdahl et al., we used 
a Vineland interview (Dutch adaptation: Vineland-Z) to assess adaptive functioning 
and to calculate participants’ developmental age. 
Unlike Dr. Havdahl et al., we included only participants with a rare to very rare mono-
genetic disorder (N=58, patient characteristics are presented in Table 5.1). 
The Pearson correlation coefficient was calculated between the calibrated severity 
scores of the ADOS-2 (in which biological age is contained) and level of adaptive func-
tioning (Vineland total score) overall was not significant (r= 0.043, p=0.750).
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Table 5.1: Characteristics of Participants
Total sample Male/Female, 
n (%)
Biological 
Age (y), 
Mean 
(SD; range)
Vineland 
Total Score, 
Mean 
(SD; range)
Developmental 
Age (mo), 
Mean 
(SD; range)
N=58* 28 males (48.3)/
30 females (51.7)
14.76 years 
(10.18; 3-40)
165.14 
( 91.23; 44-477)
36.84 months 
(27.91; 11-145)
Note: SD= standard deviation
*Monogenetic disorders: Kleefstra Syndrome (EHMT1 gene, n=24), KoolendeVries Syndrome (KANSL 
gene, n=13), GATAD2B related syndrome (n=6), extremely rare gene mutations in ANKRD11 (KBG syn-
drome, n=3) , SIN3a (n=3), PACS1 (n=2), AUTS gene mutation (n=1), FOXP2 mutation (n=1), microdeletions 
of 7q36.1 (n=1), 2p16.3 (FBOX17 gene, n=1)microduplication of 17q13.3 (YWHAE gene, n=1) and unknown 
results of whole exome sequencing with high clinical suspicion of genetic disorder (n=2)). 
The same calculation was made for the CBCL-pervasive developmental disorder 
(CBCL-PDD) subscale t score and Vineland total score and for the SCQ total score and 
Vineland total score. These latter 2 correlations were highly significant (CBCL-PDD: 
n=49, r= -0.492, p= .001; SCQ: n=44, r=-0.478, p=.001). Table 5.2 presents these results.
Consistent with Dr. Havdahl et al., we conclude that parent-rated ASD measures show 
a significant relation with the level of ID. Contrary to Dr. Havdahl et al., we argue that 
the ADOS-2 is very applicable for the diagnosis of ASD in patients with ID. Diagnosis 
involves the interpretation of clinical data from different sources in the context of the 
patient. Clinicians with extensive experience in ID and ASD are typically accustomed 
to doing this. Nonetheless, since the ADOS-2 is a widely used measure for ASD symp-
toms, we recommend the use of video training and the addition of clues to the manual 
to facilitate administration and interpretation of the results in patients with ID. This 
would help to avoid high rates of false positive and false negative findings of ASD in 
the ID population. 
Table 5.2: Correlations 
Test Informant/ Measurement Pearson correlation (r)
 to Vineland total score
P Value
ADOS-2 (n=57) Clinician/ observation r=0.043 .750
CBCL-pdd subscale (n=49) Parent/ questionnaire r=-0.494 < .001
SCQ (n=49) Parent/ questionnaire r=-0.518 < .001
Correlations of the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Child Behavior Check-
list (CBCL), and Social Communication Questionnaire (SCQ ) with Vineland total score in a sample of ID 
patients with etiologically involved monogenetic disorders (N=58) 
Note: Boldface type indicates statistical significance. PDD= pervasive developmental disorder. 
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Abstract
Specific knowledge on neurocognitive functioning in (syndrome based) intellectual disability 
(ID) is important for the assessment, treatment and support of patients in whom this condition is 
present. The present study investigates the applicability of computerized neurocognitive testing 
in patients with rare monogenetic ID disorders by (1) determining the developmental age at which 
the use is contributive and (2) investigating the specificity of the tests for neurocognitive functions, 
independent of the ID. 
A total of 56 patients with monogenetic ID disorders, including Kleefstra Syndrome (n=24), and 
a contrast group of various rare disorders (n= 32) participated. Assessments included (a) the 
Vineland Adaptive Behavior Scale (VABS) interview to calculate developmental age and (b) four 
simplified subtests of the Cambridge Neuropsychological Test Automated Battery (CANTAB). A 
cut-off in developmental age was estimated based on the ability to complete the CANTAB-tasks. 
A developmental age of 2,5 years and older allows practical application in our cohort. There was 
no significant correlation between developmental age and results on cognitive tests (range: -0,171 
≤ ρ ≤ 0,336 with p-values > 0,07). A between-group comparison shows a larger dropout in the KS 
sub cohort (based on cross tabulation) and longer latencies on the motor screening test.
Our results indicate that simplified CANTAB tasks are suitable for application in the ID popu-
lation to unravel individual neurocognitive characteristics and, hence also, syndrome specific 
neurocognitive features. Furthermore, successful employment of computerized testing in this 
complex population may be the only way to avoid the restraints of standard classificatory clinical 
procedures that aim at categories of patients rather than at the individual patient with its unique 
cognitive neuropsychiatric complexion. 
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Introduction
With recent advances in genetic techniques, people with intellectual disabilities (ID) 
are more often diagnosed with a genetic syndrome underlying their ID (DDD-study, 
2017; Gilissen et al., 2014; Vissers et al., 2016; M. Willemsen & T. Kleefstra, 2013). 
From a clinical perspective, in particular when challenging behaviors are present, 
it is not only important to have an estimate of a patient’s level of intellectual func-
tioning, but also to obtain full understanding of the neurocognitive functioning by 
including measures of attention, memory, executive functioning, and affective infor-
mation processing. Since these various cognitive-affective processes are essential 
for adequate daily functioning and can have a major impact on the quality of life, 
strengths and weaknesses thus identified are of utmost importance for the design 
and selection of targeted treatment (e.g., Egger, De Mey, & Janssen, 2007; Verhoeven 
& Egger, 2014). As a matter of fact, with the advance of genetic testing and the rise of 
novel defined syndromes, it is increasingly noticed that such profiles of neurocogni-
tive functioning are associated with specific genetic disorders (Egger, Zwanenburg, 
van Ravenswaaij-Arts, Kleefstra, & Verhoeven, 2016; Roelofs et al., 2015). Results on 
neuropsychological tests in more established genetic syndromes, such as Down syn-
drome, 22q11.2 deletion syndrome, Williams syndrome, Prader-Willi syndrome, and 
Noonan syndrome, showed potential to optimize daily guidance as well as to obtain 
objective measures for follow-up studies and therapeutic interventions (Edgin et 
al., 2010; Liogier d’Ardhuy et al., 2015; Rhodes, Riby, Park, Fraser, & Campbell, 2010; 
Roelofs, Janssen, Wingbermühle, Kessels, & Egger, 2016; van Nieuwpoort, Deijen, 
Curfs, & Drent, 2011; Wingbermühle et al., 2012).
While neurocognitive functioning has shown to be a well-established factor in the 
understanding of neurodevelopmental (genetic) disorders, there are specific complica-
tions that may arise when performing neurocognitive assessment in patients with ID. 
For instance, several tests rely on (verbal) instructions that require abilities in concep-
tual reasoning on average-and-above levels of intelligence. In addition, regarding the 
development of normative scores, patients with ID are not included and, consequently, 
differential performance in the low-IQ range may not reliably and validly detected. 
Furthermore, to address above issues, data are often obtained through indirect mea-
surement, for example with proxy ratings via interviews or questionnaires. Although 
these are invaluable sources of information, they may be less reliable due to specific 
biases in particular when applied within the ID population (Havdahl et al., 2016; Ver-
meulen, Egger, et al., 2017). All this often leaves the clinician relatively empty-handed, 
that is, with few possibilities to disentangle syndrome specific features from features 
caused by the level of ID and to build their interventions on the individual neurocog-
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nitive profile. Therefore, it is important to consider if and how neurocognitive tests, 
which were originally developed for the general population, can be applied in the ID 
population.
In this study, we aim to determine the applicability of computerized neurocognitive 
testing for diagnostic assessment and phenotyping of genetic syndromes. Specifically, 
we are interested in what level of functioning is required to perform such neurocog-
nitive tests and to what extent neurocognitive data are syndrome specific. Therefore, 
the use of 4 simplified tablet based neuropsychological tests from the widely used 
Cambridge Neuropsychological Test Automated Battery (CANTAB; (“CANTAB® [Cog-
nitive assessment software].”, 2017)) is investigated in patients with rare monogenetic 
disorders, with a main focus on Kleefstra Syndrome (KS, main clinical characteristics 
are listed in Table 6.1) (Kleefstra et al., 2006; Willemsen, Vulto-van Silfhout, et al., 
2012). The specific group of KS patients has been chosen because we can build upon 
our expertise with this syndrome, already inventoried knowledge about the clinical 
picture, both adaptive as well as maladaptive (summary in Table I). Furthermore, for 
a rare neurodevelopmental disorder, this cohort is relatively large (n= 24) and com-
prises, at the time of inclusion, all known patients in the Netherlands and Belgium 
(Vermeulen, de Boer, et al., 2017a).
In sum, the purpose of this study is fourfold, namely (1) to define at a group level (the 
“overall”-level) a cut-off value in developmental age for the meaningful application of 
these tests. In other words, we examine whether it is possible to disentangle the level 
of functioning from other cognitive characteristics (for example memory, cognitive 
flexibility and processing time) in a population with low general levels of functioning. 
Then, we want to establish at the inter-individual level (2) whether these tests provide 
additional information on neurocognitive functioning, incremental to the information 
already available from the lower general level of functioning. Consequently, (3) at 
this inter-individual level, we expect higher levels of dropout on these neuropsycho-
logical tests at lower levels of developmental age. And finally, we want to explore at 
the intra-individual level (4) if these tests provide additional information about the 
individual patient for personalized diagnosis and treatment and how this results in a 
personalized practice. Thus, across the overall, inter-individual, and intra-individual 
levels, four questions are examined to systematically map the additional value of these 
simplified computerized neuropsychological tests for application in the ID population 
with monogenetic disorders.
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Table 6.1: Background information on Kleefstra Syndrome
Genetic defect
Kleefstra et al., 
(2006)
Chromosomal microdeletion or intragenic EHMT1 mutation, both resulting in 
a similar clinical phenotype
Clinical characteristics, somatic and psychiatric comorbidity
Kleefstra et al., 
(2006); Willemsen 
et al., (2012); 
Verhoeven et al., 
(2011); Vermeulen 
et al., (2017a); 
Vermeulen et al., 
(2017b)
General: Trias ID, childhood hypotonia and prominent facial features
Somatic: Congenital heart abnormality, epilepsy, constipation
Psychiatric: Autism spectrum disorder, psychosis, apathy, major depressive 
disorder
Translational research in animal models
Kramer et al., 
(2011)
Mutant EHMT1 Drosophila melanogaster: Disturbed motor behavior, non-
associative learning and courtship complex memory 
Balemans et al., 
(2010)
EHMT1 knock-out mice: Problems with stimulus processing, high levels of 
anxiety, low levels of baseline activity, perseveration and deviation in social 
reactions to strangers
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Method
For a detailed description of the recruitment of patients and the psychometric prop-
erties of the Vineland Adaptive Behavior Scale (VABS), we refer to our previous study 
(Vermeulen, de Boer, et al., 2017a). 
Participants
A total of 56 patients were included: 24 with Kleefstra Syndrome (EHMT1 intragenic 
deletion or mutation) and 32 contrast participants with various monogenetic disorders. 
Patient characteristics and the monogenetic disorders are displayed in Table 6.2.
Informed consent was obtained by legal representatives and included in the patient 
file. The medical research ethics committee CMO/METC Arnhem-Nijmegen, the 
Netherlands, approved the study (NL43187.091.13), which was performed in full accor-
dance with the Declaration of Helsinki. 
Table 6.2: Patient Characteristics
Group Genetic Defect Male: female ratio 
(%)
Biological age: 
mean (SD; min-max) 
in years
Total 26: 30 15,00 (± 10,248; 3-40)
Kleefstra Syndrome, 
n= 24
EHMT1 gene
16x Microdeletions
8x Mutations
9:15 (37,5% vs 62,5%) 15,42 (±10,421; 3-37)
Contrast Group, 
n= 32
12x KANSL gene 
microdeletions
1x KANSL gene mutation
6x GATAD2B gene 
microdeltion
3x ANKRD11 gene 
mutation
3x SIN3A gene mutations
2x PACS1 gene mutations
1x FOXP2 gene mutation
1x FBOX17 gene 
microdeletion (2p16.3)
1x AUTS2 gene 
microdeletion (7q11.22)
1x YWHAE 
microduplication (17p13.3)
17:15 (53,1% vs 46,9%) 14,69 (± 10,272; 3-40)
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Instruments
Vineland Adaptive Behavior Scale. The Dutch adaptation of the Vineland Adaptive 
Behavior Scale (Sparrow, Balla, Cicchetti, 1984) is a widely used clinical interview, for 
determining the level of adaptive functioning (expressed in a developmental age) of 
people with an intellectual disability of three domains: communication skills, daily 
living skills, and social skills. Based on these, a total score is available. 
Cambridge Neuropsychological Test Automated Battery The Cambridge Neuropsy-
chological Test Automated Battery (CANTAB) consists of a computer administrated 
set of (nonverbal) neuropsychological tests developed to examine specific components 
of cognition. The CANTAB has been widely used in academic research and in clinical 
trials, and tests hold acceptable levels of concurrent validity and test–retest reliability 
(Lowe & Rabbitt, 1998). Subtests are graded in difficulty, minimizing floor and ceiling 
effects, and allow for use in a wide variety of ages and conditions. Participants are given 
multiple training trials to learn the requirements of each task, and detailed recording 
of responses is made possible by using a touch-sensitive screen.
From earlier research with CANTAB tasks in Down syndrome (Edgin et al., 2010), 
Edwards & Del Campo (Edwards & Del Campo, 2013) developed simplified versions 
of four CANTAB subtests that were applied in the present study. They are described 
below and were performed in the presented sequence
1.  The Motor Screening Test (MOT) is a training procedure designed to introduce 
the subject to the touch screen. In our cohort it also is an estimate to reactivity, 
which could not be tested with an official reaction time test, because of the com-
plexity of the latter (pushing a button instead of the touchscreen during the task). 
The simplified version is comparable to the normal clinical mode, but uses a high 
visibility mode.
2a. The Pattern Recognition Memory (PRM) is a test of visual pattern recognition 
memory in a 2-choice forced discrimination paradigm. These patterns are 
designed in a way that they can’t easily be given verbal labels. The simplified 
version has the same amount of patterns (12). Stage 1 is exactly comparable to 
the normal clinical mode. Stage 2 in the simplified version includes direct testing 
of the displayed patterns, followed by delayed testing of these patterns. In the 
normal clinical mode, stage 2 only includes displaying the patterns without direct 
testing, so without repeat. 
2b.  The delayed recognition phase in our cohort is administered 10 to 20 minutes 
after the initial one, depending on the duration of the IED test performance.
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3.  The Intra-ExtraDimensional Test Shift (IED) is a test of rule acquisition and 
reversal. Visual discrimination, cognitive flexibility and sustained attention are 
tested. The structure is the simplified task is similar to the clinical mode, with 
exception of the termination criterium. In the simplified version the test termi-
nates after 30 failing trials whereas the clinical mode terminates after 50 failing 
trials.
4.  Paired Associate Learning (PAL) assesses visual memory and new learning. The 
simplified version is largely/ mainly comparable to the clinical mode. It also con-
sists of 8 stages. The first 5 stages are similar between the simplified version and 
the clinical mode. In stage 6 the simplified version shows 4 patterns instead of 3 in 
the clinical mode. Stage 7 and 8 are comparable. (8 stages. Stage 1 → 1 pattern out 
of 6 boxes. Stage 2 → 1 pattern out of 6 boxes. Stage 3 → 2 patterns out of 6 boxes. 
Stage 4 → 2 patterns out of 6 boxes. Stage 5 → 3 patterns out of 6 boxes. Stage 6 → 3 
patterns out of 6 boxes. Stage 7 → 6 patterns out of 6 boxes. Stage 8à 8 patterns 
out of 8 boxes). Each stage is composed of several trials, consisting of the first pre-
sentation of the shape(s) and followed by representation when the subject makes 
an error. The simplified version terminates when 6 attempts are not successful, 
whereas the clinical mode terminates after 10 repeat presentations.
Procedures
Patients were tested in a familiar place to reduce risk on sub-optimal results, e.g. dis-
tortion by fear of the unknown. The investigation started with a VABS interview with 
the parents/ representatives to assess the followed by the simplified version of the 
CANTAB. All tests were performed in the vicinity of a proxy (parent, caregiver), who 
was completing questionnaires in the same or an adjacent (open) room. Further details 
on test procedures are described in detail in our previous report (Vermeulen, de Boer, 
et al., 2017b). Questionnaires and an additional interview with the parents as well as 
the play observation with the patient were part of a larger study on genes and behavior 
(study NL43187.091.13). 
Analyses
Statistical analyses were performed using IBM SPSS Statistics 22.
Three different levels of measurement were examined when processing the results, 
(1) Overall level. The overall performance of all participants was assessed by using 
cross tabulations to answer the question at what developmental age testing is useful. 
Thereafter, the role of developmental age for the total group on results was assessed by 
using bivariate correlations for each of the CANTAB subtests and the developmental 
age. (2) Inter-individual level: results between groups were compared. Distribution of 
the variables under research did not meet the normality-criterion, hence Mann-Whit-
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age. (2) Inter-individual level: results between groups were compared. Distribution of 
the variables under research did not meet the normality-criterion, hence Mann-Whit-
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ney U test was used to compare results of KS and contrast subjects. Finally, (3) at the 
intra-individual level, a profile of neurocognitive functioning was composed for each 
of the participants who were able to complete all tests. These profiles were inspected 
on strengths and weaknesses for the provision of clues for daily guidance and optimal 
functioning. 
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Results
Results are presented following the above-mentioned subdivision.
Overall 
The number of completed CANTAB-tests is displayed in Figure 6.1. Some subjects 
were not able to complete any of the tests. As can be deduced from Figure 1, in our 
cohort, MOT can be properly accomplished from a developmental age of 2 years (cut-
off ≥ 22 months) while PRM can be completed from a developmental age of 2.5 years 
(cut-off ≥ 31 months). The results for IED and PAL are less clear: at a developmental 
age of 2.5 years and older, however, most subjects were able to complete the tests, with 
completing percentages of 79,2% for IED and 70,8% for PAL.
None of the subtests showed a significant correlation between developmental age and 
test performance. P-values for correlation of the several subtests between developmen-
tal age and test results are displayed in Table 6.3.
Table 6.3: p-values for correlation between subtest results and developmental age
Subtest Pearson’s correlation 
coefficient
P-value
MOT mean latency -0.171 0.268
PRM numbers correct 0.336 0.070
PRM scoring difference between direct and delayed recall -0.17 0.932
IED stages completed -0.052 0.829
PAL stages completed 0.256 0.306
Inter-individual factors: 
Performance, expressed in completion rate, between KS and the contrast group was 
compared. Differences between the groups were calculated by cross tabulations for 
the several subtests of the CANTAB. The results are displayed in Table 6.4 and show 
a large drop-out in the KS group for all subtests. Interestingly, the KS patients with a 
younger biological age are more often able to complete the tests.
The crosstabulations show for all tests a significant (**) higher drop-out than expected 
by chance.
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Table 6.4: Crosstabulations of simplified CANTAB tasks
MOT KS Contrast group
Completed 17 30
Expected 20,1 26,9
Pearson X2, Monte Carlo 2-zijdig= 0,048**
PRM 1st trial KS Contrast group
Completed 8 24
Expected 13,7 18,3
Pearson X2, Monte Carlo 2-zijdig= 0,004**
PRM delayed KS Contrast group
Completed 6 24
Expected 12,9 17,1
Pearson X2, Monte Carlo 2-zijdig=0,001**
IED KS Contrast group
Completed 1 19
Expected 8,6 11,4
Pearson X2, Monte Carlo 2-zijdig= 0,00**
PAL KS Contrast group
Completed 1 17
Expected 7,7 10,3
Pearson X2, Monte Carlo 2-zijdig= 0,001**
After this, the results of the completed tests of KS subjects and subjects in the con-
trast group were compared. For the CANTAB subtests, only MOT was completed by 
enough subjects to compare results. Non-parametric testing on MOT latency (only 
in subjects who completed the test), using a Mann Whitney U test, shows a signif-
icant result between the groups on median latency (p < .05). Patients with KS had 
longer latencies compared to the contrast group. The mean latency was not significant 
(p=0.74) most probably due to the large variance in the contrast group. 
Intra-individual factors:
Finally, we looked at intra individual results. In Box 1, by means of three case examples, 
the relation between individual test results and treatment advice is described in detail. 
In a number of patients with KS, the slow latency time was not taken into account in 
daily living tasks (for example at school). Adjustments like giving a person more time 
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to perform a task and stimulating activities, lead to a more optimal daily guidance. 
Other examples include the optimal benefit taking of the attention span (which could 
be measured exactly during test performance) for school tasks and the lowering the 
level of anxiety by providing more external structure and overview. 
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Figure 6.1: Performance on CANTAB tasks
Figure 1: Performance on the CANTAB. For the range of developmental age (displayed in categories 
on the X-axis) the number of participants who completed (blue) vs not completed (red) the tests are 
displayed on the Y-axis. The results for 4 simplified subtests of the CANTAB are displayed in each cat-
egorie on the X-axis: MOT= motor screening test. PRM= pattern recognition memory. IED= intra-extra 
dimensional test shift. PAL= paired associated learning. 
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Box 1: case descriptions
Subject X is a 30 years old female, who completed all 4 simplified CANTAB tasks.
Results: She showed remarkable accuracy in her performance and reduced latency times for all tests, com-
pared to her results. Direct recall was present for simple stimuli. However, direct recall of more complex 
stimuli and visual memory were impaired. Switching between paradigms was too complex for her. She was 
able to complete all tests, but with continuation of test administration, she showed problems with sustained 
attention and her latency time reduced even more. 
Advice: The high level of accuracy in combination with her reduced latencies point out the importance of 
having enough time to complete tasks. In other words, based on her output, her environment will easily 
ask too much from her, leading to overstimulation. We advice to give her extra time to complete daily living 
tasks, like getting dressed in the morning.
Based on the problems with switching, her cognitive flexibility will be low. She needs help for this by making 
daily life more predictable. For example with a visualized (part-time) day program. Tasks that are offered, 
should ask a maximum of 15 minutes effort from her, due to her limited attention span. Ideally, these are 
interspersed with moments of rest. 
Subject Y is a 5,5 years old girl, diagnosed with a microdeletion at chromosome 17q21.31 resulting in 
Koolen-deVries syndrome. She was able to complete all 4 subtests and was keen in managing the tablet. 
Results: This girl scored at the norm for biological age for speed of processing and accuracy at simple tasks. In 
the more complex tasks (after some patterns of the PRM and the complete IED and PAL) she showed a worse 
performance at learning ability, cognitive flexibility and memory. She took advantage of repeated practice.
Advice: It was advised to help this girl with external structure and overview as well as repetition of daily 
tasks. External help was also advised to practice skills in new situations. Her level of anxiety declined 
after the help was more focused on training and providing help rather than on taking things over. Her 
self-esteem increased. 
Subject Z is a 8 year old boy, diagnosed with a ANKRD11 mutation (KBG Syndrome). He was able to 
complete all 4 tasks with some positive feedback (“wow, you already finished 3 tests, just one left!)”.
Results: He had norm scores, adequate for biological age, on the visual memory tasks, but during the test 
performance, his attention span declined. For this reason the results on the last memory task (visuospatial 
memory) was poor. His speed of processing was high, but this was at the expense of his accuracy. The 
performance on task switching was at the lower end of the norm for his biological age. 
Advice: It was advised to provide short, concrete/actual instruction before starting a new task and sub-
stantiate this with a visual clue. Independent task performance at school was adapted to his attention span 
and after 5-10 minutes another visual clue together with positive feedback was given (“well done!”) to help 
him sustain attention. External help and extra tasks on accuracy were provided to practice and these were 
planned at the start of a school day, when his attention was best. 
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Discussion
In this study, we set out to determine the applicability of computerized neurocog-
nitive testing in patients with moderate to profound ID, using simplified test of the 
CANTAB. Also, we wanted to study whether neurocognitive data may have specific 
characteristics in different genetic syndromes. Firstly, our results indicate, on overall 
level of performance, that computerized neurocognitive testing with the simplified 
subtests of the CANTAB can be successfully applied in subjects with a moderate to 
severe ID and some tests even in profound ID. Previously, some computerized neu-
rocognitive tests were successfully applied in Down Syndrome (Edgin et al., 2010; 
Liogier d’Ardhuy et al., 2015) and Williams Syndrome (Rhodes et al., 2010), but in both 
groups, the level of ID is less pronounced with a main focus on borderline, mild and 
moderate ID. However, to the best of our knowledge, the current simplified versions 
of the four CANTAB subtests have never been tested before in the ID population. 
This may provide opportunities to collect data in different countries, since the tests 
are independent of language.
Secondly, on inter-individual level, our results indicate that there is no significant 
relation between subtest-performance and the level of functioning. In continuation 
of this, it turned out that the KS group had a lower performance rate and a longer 
median latency. This was consistent with our observations that subjects with KS 
needed much more time for action and reaction and were easily over stimulated. 
Because of high levels of defocused attention, it was often not possible to complete 
IED and PAL for which sustained attention is needed. Their latency results on the 
MOT subtest, expressed in milliseconds, was even longer than had been estimated on 
the basis of observation and clinical impression. Translating this to daily guidance, the 
speed of talking, providing instructions and waiting for responses should be lowered 
significantly in this group of patients. Whether the prolonged MOT-latency time and 
the high dropout on the other subtests may be associated with the clinical presence 
of ASD in subjects with KS (Edgin et al., 2010; Schmidt et al., 2016; Vermeulen, de 
Boer, et al., 2017a) remains to be seen. Literature on ASD often mentions impairments 
in executive functioning (Chen et al., 2016; de Vries & Geurts, 2015; Hill, 2004; Van 
Eylen, Boets, Steyaert, Wagemans, & Noens, 2015), which seems in agreement with 
the large dropout in our KS-cohort on the IED. Most literature regarding the use of 
CANTAB tests in neurodevelopmental disorders, however, do not mention the scores 
on the MOT, because this is only the first step to make participants familiar with the 
CANTAB. Nevertheless, the results of this subtest provide important information. 
Because of the large dropout, it was not possible to compare our results to those of 
EHMT animal models (Benevento et al., 2017). Nor could we relate our results to pre-
Chapter 6
102
Chapter 6
Discussion
In this study, we set out to determine the applicability of computerized neurocog-
nitive testing in patients with moderate to profound ID, using simplified test of the 
CANTAB. Also, we wanted to study whether neurocognitive data may have specific 
characteristics in different genetic syndromes. Firstly, our results indicate, on overall 
level of performance, that computerized neurocognitive testing with the simplified 
subtests of the CANTAB can be successfully applied in subjects with a moderate to 
severe ID and some tests even in profound ID. Previously, some computerized neu-
rocognitive tests were successfully applied in Down Syndrome (Edgin et al., 2010; 
Liogier d’Ardhuy et al., 2015) and Williams Syndrome (Rhodes et al., 2010), but in both 
groups, the level of ID is less pronounced with a main focus on borderline, mild and 
moderate ID. However, to the best of our knowledge, the current simplified versions 
of the four CANTAB subtests have never been tested before in the ID population. 
This may provide opportunities to collect data in different countries, since the tests 
are independent of language.
Secondly, on inter-individual level, our results indicate that there is no significant 
relation between subtest-performance and the level of functioning. In continuation 
of this, it turned out that the KS group had a lower performance rate and a longer 
median latency. This was consistent with our observations that subjects with KS 
needed much more time for action and reaction and were easily over stimulated. 
Because of high levels of defocused attention, it was often not possible to complete 
IED and PAL for which sustained attention is needed. Their latency results on the 
MOT subtest, expressed in milliseconds, was even longer than had been estimated on 
the basis of observation and clinical impression. Translating this to daily guidance, the 
speed of talking, providing instructions and waiting for responses should be lowered 
significantly in this group of patients. Whether the prolonged MOT-latency time and 
the high dropout on the other subtests may be associated with the clinical presence 
of ASD in subjects with KS (Edgin et al., 2010; Schmidt et al., 2016; Vermeulen, de 
Boer, et al., 2017a) remains to be seen. Literature on ASD often mentions impairments 
in executive functioning (Chen et al., 2016; de Vries & Geurts, 2015; Hill, 2004; Van 
Eylen, Boets, Steyaert, Wagemans, & Noens, 2015), which seems in agreement with 
the large dropout in our KS-cohort on the IED. Most literature regarding the use of 
CANTAB tests in neurodevelopmental disorders, however, do not mention the scores 
on the MOT, because this is only the first step to make participants familiar with the 
CANTAB. Nevertheless, the results of this subtest provide important information. 
Because of the large dropout, it was not possible to compare our results to those of 
EHMT animal models (Benevento et al., 2017). Nor could we relate our results to pre-
        
Computerized Neurocognitive Assessment
103
Chapter 6
vious research in Down Syndrome (Edgin et al., 2010; Liogier d’Ardhuy et al., 2015) 
or Williams syndrome (Rhodes et al., 2010). The patients with a younger biological 
age showed plenty of practice operating the touchscreen compared to the older ones. 
This might be due to the spirit of the times, in which the younger ones grew up with 
regular exposure to touchscreens, e.g. of smartphones and tablets. 
Finally, on intra-individual level, it was possible to point out strengths and weaknesses 
of the subject, based on test results and systematic observation associated with test 
administration. Based on these, specific targets can be formulated for individualized 
treatment and daily guidance. In our cohort, in several cases, this turned out to be 
useful in providing directions for stimulating the development and breaking through 
problem behaviors and/ or psychiatric symptoms. Although the advices were not new 
(slowing down speed of processing, providing external structure and overview), the 
CANTAB was helpful in the precise tailoring of the advices to the subject’s needs 
and in particular, in matching the timing of help to the needs. This appeared to be 
specifically useful for (specialized) schools and day care centers but also for guidance 
at home. 
A possible weakness of this study is the relatively small number of participants. This 
study nonetheless shows that with proper assessment tools, a more personalized treat-
ment and guidance of people with moderate to severe ID is to some extent feasible. 
Previous work in Noonan Syndrome has also shown this to be the case (Roelofs et 
al., 2015; Roelofs et al., 2016). Those who work with people with moderate to severe 
ID should be aware of this and make efforts to provide adequate neurocognitive 
assessment for their patients. The focus is often on controlling disruptive behavior, 
rather than focusing on neurocognitive characteristic’s that could provide insight in 
capacities and limitations of a patient. Furthermore it provides opportunities to col-
lect and combine data on genetic syndromes in different countries, since these tests 
are independent of language. This is an important aspect for future research and 
the field should built international networks for exchanging data of relatively rare 
genetic neuropsychiatric disorders and make an effort to develop standardized tests to 
achieve good standard scores. Ideally, for adequate neurocognitive testing, an observa-
tion schedule should be developed, to standardize observations during computerized 
test performance. This is important because not only performance results, but also 
behavioral aspects during performance give clues about strengths and weaknesses 
of the subject. 
In sum, the use of computerized neurocognitive assessment provides the opportunity 
to collect objective measures in a population where it is often difficult to get direct 
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information of the subjects themselves. We suggest that a first step could be to enhance 
of the accessibility of the CANTAB-tests for the ID population. An advantage of the 
simplified versions is that verbal instruction is hardly necessary. The principle of Com-
puterized Adaptive Testing (CAT), in which test administration can be specifically 
adjusted to the abilities of the subjects, should be applied in this population. The CAT 
method has its theoretical roots in multidimensional assessment of personality, and 
allows to leave fixed algorithms for test-items, adjust the items more specific to the 
test-subject (Segall, 1996). According tot Wang et al, 2012, the application of CAT in the 
neurocognitive domain holds the promise of more accurate measurement of intra-in-
dividual diagnostic factors. It therefore may be an important tool for tailored treatment 
and treatment monitoring. The latter may hold in particular for the objective observa-
tion of the natural course of genetic disorder, not only to establish cognitive decline, 
but also to monitor and clarify putative treatment effects in the ID population. 
In all, we recommend the use of the simplified CANTAB versions in neurocognitive 
assessments in the ID population. The results of these tests are helpful in diagnostic 
procedures, formulating personalized treatment and guidance as well as to enhance 
specific knowledge about genetic syndromes. 
Chapter 6
104
Chapter 6
information of the subjects themselves. We suggest that a first step could be to enhance 
of the accessibility of the CANTAB-tests for the ID population. An advantage of the 
simplified versions is that verbal instruction is hardly necessary. The principle of Com-
puterized Adaptive Testing (CAT), in which test administration can be specifically 
adjusted to the abilities of the subjects, should be applied in this population. The CAT 
method has its theoretical roots in multidimensional assessment of personality, and 
allows to leave fixed algorithms for test-items, adjust the items more specific to the 
test-subject (Segall, 1996). According tot Wang et al, 2012, the application of CAT in the 
neurocognitive domain holds the promise of more accurate measurement of intra-in-
dividual diagnostic factors. It therefore may be an important tool for tailored treatment 
and treatment monitoring. The latter may hold in particular for the objective observa-
tion of the natural course of genetic disorder, not only to establish cognitive decline, 
but also to monitor and clarify putative treatment effects in the ID population. 
In all, we recommend the use of the simplified CANTAB versions in neurocognitive 
assessments in the ID population. The results of these tests are helpful in diagnostic 
procedures, formulating personalized treatment and guidance as well as to enhance 
specific knowledge about genetic syndromes. 
        
        
        
Part 3
Management of disease outcomes
Part 3
Management of disease outcomes
        
        
7
Sleep disturbance as a precursor of 
severe regression in Kleefstra syndrome 
suggests a need for firm and rapid 
pharmacological treatment
This chapter has been published as:
Vermeulen K., Staal W.G., Janzing J.G., van Bokhoven H., Egger J.I.M., Kleefstra T., (2017) Sleep 
Disturbance as a Precursor of Severe Regression in Kleefstra Syndrome suggests a Need for Firm 
and Rapid Pharmacological Treatment. [Clinical Neuropharmacology, vol 40 (4) pp 185-188]
7
Sleep disturbance as a precursor of 
severe regression in Kleefstra syndrome 
suggests a need for firm and rapid 
pharmacological treatment
This chapter has been published as:
Vermeulen K., Staal W.G., Janzing J.G., van Bokhoven H., Egger J.I.M., Kleefstra T., (2017) Sleep 
Disturbance as a Precursor of Severe Regression in Kleefstra Syndrome suggests a Need for Firm 
and Rapid Pharmacological Treatment. [Clinical Neuropharmacology, vol 40 (4) pp 185-188]
        
Chapter 7
110
Chapter 7
Abstract:
Intellectual disability (ID) is frequently accompanied by psychiatric symptoms that require phar-
macological interventions. Treatment guidelines often provide a general treatment approach for 
these symptoms in intellectual disabilities. However, this may not always be the best strategy, 
as illustrated here in Kleefstra syndrome. We present 3 patients showing severe regression after 
sleep disturbances. If these are treated with care as usual (e.g. behavioral programs and sleep 
medication) deterioration is likely to follow. It is observed that rapid treatment with relatively 
high dosages of antipsychotics contributes to restore sleep, halt further regression and improve 
daily life functioning.
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Kleefstra Syndrome, EHMT1 gene, Antipsychotics, Psychotic disorders, Treatment
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Introduction
Intellectual disability (ID) is present in a heterogeneous group of clinical conditions, 
with etiologies ranging from genetic disorders to infectious diseases (Salvador-Carulla 
et al., 2011) and is frequently accompanied by psychiatric symptoms. In terms of 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition comorbidity, prev-
alence studies have estimated that approximately 38.6% of children with a full scale 
IQ between 30 and 80 are fulfilling criteria for additional diagnostic classifications 
(Dekker & Koot, 2003); in which case, often pharmacological treatment is started. 
Because of an increased prevalence of adverse effects from medication, treatment is 
often initiated with a low dosage and a gradual titration towards a therapeutic effect 
(Handen, Feldman, Lurier, & Murray, 1999; Zarcone et al., 2001). We noticed disad-
vantages of this “start low and go slow” approach in several patients with Kleefstra 
Syndrome (KS), who were systematically investigated in a large cohort in the Neth-
erlands and Belgium (Table 7.1: Neuropsychiatric Characteristics of the KS population).
Kleefstra syndrome, formerly known as the 9q34 microdeletion syndrome, is a rare 
genetic syndrome caused by haploinsufficiency of the euchromatin histone methyl-
transferase-1 gene (EHMT1) due to either heterozygous microdeletions or intragenic 
mutations (Stewart & Kleefstra, 2007). The EHMT1 haploinsufficiency is also associ-
ated with some cases of schizophrenia (Kirov et al., 2012). The corresponding protein 
EHMT1 is capable to catalyze the dimethylation of histone H3 at lysine 9, a posttrans-
lational modification associated with transcriptional repression (Shinkai & Tachibana, 
2011). Interestingly, our group recently showed that Histone H3 at lysine 9 is dynam-
ically altered during synaptic scaling and that EHMT1 is required for homeostatic 
synaptic scaling up (Benevento et al., 2016).
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Table 7.1: Neuropsychiatric Characteristics of the KS populationa including described cases. 
N=24, cohort patients with Kleefstra Syndrome in the Netherlands and Belgium
Genetic Defect: microdeletion versus intragenic mutation 15 (62,5%)/ 9 (37,5%)
Mean biological age 15,42 years (range 3-37 years)
Mean developmental age 23, 75 months (range 11-82 months)
Male/female ratio (%) 9/15 (37,5/62,5%)
Autism Spectrum Disorderb 22/23b
Number of patients aged ≥18 yearsc 8/24, (1 male; 7 females/ 4 microdeletion; 4 intragenic mutation).
Sleep Disturbances during/after adolescence 8/8
Regression during/ after adolescence d 8/8
Summary of clinical features
Case 1 Case 2 Case 3
 Sexe/ Age
Genetic defect
Female, 15
EHMT1 mutation
c.3072_3073del
(p.Val1026fs)
Female, 23 
46,XX.ishdel(9)(q34.3)
Female, 23 
0.5 Mb deletion (140,67-141,12)
Current psychiatric diagnosis Bipolar I Disorder, manic episode Major Depressive Episode with psychotic features Psychotic disorder, not otherwise specified (NOS) 
Effective pharmacological intervention Olanzapine additional to Valproic acid Aripiprazole 15 mg daily Clozapine, 50 mg daily
Medical History Perinatal complications  
Regurgitation
Developmental delay
Mild hearing and visual difficulties
Irregular periods  
Extreme constipation
polydipsia- and poly-uria
Developmental delay  
Constipation  
Irregular periods
Pulmonal surgery
Recurrent upper airway infections
Developmental delay
Hypertension
Constipation
Behavioral problems during (irregular) periods.
Psychiatric History ASD, ADHD
Mood disorder
ASD ASD symptoms
Somatic medication Desmopressine  
Macrogol
Provera Macrogol
Oral anticonception
Regression:  lost skills Talking 
 toilet trainedness
Talking in sentences  
Simple reading and writing
Dressing and personal hygiene
Talking
Dressing
Swimming
Toilet trainedness
Decency
% Decline in developmental agee 29% 37% 54%
Absolute reduction of VABSf score 49 points 45 points 96 points
a Based on the population KS patients in the Netherlands and Belgium (n=24)  b  Based on the ADOS2,. 
The total score of 1 subject was below the ‘high suspicion cut-off’ due to severe sedation, which made it 
impossible to evaluate several key items of the ADOS2. Another subject dropped out, because he became 
to aggressive to complete the ADOS2 schedule.
c Note: not all the participants completed their puberty at this age.
d Sleep Disturbances and Regression measured by the mini PAS-ADD interview (interviewing relatives) 
e  Measured by the percentage reduction of the calculated developmental age, based on the Vineland 
Adaptive Behavior Scaled.   
f Vineland Adaptive Behavior Scale [10] , Dutch version.
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The clinical phenotype of KS is typically characterized by the trias of a (mostly) mod-
erate to severe ID, (childhood) hypotonia and characteristic facial dysmorphisms 
(Kleefstra et al., 2006; Kleefstra et al., 2009; Stewart & Kleefstra, 2007; Willemsen, 
Vulto-van Silfhout, et al., 2012). Various somatic comorbidity can occur, including 
congenital cardiac and renal defects, severe (respiratory) infections, constipation and 
epilepsy. Autism spectrum disorders and behavioral problems are highly prevalent 
(Schmidt et al., 2016; Verhoeven et al., 2011; Vermeulen, de Boer, et al., 2017a; Willem-
sen, Vulto-van Silfhout, et al., 2012). Our previous observations (Verhoeven et al., 2011; 
Vermeulen, de Boer, et al., 2017a) prompted us to study the natural course, with extra 
attention for the progressive deterioration occurring in a subset of patients with KS. 
The current clinical experience with a cohort of KS patients (Table 7.1: Neuropsychiatric 
Characteristics of the KS population) shows that (post-)puberty severe sleep disturbances 
may precede severe psychiatric disturbances and loss of functioning. Adolescence is 
a critical period in development of major psychiatric diseases, such as a psychotic 
disorder, bipolar disorder, and a depressive disorder. These can all present with a 
sudden behavioural change, aggressive outbursts, apathy, loss of initiative, affective 
flattening, and/or mood disturbance. In all these disorders, urgent and adequately 
dosed treatment with antipsychotics, and if necessary combined with other psycho-
tropic drugs, is important, but in people with ID pharmacotherapy is usually started 
cautiously and in low dosages. We selected 3 cases from our KS cohort to illustrate this 
approach may also have harmful effects. Based on our experiences on these 3 cases, 
we suggested specific treatment procedures, on which remarkable recovering in daily 
functioning was observed. 
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Case descriptions
The first patient, a female, was referred to our center at age 15. She has a moderate 
intellectual disability and her medical history reports perinatal complications, irregu-
lar menstrual cycle, extreme constipation, polydipsia and polyuria of unknown origin, 
which needed pharmacological treatment (macrogol and desmopressine). Her psy-
chiatric history reports attention-deficit/hyperactivity disorder and autism spectrum 
disorder (ASD) since childhood and a mood disorder, with a bipolar rapid cycling 
component, since she was 8 years old. The mood disorder was treated with valproic 
acid (up to 3x 500 mg daily, based on serumlevels) combined with increasing dosages 
of olanzapine (up to 10 mg/d). 
Severe sleep disturbances started gradually after pneumonia. The sleep problems 
accumulated within 7 months, until she entirely stopped sleeping for at least 72 hours. 
This was followed by nonstop vocalization, hyperactive behavior, restlessness, aggres-
sion and refusal to eat. The symptoms reflected a manic-psychotic episode for which 
acute psychiatric admission was necessary. She was initially treated with benzodiaze-
pines to recover sleep, however ineffectively. After treatment with olanzapine 17,5 mg/d, 
sleep normalization occurred within 24 hours. Immediately thereafter, the aggressive 
outbursts stopped and vocalization, behavior and appetite normalized.
Her level of adaptive functioning, tested with the Vineland Adaptive Behavior Scale 
(VABS, (Sparrow, Balla, Cicchetti, 1984)) was 2 years at the biological age of 12 years. 
Retesting at the biological age of 15 (6 months after recovery of the described psychi-
atric decompensation) her level of functioning had decreased to 1 year and 5 months. 
She had lost her ability to talk in sentences and her continence and showed more 
self-injurious behavior.
 The second patient, also female, was referred to our center at 23 years of age. She has 
a moderate ID, and her medical history reports a developmental delay, constipation 
and ASD. She had irregular periods, which were treated with an intramuscular pre-
servative drug (Provera). After an unrequited love at the age of 18 years, she developed 
a major depressive disorder and an anxiety disorder with sleep problems: she was 
afraid of going to bed and woke up hours earlier than normal (slept <4 hours/night). 
Treatment with aripiprazole was started at a dosage of 2,5 mg daily to reduce irrita-
bility in ASD. Because of drowsiness this was reduced to 2 mg. Significant regression 
occurred and during the following 2 years she lost s many abilities: dressing herself, 
reading, writing, talking in sentences and taking care of personal hygiene. Because of 
these losses, she needed care 24 hours a day and 7 days a week and was permanently 
Severe regression & pharmacological treatment
115
Chapter 7
Case descriptions
The first patient, a female, was referred to our center at age 15. She has a moderate 
intellectual disability and her medical history reports perinatal complications, irregu-
lar menstrual cycle, extreme constipation, polydipsia and polyuria of unknown origin, 
which needed pharmacological treatment (macrogol and desmopressine). Her psy-
chiatric history reports attention-deficit/hyperactivity disorder and autism spectrum 
disorder (ASD) since childhood and a mood disorder, with a bipolar rapid cycling 
component, since she was 8 years old. The mood disorder was treated with valproic 
acid (up to 3x 500 mg daily, based on serumlevels) combined with increasing dosages 
of olanzapine (up to 10 mg/d). 
Severe sleep disturbances started gradually after pneumonia. The sleep problems 
accumulated within 7 months, until she entirely stopped sleeping for at least 72 hours. 
This was followed by nonstop vocalization, hyperactive behavior, restlessness, aggres-
sion and refusal to eat. The symptoms reflected a manic-psychotic episode for which 
acute psychiatric admission was necessary. She was initially treated with benzodiaze-
pines to recover sleep, however ineffectively. After treatment with olanzapine 17,5 mg/d, 
sleep normalization occurred within 24 hours. Immediately thereafter, the aggressive 
outbursts stopped and vocalization, behavior and appetite normalized.
Her level of adaptive functioning, tested with the Vineland Adaptive Behavior Scale 
(VABS, (Sparrow, Balla, Cicchetti, 1984)) was 2 years at the biological age of 12 years. 
Retesting at the biological age of 15 (6 months after recovery of the described psychi-
atric decompensation) her level of functioning had decreased to 1 year and 5 months. 
She had lost her ability to talk in sentences and her continence and showed more 
self-injurious behavior.
 The second patient, also female, was referred to our center at 23 years of age. She has 
a moderate ID, and her medical history reports a developmental delay, constipation 
and ASD. She had irregular periods, which were treated with an intramuscular pre-
servative drug (Provera). After an unrequited love at the age of 18 years, she developed 
a major depressive disorder and an anxiety disorder with sleep problems: she was 
afraid of going to bed and woke up hours earlier than normal (slept <4 hours/night). 
Treatment with aripiprazole was started at a dosage of 2,5 mg daily to reduce irrita-
bility in ASD. Because of drowsiness this was reduced to 2 mg. Significant regression 
occurred and during the following 2 years she lost s many abilities: dressing herself, 
reading, writing, talking in sentences and taking care of personal hygiene. Because of 
these losses, she needed care 24 hours a day and 7 days a week and was permanently 
        
Chapter 7
116
Chapter 7
admitted. Because the regression proceeded, the dosage of aripiprazole was gradually 
increased. At a dosage of 15 mg/d the sleep problems recovered as well as the other 
depressive symptoms. The regression stopped and she was able to retake some skills 
again: talking in short sentences and some awareness of personal hygiene.
At the biological age of 19 years, her level of adaptive functioning was 3 years and 10 
months according to the VABS. One year after remission of the MDD and anxiety 
disorder, at the age of 23 years, her developmental age had decreased to 2 years and 
5 months. 
The third patient, female again, was referred to our center at age 23. She has a moder-
ate ID and her medical history reports pulmonic surgery at infancy, frequent airway 
infections, hypertension, constipation and behavioral problems during periods. Her 
psychiatric history reports autistic behavior since childhood and psychotic symptoms 
since the age of 20 years, when her grandfather died. She stopped sleeping for several 
nights, which was accompanied by delusions and hallucinations. She was treated with 
several antipsychotics, but these were not effective at low to normal dosages, including 
pipamperone two times 20 mg daily and haloperidol two times 2 mg daily. Additional 
treatment with lorazepam 4dd 2 mg followed by treatment with zuclopentixol 50 mg/d 
and promethazine 50 mg/d were ineffective. Major regression of functioning occurred 
in the following 2 years: she lost her ability to talk, write, read, dress, swim, and con-
tinence. Sudden aggression occurred after stopping oral anticonceptive medication. 
At the age of 22 years she was admitted to the psychiatric ward for several months and 
was treated with olanzapine 25 mg daily. She was still experiencing insomnia despite 
sedation and suffered from hallucinations. After switching the olanzapine to clozap-
ine, 50 mg daily, she recovered from the sleep disturbance and psychotic symptoms. 
During this episode her level of adaptive functioning, (based on the VABS), was 1 year 
and 3 months while in the past (biological age 16 years), a developmental age of 3 years 
had been measured. 
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Discussion and conclusions
These cases and observations in our cohort (Table 7.1) illustrate 2 important clinical 
aspects. First, sleep disturbances in KS patients especially occur during adolescence 
or young adulthood and may be followed by rapid regression. This period is crucial in 
precipitating hormonal shifts as well as the appearance of psychiatric disorders. Puber-
tal development in KS therefore deserves special attention and actively monitoring of 
sleep patterns. Consultation for psychiatric expertise and implementation of a mul-
tidisciplinary team is essential for this and many other rare genetic syndromes. This 
team ideally consists of a clinical geneticist, pediatrician, (child)psychiatrist, (neuro)
psychologist and a (child)neurologist. 
Second, our cases illustrate the benefit of immediate treatment with adequately dosed 
second-generation antipsychotics in this specific syndrome. Diagnosing a specific psy-
chiatric disorder facilitates optimal treatment, which is also true for the ID population. 
Conform the National Institute for Health and Care Excellence/ international guide-
line of treating (a first episode) psychoses, oral antipsychotics should be administered, 
together with psychosocial interventions and parent training. In this article, we focus 
on the pharmacological side of treatment, but this does not alter the fact that psy-
chological treatment and guidance, for the carers are necessary as well. The drug of 
choice is determined by efficacy, side effects and individual preferences. Clozapine is 
the most effective antipsychotic drug (Leucht et al., 2013), but because of severe and life 
threatening side-effects (eg, agranulocytosis) this is often not the drug of first choice. 
Olanzapine is the second most effective antipsychotic available in the Netherlands 
(amisulpride is not registered) (Leucht et al., 2013), which does not cause this relatively 
high risk of agranulocytosis. It acts by blocking the cerebral receptors of serotonine 
(5-HT2A/C and 5-HT-3) as well as dopamine (D1-5), muscarine, (nor)ephinephrine (α1) and 
histamine(“www.farmacotherapeutischkompas.nl,”, Monti, 2016). It is available in an 
orodispersible tablet, which melts and dissolves easily in the oral mucosa. This favors 
ingestion in people with ID. Olanzapine has proven its ability to restore sleep continu-
ity as well as sleep architecture (Monti, 2016). However, because of weight gain and/or 
cardiac interval prolongation, in individual cases, this drug might not be preferred as 
drug of first choice. Aripiprazol can be effective in these cases, although its efficacy is 
less compared to olanzapine (with a standard mean difference of 0.76; (Leucht et al., 
2013)), its profile of side effects in general is milder, specifically for weight gain and 
cardiac interval prolongation. Aripiprazol is a partial agonist for D2, 5-HT1a and 5-HT2 
receptors and an antagonist for the α1 receptor. 
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Both, Olanzapine and Aripiprazole, were effective in our patients, when the dosage 
was optimized unto a high-normal dosage. Although speculative, the combination of 
targets on the serotonine, dopamine and (nor)epinephrine receptors may contribute 
to clinical improvement. Based on our clinical experiences with KS we suggest, to leave 
the general paradigm of ID treatment (‘start low and go slow’) and follow treatment 
procedures similar to guidelines for the non-ID population with psychosis. This may 
help to reduce or prevent episodes of severe regression and will contribute to the 
quality of life in these vulnerable patients. 
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Abstract: 
Background/ Introduction: The increasing presence of genetic diagnoses in neurodevelopmental 
disorders (NDDs) results in greater demands for counseling. Many studies in this field focus on the 
clinical characteristics of patients, but less so on family functioning and parental stress. Yet, the 
latter typically plays an important role in quality of life, levels of psychopathology, and regulation 
of disease burden. It has been described that parents of children with NDD experience higher 
levels of stress. The aim of the present research is to objectify the overall stress level in parents of 
children with genetically determined NDDs, ‘genetic syndromes’, and to study its relationship 
with child characteristics and family environment factors across several syndromes. 
Method: A total of 56 individuals (30 females) with NDD participated in the study. Of these, 24 
were diagnosed with Kleefstra Syndrome (KS), 13 with Koolen-de Vries Syndrome (KdVS), and 19 
with various other rare (mono)genetic disorders. The individuals’ parents were asked to complete 
the General Functioning subscale of the Family Assessment Device (FAD-GF), the Child Behav-
ioral Checklist (CBCL), and a questionnaire about demographic parental data.
Results: 25.5% Of the families scored in the range of pathological stress (cut-off >2.17). The mean 
FAD –GF score was 1.84, which corresponds to scores of other chronical childhood disorders, like 
Diabetes Mellitus (1.76) and ADHD (1.75). There was no significant difference between mean FAD 
score of the several subgroups (p=0,70). 
Discussion: At least one out of four families experience pathological levels of stress. (Para)medical 
counselors should address this and consider genetic syndromes, resulting in NDD, as complex 
chronical illnesses. During counseling, attention should be paid to child-related factors, like (mal-)
adaptive functioning, and course of the disorder, as well as to environmental factors that are 
potentially threatening the well-being of the child. 
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Introduction:
Parents of children with developmental delay experience higher levels of stress (Man-
or-Binyamini, 2011). This is due to issues related to a) the delayed development and 
diagnosis itself, b) accessing and finding their ways in the service system, c) transition 
phases, like starting school, and d) managing behavioral challenges (Minnes, Perry, & 
Weiss, 2015). Especially the relationship between challenging behaviors in the child 
and stress in the parents, has been subject of research (Abbeduto et al., 2004; Baker, 
Blacher, & Olsson, 2005). Parental stress is assumed to have a negative influence on 
family functioning, whereas family functioning is a mediator in quality of life of the 
child as well as in levels of psychopathology (Jozefiak & Wallander, 2016). Here we use 
the concept of “family” to describe a group consisting of one or two parents and their 
children (one or more), which if functioning well, is the principal institution for the 
socialization of children. In case of children with chronic diseases, a positive family 
functioning can mediate in controlling the disease burden, like in chronic somatic 
illness such as diabetes mellitus type I. Family dysfunction on the other hand, is for 
instance associated with higher level of blood glucose (HbA1c) (Leonard, Jang, Savik, 
& Plumbo, 2005). 
In research on neurodevelopmental disorders (NDD), most studies focus on broad 
patient diagnostic categories such as intellectual disabilities (ID) and autism spectrum 
disorders (ASD). However, differentiation of subgroups with specific genetic causes 
of NDD may be of extra value within this broad category. Each genetic syndrome is 
associated with its own pattern of needs, concerns, associated disease(s) and behavior 
(Vermeulen & Willemsen, 2016). Consequently, etiological differentiation is a prerequi-
site not only for adequate diagnosis and treatment in general (Verhoeven & Egger, 2015; 
Verhoeven & Egger, 2014) but also for a syndrome specific approach to parental stress 
and to improve family functioning. Such studies are already performed in well-estab-
lished genetic syndromes. For instance, mothers of children with Down syndrome 
experience less stress than mothers of children with other developmental disabilities. 
On the other hand, previous research indicated higher stress levels in families with 
Down syndrome compared to families with typically developing children (Norton et 
al, 2016, Hodapp, 2007). 
In our previous study (Vermeulen, de Boer, et al., 2017a) we have focused on child 
factors in several rare monogenetic neurodevelopmental disorders, in particular on 
the level of adaptive functioning and presence of psychopathology (e.g., in Kleefstra 
syndrome) and found great variation across syndromes. Specifically, we observed that 
parents struggled with the burden of care that co-occurs with raising a child with 
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both intellectual disability as well as psychiatric symptoms. Since the prevalence of 
these rare monogenetic disorders is rapidly increasing (DDD-study, 2017; Willemsen 
& Kleefstra, 2013), there is a need for leads in counseling these families. (Para)medical 
counseling is typically focused on the (somatic) phenotype of these syndromes, which 
is centered on child factors. 
Hence, the primary objective of this study is to identify the prevalence of pathological 
stress within parents of children with (very) rare monogenetic neurodevelopmental 
disorders as well as its prevalence within the specific syndromes. Our second objective 
is to study its relationship with child characteristics and family environment factors 
across several syndromes.
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Method:
Participants:
Participant characteristics have already been described in our previous study (K. 
Vermeulen, de Boer, et al., 2017b) and listed in Table 8.1. In this study, 56 of the 58 par-
ticipants of our previous study on Kleefstra syndrome and other rare genetic disorders 
(Vermeulen et al., 2017a) were included. In two participants, Whole Exome Sequencing 
did not show a causative genetic defect, hence they were excluded. The participants 
in this study can be subdivided into 3 categories: 24 with KS, 13 with KdVS and 19 
with other rare genetic neurodevelopmental disorders. Participant characteristics are 
summarized in Table 8.1.
Patients were recruited from the department of Human Genetics, Radboud university 
medical center in Nijmegen and from the department of child and adolescent psychia-
try for intellectual disabilities at Karakter in Horst, both in the Netherlands. Informed 
consent was obtained by legal representatives and included in the patient file. The 
regional medical ethical committee (medical research ethics committee CMO/METC 
Arnhem-Nijmegen, the Netherlands) approved the study (NL43187.091.13), which was 
performed in full accordance with the Declaration of Helsinki.
•	 Kleefstra Syndrome (KS, n=24): This is a rare genetic syndrome, which is caused 
by haploinsufficiency of the EHMT1 gene, resulting in a clinical phenotype char-
acterized by ID, childhood hypotonia and a typical facial appearance (Kleefstra 
et al., 2006; Kleefstra et al., 2009; Willemsen, Vulto-van Silfhout, et al., 2012). The 
course of this syndrome is complicated by several psychiatric disorders, like 
autism spectrum disorder (prevalence of almost 100%) and psychotic episodes, 
which occur in the context of primary psychotic disorder or bipolar disorder, 
with a lifetime prevalence of 29.2% in these patients (K. Vermeulen, de Boer, et 
al., 2017b) .
•	 KoolendeVries Syndrome (KdVS, n=13) results from 17q21.1 and is associated 
with an ID, expressive language problems and in about half of the patients there 
are behavioral problems (Koolen et al., 2006; Sharp et al., 2006; Shaw-Smith et 
al., 2006). In a small sample, the (lifetime) prevalence of anxiety disorders was 
high, with 69.2% suffering from (a range of ) anxiety disorders. In contrast, the 
prevalence of obsessive-compulsive disorder was extremely low in this cohort 
compared to other rare genetic syndromes (Vermeulen, de Boer, et al., 2017a).
•	 Mixed group of other rare genetic disorders (MG, n=19). Individuals in this group 
carry causative mutations for their condition as listed in Table 8.1. 
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Table 8.1: Patient Characteristics
Group Genetic Defect Male: 
Female 
ratio 
(%)
Biological age: 
mean 
(SD; min-max) 
in years
Kleefstra Syndrome 
(n=24)
EHMT1 gene
16x Microdeletions
8x Mutations
9:15 
(38% vs 62%)
15.42 
(±10.421; 3-37)
KoolendeVries 
Syndrome (n=13)
12x KANSL gene microdeletions
1x KANSL gene mutation
6: 7 
(46% vs 54%)
18.31 
(± 10.696; 5-34)
Mixed Group 
(n=19) 
6x GATAD2B gene microdeltion
3x ANKRD11 gene mutation
3x SIN3A gene mutations
2x PACS1 gene mutations
1x FOXP2 gene mutation
1x FBOX17 gene microdeletion 
(2p16.3)
1x AUTS2 gene microdeletion 
(7q11.22)
1x YWHAE microduplication 
(17p13.3)
1x 7q36.1 microdeletion
11:8 
(58% vs 42%)
12.21 
(± 9.461; 3-40)
Total (n=56) 26: 30 
(46% vs 54%)
15.00 
(± 10.248; 3-40)
Instruments:
The instruments we used focus on the one hand on family characteristics and on the 
other hand on child-centered factors. 
1. Family functioning and characteristics of the family 
a. Mc Master Family Assesment Device: General Functioning Scale (FAD-GF), Dutch 
version: The McMaster Model of family functioning originates from clinical 
psychiatric experience and research. It covers the continuum from healthy to 
unhealthy family functioning in six dimensions: (a) problem solving, (b) com-
munication, (c) roles, (d) affective responsiveness, (e) affective involvement and 
(f ) behavioral control. The complete family assessment device (FAD, 60-items) is 
based on this model. The FAD-GF is a shorter version and measures the overall 
health and pathology of the family. It consists of 12 questions about healthy (6) 
and unhealthy (6) family functioning and is scored by the parents. Each item is 
scored on a 4-point scale (ranging from strongly agree to strongly disagree). The 
sum scores of these items are divided by the number of questions answered to 
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calculate an overall score. An overall score of 2.17 is regarded as unhealthy (Byles, 
Byrne, Boyle, & Offord, 1988; Guxens et al., 2013).
b. Data on educational level and psychopathology in parents were obtained in an 
additional Dutch questionnaire. Educational level was scored in the Verhage cat-
egories (Verhage, 1964). Presence of psychopathology was scored in accordance 
with the overall categories of the DSM-IV (for example: psychotic disorders, 
mood disorders etc). We dichotomized this variable into ‘present’ or ‘absent’. We 
did not include the number of psychiatric diagnoses in our analyses, because 
only very few parents had multiple diagnosis. 
2. Child-related factors
a. Vineland Adaptive Behavior Scale (VABS, In Dutch adaptation Vineland-Z), which is 
a widely used clinical interview is to determine the level of adaptive functioning 
of people with an intellectual disability. This instrument has a good reliability 
and validity in this specific population (de Bildt et al., 2005). Primary caregivers 
were interviewed about the participants. 
b. The mini Psychiatric Assessment Schedules for Adults with Developmental Disabilities 
(mini PAS-ADD); (Moss S., 1997); in Dutch translation (Janssen & Maes, 2012; Prosser 
et al., 1998). This instrument determines behavioral problems and psychiatric 
disease in subjects with an intellectual disability by interviewing the proxy.
c. Autism Diagnostic Observation Schedule, second version (ADOS-2) is a semi-struc-
tured play to assess autism features ( Lord et al., 1999; Lord et al., 1989) It has 
proven psychometric properties in the ID-population (Havdahl et al., 2016) and 
also in genetic ID-syndromes (Vermeulen, Egger, et al., 2017).
d. Child Behavior Checklist (CBCL/1,5-5)(Achenbach, 2000); Dutch version (Verhulst & 
van der Ende, 1992). This questionnaire measures problem behavior on a 3-point 
scale: 0= symptom is absent, 1= sometimes present, 2= often present. It is intended 
for children between 1,5 and 5 years of (developmental) age and is completed by 
the parent(s). It consists of 100 items, which reflect problem behaviors. The psy-
chometric properties of this questionnaire were proved in a population sample of 
Dutch normally developing children (Verhulst & van der Ende, 1992) as well as in 
a sample of children with an intellectual disability (Borthwick-Duffy et al., 1997).
In our previous work, we have reported on results of the first three child-related inter-
views and the observation schedule (2 a-c) and their subsequent results in more detail 
(Vermeulen, de Boer, et al., 2017a). 
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Procedure:
Parents were asked to complete the questionnaires, comprising FAD-GF, CBCL1,5-5 
and additional questionnaire on educational level and psychopathology, together (in 
cases where both parents have legal parental authority; if there was only one parent 
with legal parental authority, than only this parent was asked to complete the ques-
tionnaire). The clinical interviews were performed by the first author, who is a certified 
child psychiatrist. 
For the FAD-GF, questionnaires with less than 10 questions answered were regarded 
as not completed and therefore not included in the statistical analysis.
Statistical analysis
Mean FAD scores for the total group as well as the subgroups were calculated. To 
determine whether specific child and parent-related factors contribute to this, bivari-
ate correlations were calculated and correction for multiple testing was applied. 
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Results 
In total, 51 out of 56 FAD-GF forms were completed with ten or more answers. The 
mean FADscore was 1.84 with a median of 1.83. There was no significant difference 
between mean FADscore of the several subgroups (p=0,70). Raw scores, including 
confidence intervals (CI) and standard deviations (SD), are presented in Table 8.2. 
Table 8.2: FADscores for the several syndromes
Subgroup FAD score 
mean 
(median)
95%-CI (SD) % families 
with 
pathological 
stress (n)
Total (n= 51) 1.84 (1,83) 1.69-1.99 (0.53) 25.5% (13)
Kleefstra Syndrome (n=23) 1.90 (1.92) 1.65-2.14 (0.57) 30.4% (7)
KoolendeVries Syndrome (n=12) 1.76 (1.79) 1.56-1.95 (0.31) 8.3% (1)
Mixed group of super rare 
disorders (n=16)
1.83 (1.82) 1.50-2.16 (0.62) 31.3% (5)
Bivariate correlations between the overall FADscore and child-related factors as well 
as parent-related factors were calculated for nominal variables and displayed in Table 
8.3. Presence of psychopathology in one of the parents was highly correlated to the 
level of stress within the family (p= 0,002 to p=<0,0001). Educational level of mother 
was slightly negative correlated to the stress level, with lower educated mothers expe-
riencing more stress compared to higher educated mothers. Several categories of the 
CBCL were also related to stress within the family. 
The dichotomous variables (gender of the child, living at home or in an institution) 
were tested using an independent t-test and showed no significant results, respectively 
p=0,936 for gender (r=-0.012; 23 males/ 28 females) and p=0,207 (r=-0.180) for place of 
living with a slightly higher mean FADscore for the ones living at home (1,90 versus 
1,69; 14 patients were institutionalized). There was no significant differentiation in 
stress level between these groups (p=0,685): 27% of the families, whose child is living 
at home, have pathological stress levels compared to 21% of the families, whose child 
is living at an institution. In addition to this an analysis was performed for each of the 
syndromes, because their mean scores substantially deviated. This also did not show 
a significant difference. 
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Table 8.3: Correlations between stress in the families and child- and parent-related factors
N= Correlation coefficient 
(Pearson’s r)
p-value
Child related factors
Gender 51 -0.012 0.936
Biological age 51 -0.251 0.076
Developmental age1 51 -0.253 0.073
Autism traits2 50 0.027 0.853
Sleep problems (at present)3 48 -0.171 0.245
Depressive traits3 48 -0.17 0.909
Anxiety traits3 48 0.045 0.759
Bipolar traits3 48 0.062 0.676
Psychotic traits3 48 -0.006 0.969
Unspecified psychiatric traits3 48 -0.021 0.887
Total score CBCL4 42 0.438 0.004**
Internalizing score CBCL4 42 0.371 0.016*
Externalizing score CBCL4 42 0.443 0.003**
Parent-related factors
Educational level father 47 -0.266 0.07
Educational level mother 48 -0.332 0.021*
Psychopathology father 47 0.331 0.023*
Psychopathology mother 46 0.595 <0.001**
1 measured as the total score on the VABS
2 measured with the comparison score on the ADOS-2
3 measured with the mini PAS-ADD interview, which is scored by a clinician
4 measured with the CBCL, which is completed by the parents
*p< 0,05
**p < 0,01
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Discussion
This study focuses on the stress levels experienced by the parents of children with 
rare genetic NDD syndromes. Subsequently it aims at the relationship between child 
and family characteristics across several syndromes. In our cohort, a mean of 1.84 was 
scored on the GF-subscale of the FAD. Furthermore, our results indicate a mean prev-
alence of 25.5% of parents with pathological stress levels. Compared to other chronic 
diseases of childhood, these are both markedly high scores. For instance, families of 
children with diabetes mellitus type I, which also requires a lot of (family) adjustments 
in daily life, had a mean score of 1.76 and a standard deviation of 0.39 (Leonard et al., 
2005), suggesting that at most ~15% (> +1 standard deviation) of the parents have a 
pathological level of stress. A study in a small sample of families with a child diagnosed 
with ADHD scored also around 1.75 (Young et al., 2013) on the FAD-GF.
For the subgroup of parents of KS-children in our cohort, the average was even higher 
at 1.90 with almost one out of three parents reporting pathological stress. The mean 
score on the FAD-GF did not differ significantly between the various groups in our 
cohort. Nor did the percentage of parents with pathological stress. However, differences 
between the several syndromes are still visible (Table 8.2). This raises the question 
whether specific factors can be identified that increase the risk of pathological stress. 
Risk factors that directly correlate to the experienced level of stress in the family were: 
1. The presence of psychopathology in (one of ) the parents, 2. Educational level of the 
mother and 3. The several domains on the CBCL. Though these correlations indicate 
coherence, they do not necessarily give direction to this coherence. For example, stress 
enhances the risk to develop psychopathology, but psychopathology itself does also 
generate stress. The presence of psychopathology in (one of ) the parents is strongly 
correlated (respectively fathers versus mothers: r= 0.023 and r=<0.001) to the presence 
of pathological parental stress. This can be understood from facing dual strain as they 
have to deal with their own disease burden and, on top of that, the disease burden of 
their child. In addition, raising a child requires a certain degree of flexible adaptation 
to the child’s needs. (Sturge-Apple, Jones, & Suor, 2017). The presence of psychopathol-
ogy in one of the parents may interfere with this ability to adapt. The DSM-5 manual 
(APA, 2013a) describes this by means of the criterion D, in which current functioning 
needs to be affected in several areas of daily life. 
Furthermore, in this study, the educational level of mothers significantly connects to 
higher parental stress levels, with an inverse correlation in our cohort. Lower educated 
mothers face more stress than the higher educated mothers. A study of Parkes et al. 
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(Parkes, Sweeting, & Wight, 2015) has shown that parental stress was higher at both 
ends of the educational spectrum, with lower educated mothers having most parental 
stress followed by the higher educated mothers. The latter was explained by difficulties 
fulfilling the needs of both work and the child. Intermediate educated mothers showed 
the lowest stress levels in this study. Although we expected to find same results, this 
was not the case in our cohort. The highest educated mothers showed the lowest mean 
FAD scores as well as low scores for the presence of pathological stress. Although the 
results of educational levels of fathers were not significant in our cohort, a same trend 
was evident.
It is a well-known fact that lower educational levels are associated with lower socio-
economic status (SES) and vice versa. Several stressors, like financial problems, health 
problems, unhealthy lifestyle as well as social isolation and psychopathology are 
associated with lower SES (Chen & Miller, 2013). Moreover, the capacity of executive 
functioning (EF) is vulnerable to stress. EF comprises attention, memory, working 
memory capacity and emotion regulation capacity (Diamond, 2013). So one can 
hypothesize that parenting stress results in less flexibility to provide care. Moreover, 
it was found that a lower SES is associated with a reduced well-being and alterations 
in brain development of the child (Bradley & Corwyn, 2002; Johnson, Riis, & Noble, 
2016). As a consequence, the sum of stressors could be detrimental to these parents 
and their children. 
Finally, the significant correlation between overall-domains (total score, internalizing 
score and externalizing score) of the CBCL requires some explanation. The CBCL is a 
parent-based questionnaire, designed to detect symptoms of psychopathology in the 
child. (Achenbach, 2000). The significant correlations at all domains are suggestive 
that this instrument in this population is subject to bias. Higher levels of stress in the 
parents seem to be related to significant higher scores (indicative) for psychopathology 
in the child. This presumption is strengthened by the lack of even a single correla-
tion between psychopathology, scored by an independent informant (mini PAS-ADD 
subscales). 
Besides those statistical significant correlations, the factors biological and devel-
opmental age do also show a trend towards significant correlation. These inverse 
correlations can be understood from the fact that young children, whether they are 
biologically young or developmentally young, need a lot of sensitivity and responsive-
ness from their parents. Critical in sensitive parenting is the ability to adapt parental 
behavior in a flexible way to the child’s needs. 
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(Para)medical counselors, like clinical geneticists and pediatricians working with chil-
dren diagnosed with a genetic syndrome, should be aware of these high levels of stress 
in the families. In medicine, genetic disorders resulting in NDD are still considered 
to be a fixed state rather than a chronical developmental disorder, with a fluctuating 
course during the span of life. The disease burden, as our data clearly indicate, is con-
siderable and especially the stress, experienced by parents and caregivers, is extensive. 
An optimal organization of care for these children and their families should take the 
complexity of these factors into account and pay attention to both child factors, adap-
tive factors, as well as maladaptive (e.g. psychiatric and somatic), and environmental 
factors. Specific attention should be paid to the transition phases, like starting school 
and puberty. 
Besides the way in which professionals regard and cope with the disease, which is 
primarily focused on child characteristics, it is also important to help parents deal with 
the diagnosis as well as the associated daily life problems. Parents should receive edu-
cation about their child’s developmental level, including cognitive, psychological and 
behavioral features, but also about the disease burden (recognition) and opportunities 
to find support for themselves. Ideally, short training modules for parents should be 
offered to promote better coping and acceptance of their child’s diagnosis (for exam-
ple mindful parenting(Petcharat & Liehr, 2017; Roberts & Neece, 2015)). The parents 
should be familiarized with, as well as to gain access to, the web of care requests and 
agencies for their child. Besides, extra attention should be on psychopathology in the 
parents and referral for this. The well-being of the parent does relate to well-being of 
the child (Bornstein, Putnick, & Suwalsky, 2017; Minnes et al., 2015). Therefore, it is of 
clinical importance to identify maladaptive family functioning. This study provides 
a first step for detecting parental stress in daily clinical practice of managing mono-
genetic disorders. 
Limitations of this study are the relatively small sample size, although it is already a 
fairly large group for rare syndromes. Ideally, we feel that the groups would all have 
included over 20 participants. Another limitation is the single moment at which the 
FAD questionnaire was completed by both parents. The question is whether these 
results are equal or fluctuate in time. Additional, we question whether there are 
differences in the scoring between each of the parents. For instance in autism spec-
trum disorders, parental scores may differ significantly between fathers and mothers 
(Möricke, Buitelaar, & Rommelse, 2016). We recommend considering these issues in 
future research on this topic. In order to properly interpret the results, it is necessary 
to have repeated measures of the FAD as well as other parameters, related to stress. 
Additional socio-economic factors, for example the family income, amount of involved 
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health care workers and temperament features can be of value to further specify risk 
factors. However, this deserves a separate/ follow-up study. Furthermore, repetition in 
a larger number of participants is recommended. Specific attention in future research 
should be on stress sensitivity of parents. 
In summary, the data from this study implicate strongly that more attention should be 
payed to stress levels in the parents, who raise a child with a (rare) genetic syndrome. 
Although the heterogeneity of maladaptive family functioning is high, the average 
level of stress in the parents should raise concerns. Indeed, these are even higher than 
in a number of other chronic diseases, which are associated with major changes in 
daily life. A sum of factors plays a role in the pathological development of this stress 
and threatens the well being of the child (as well as other family members). Screening 
for increased stress levels in the patient’s parents should therefore be an essential part 
of the medical consultation. 
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Summary and general discussion
Intellectual disability (ID) comprises a clinical heterogeneous group of conditions, 
resulting in problems with cognitive and adaptive functioning (APA, 2013a). Subjects 
with ID are vulnerable to develop psychiatric disorders ( Tsakanikos & McCarthy, 
2014). This combination seriously hampers the process of diagnostics and treatment, 
which may also be complicated by the often-noticed lack of specific professional skills 
and expertise in this area. Deficiencies in the organization and financing of care fur-
ther add to this. An etiology-based approach in these patients, who often have an 
underlying genetic defect, may provide important directions to diagnosis and treat-
ment. The overall aim of this thesis was to study in detail the neurocognitive and 
psychiatric characteristics resulting from loss-of-function mutations of the EHMT1 
gene causing the ‘Kleefstra Syndrome’ in humans. The results from this study and 
from diagnostic assessments and disease outcome management can well serve as a 
model for similarly affected rare genetic syndromes. 
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Thesis summary
Part I: Clinical characteristics
In the etiology of neuropsychiatric diseases, comprising ID, rare genetic disorders 
make a major contribution (DDD-Study, 2017; Willemsen & Kleefstra, 2013). However, 
knowledge about how molecular pathways affect neurocognition is highly fragmen-
tary. The Euchromatin Histone Methyl Transferase 1 gene (EHMT1) is an example of a 
gene, known to be involved in chromatin modification and presumed to have a role in 
neurocognitive functioning (Balemans et al., 2013; Benevento et al., 2016; Kramer et al., 
2011; Schaefer et al., 2009). Therefore, it is interesting to take the effect of loss-of-function 
(LOF) mutations resulting in haploinsufficiency of this particular gene as a blueprint 
and to map it in more detail. In humans, haploinsufficiency and heterozygous loss-
of-function (LOF) mutations of the EHMT1 gene result in Kleefstra Syndrome (KS), 
which is characterized by the trias of ID, childhood hypotonia and a typical facial 
appearance (Kleefstra et al., 2006; Stewart & Kleefstra, 2007; Willemsen, Vulto-van 
Silfhout, et al., 2012). Although this syndrome has been accurately mapped in terms of 
somatic features, little is known about the neurocognitive and psychiatric component. 
Interestingly, the gene was also found in relation to schizophrenia (Kirov et al., 2012) 
and in a patient with autism spectrum disorder (ASD) with a normal intelligence 
profile (Bock et al., 2016).
Chapter 2 summarizes results from animal studies with mutant EHMT-species, 
which show deviations in learning, attention and social processes (Balemans et al., 
2010; Kramer et al., 2011). It also connects to the results in human adult case series, in 
which behavioral disturbances and a sudden decline in functioning were reported 
(Verhoeven et al., 2011; Verhoeven et al., 2010). Thereafter, a pilot study by four case 
descriptions of school-aged children was performed, zooming in on their development 
and current complaints. All four children met the criteria for autism spectrum disor-
der (ASD) on top of their ID. Sleep problems and mood as well as anxiety symptoms 
were frequently reported in the past and/or current situations. These results are in 
line with the expectation that EHMT1 has an important role in cognitive processing 
in human and that disruptions in this gene result in early deviations in the neurocog-
nitive and behavioral development. 
Subsequently, we have repeated this study in a larger cohort of individuals with KS 
(n=24) to map the symptoms in more detail from early childhood (a biological age of 
3 years) to adulthood/ middle age. To rule out confounding effects introduced by the 
ID, we contrasted the results of this group to a mixed group comprising several other 
monogenic ID syndromes. Subjects with KS were significantly more prone to develop 
ASD, major depressive disorder, psychotic disorder or an unspecified disorder (p<0.05). 
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The prevalence of ASD is nearly 100%, which is suggestive for a strong link with the 
genetic origin (haploinsufficiency of the EHMT1 gene). Such a high prevalence of ASD 
is exceptional, even for genetic ID syndromes. For example, in Fragile X syndrome, 
which is often alluded to as the most common single genetic cause of ASD, the co-oc-
currence of ASD is only 30-54% (Kaufmann et al., 2017). Another important finding in 
this study is the high prevalence of psychosis in KS. Although a significant number 
of the patients met the criteria for a psychotic disorder, treatment with antipsychotics 
(in accordance with clinical guidelines) was hardly initiated. The majority of these 
patients also experienced severe cognitive, psychological and emotional regression 
in functioning, most explicit in the social domain. This illustrates the complexity of 
psychiatric diagnosis in this group. This complexity can partially be countered by 
adjustments in general psychiatric criteria and care.
To further complete the translational model, we have mapped the neurocognitive 
and psychiatric characteristics in three parents, who are mosaic of the aberrant 
EHMT1 gene causing KS in their child. Mosaicism means that there are two genet-
ically different cell types in one individual; one with the mutant allele of the gene 
(in this case EHMT1) and the other with the wildtype allele of the same gene. When 
it does not directly result in health or developmental problems, mosaicism is only 
occasionally detected. In the individuals that were described in chapter 4, the mosa-
icism was only identified after the diagnosis of a germline EHMT1 defect in (one of ) 
their child(ren). At first glance, these parents appear to function normally. However, a 
detailed anamnesis and developmental history combined with additional measures 
of psychiatric and neurocognitive functioning showed specific abnormalities in all 
three subjects. All three showed impaired cognitive flexibility compared to the general 
population. They all met the criteria for ASD and had a mood disorder at present 
and/or in the past. Nonetheless, they had a normal developmental age and had fin-
ished regular schooling. The results correspond to several major features in subjects 
with the full KS-phenotype (and genotype), e.g. ASD en mood disorders. Again, this 
study underscores the importance of the EHMT1 gene in neurocognitive functioning 
and associated psychiatric symptoms. In addition, a recent study shows that exonic 
mosaic mutations might be a relative common cause for ASD (3-4% of ASD patients), 
underlining the importance to carefully investigate parents of patients with a highly 
penetrant mutation causing the ASD phenotype in their offspring (Krupp et al., 2017; 
Lim et al., 2017).
Part II: Measurement issues in the assessment of psychiatric and neuropsychological profiles
Intellectual disability, with or without monogenic disorders, is often an exclusion 
criterion in research (Feldman et al., 2014), also when this concerns the reliability 
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and applicability of measuring instruments. However, in a population where the 
ID already complicates psychiatric diagnosis, it is essential to have solid additional 
instruments. In this part of thesis two specific instruments and two frequently used 
screening questionnaires are examined. To achieve this, the total research popula-
tion of this study was recruited (n=57). This genetically heterogeneous group was 
compared to the norm (general population), in which these instruments are fre-
quently used.
Chapter 5 discusses additional measures to detect autism spectrum characteristics. ID 
and ASD have a number of overlapping symptoms (Table 9.1), which made us critical 
of the use of these instruments in the ID population. The Autism Diagnostic Obser-
vation Schedule 2nd version (ADOS-2), which is golden standard in autism diagnostics 
was examined as well as two screening questionnaires: the Social Communication 
Questionnaire (SCQ) and the Child Behavior Checklist, subscale of pervasive devel-
opmental disorders (CBCL-pdd). The latter questionnaires showed both a significant 
correlation (p< 0.001) between the total score on the questionnaire and level of adap-
tive functioning, measured with the Vineland Adaptive Behavior Scale (VABS). This 
indicates a poor discriminating value between ASD en ID symptoms. For this reason, 
they seem not suitable as screening tools in this specific population. The ADOS-2 
turned out to be very useful in this population and did not show any correlation with 
the level of ID. The fact that this is an observer-based measure and the availability 
of comparison scores of subjects with the same level of spoken language is probably 
decisive. 
The next chapter concerns the use of adapted tasks from the Cambridge Neuropsycho-
logical Test Automated Battery (CANTAB); a tablet based serie of neuropsychological 
tests. Four of these tests have been specifically developed, adapted and simplified to 
make them accessible to the ID population. These comprise the Motor Screening Test 
(MOT), the Pattern Recognition Memory task (PRM), the Intra-Extra Dimensional test 
shift (IED) and the Paired Associated Learning test (PAL). These tests roughly mea-
sure whether a subject can operate the tablet (condition for other tests) and aspects 
of memory and cognitive flexibility. To my knowledge, these tests have not been used 
before in ID patients. Consequently, this study started with assessment in the total 
study population (n=56) of operational capability in relation to the developmental 
age. Subjects with a developmental age comparable to 2.5 years were able to perform 
those tests. Then, we examined to which extent the level of ID affected the test results. 
There was no significant correlation between the developmental age and test results 
(subtest range ρ=-0.171 till 0.336 with p-values>0.070). Subsequently, a comparative 
analysis was done amongst the genetic subgroups. This resulted in a significant higher 
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dropout in the KS group on the first test (MOT), based on cross-tabulations. Finally, 
these tests provide tools on intra-individual level to optimize and personalize guidance 
and treatment in daily life.
Table 9.1: Overlap in clinical symptoms of ID and ASD
ID overlap ASD
Deficits in cognitive functioning Language problems Lack of social reciprocity
Deficits in adaptive functioning Stereotypies
Sensopathic examination
Deficits in social functioning
More common in males
Part III: Management of disease outcomes
The last part of the thesis focuses on management of the disease outcome. In the first 
place, this entails the care for the patients themselves. Moreover, it is also important 
to consider the care/family system when it comes to management, since the subjects 
with ID are dependent on their caretakers.
A genetic syndrome can express itself in many ways and it would be impossible to dis-
cuss management of every expression of the disease. In general, guidelines for clinical 
management of an ID patient should be guided by an established genetic diagnosis. 
However, in some genetic syndromes there is a need to deviate from these guidelines.
Chapter 7 discusses specific recommendations regarding medication for regressive 
episodes in KS. In the medical world, there is a paradigm for treating subjects with 
ID, which states: “start low and go slow.” This paradigm seems not always adequate. 
Although it is good clinical practice to start medication carefully, the clinician needs 
to know in which situations (s)he has to continue and be more firm in the medication 
regiment. During adolescence and early adulthood in KS regressive episodes occur, 
often preceded by severe sleep problems. When a rapid onset of atypical antipsychot-
ics (olanzapine is first choice) is provided, at least recovery seems to occur (Mitra et al., 
2017; Vermeulen, Staal, et al., 2017). 
Chapter 8 deals with the stress that parents experience in caring for their child with 
a genetic ID syndrome. For all subgroups together, the average score on stress was 
slightly higher than for other chronic conditions, such as diabetes mellitus type I 
and ADHD. However, a closer look at the several genetic subgroups highlights larger 
differences. Especially, when the percentages for expressed pathological stress are 
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compared between these groups. For the KS subgroup, one out of three parent couples 
experiences pathological stress, which is associated with a large number of comorbidi-
ties such as cardiovascular disorders, gastric ulcers, respiratory diseases, inflammatory 
diseases, mental disorders (Schneiderman, Ironson, & Siegel, 2005). This is an alarm-
ing amount. Ideally, professionals recognize symptoms of pathological stress in these 
parents, acknowledge this stress and refer these parents for additional help. Some 
factors did significantly relate to pathological stress levels, like parental psychopa-
thology, education level of the mother and biological as well as developmental age of 
the diagnosed child. Considering this, a more holistic view on the patient and his/her 
environment is appropriate. 
General discussion
This is the first systematic study on neuropsychological and psychiatric characteris-
tics and their implications in a relatively large cohort of KS-subjects (n=24). A unique 
feature of this study is that the KS syndrome is mutually contrasted to several other 
syndromes and that additionally a mixed control group of various genetic syndromes 
was composed (Figure 9.1). The latter was done to illustrate what happens to the results 
when a homogeneous group is compared to a heterogeneous one. A major challenge 
in phenotypically complex disorders is to account for disorder-specific variation on 
the one hand, and shared (group) characteristics between a cluster of disorders (such 
as ID) on the other hand. One can compare this problem with the analysis of fruit on 
a bowl. Imagine that the bowl consists of apples, pears, bananas, grapes and pineap-
ple. When we compare the size of an apple with that of the average fruit size (on this 
bowl), than there is no visible deviation. However, when we compare the size or shape 
of an apple with that of a grape or a banana, than there is a striking difference. This is 
one of the things that enable us to differentiate the fruits mutually. If we translate this 
to the concept of research in ID, than this emphasizes the importance of comparing 
homogeneous groups with each other. The genetic etiology of ID, therefore may prove 
very important and should be taken into account. 
Our study shows that each of the monogenic syndromes seems to have its own profile 
in psychiatric vulnerability. In patients with ID, psychiatric diagnosis and treatment is 
notoriously complex. Objective measures are essential in identification and evaluation 
of the course of neurocognitive processes and behavioral assessments. The second 
part of this thesis includes a first inventory of operational tests for the population 
with genetic neurodevelopmental disorders. The ADOS-2 is an instrument, which 
ultimately combines clinical observation in a standardized way and adaptive mod-
ules, based on verbal functioning of the patient. Objectively assessing the presence 
of ASD in ID patients is of major clinical importance, because the comorbid occur-
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rence of ASD in an ID patient requires different attitudes of caregivers and different 
interventions. For example, in case of comorbid ASD, it is also important to include 
generalization to new situations within the range of training new skills. Tailor-made 
diagnostic measures are essential in formulating tailor-made disease management. 
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Figure 9.1: Composition of groups
In this thesis, KS is mutually contrasted to several other syndromes. To meet the traditional conditions, 
a cumulated control group was composed.
This thesis has several limitations of which I like to address three in particular. They 
surpass the discussion of the strengths and limitations of the individual studies, for 
which the reader is referred to the previous chapters. 
The design of the present cross sectional study is affected by a diverse age range in 
combination with a single moment of monitoring. It should therefore be regarded as 
an impression of problems, which may occur during the course of the genetic syn-
drome. It is desirable to perform a longitudinal and prospective study with multiple 
measurements over time in each of the subjects to better understand the course of 
the different syndromes.
The variation in size of the genetic defects is also requiring attention. In our KS 
sub-cohort, there were no clinical differences between the patients carrying intra-
genic mutations versus microdeletions of the EHMT1 gene. However, it is advisable to 
separate these groups, based on the size of the genetic defect, in the future. Now the 
number of diagnosed KS-patients increases, larger numbers for each of the different 
defects can be obtained. This may present new opportunities to examine the course 
in patients with different defects. 
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Finally, this thesis discusses pharmacological treatment within the arsenal of thera-
pies. For all disease processes in genetic syndromes, one should realize that aging in 
genetic ID might be different. Medication is only symptomatic and it may slow down 
processes that are inevitable in the long term. Other kind of therapies, like for exam-
ple psychomotor therapy, music therapy and psychotherapy (behavioral therapy) are 
beyond the scope of this thesis. Nevertheless, such therapies should also be considered 
as a part of the treatment. 
Future directions for research
Due to the steep increase of genetic diagnostic possibilities, it is expected that in the 
majority of ID patients the genetic variant underlying their disorder will now be iden-
tified. Therefore, the need for syndrome specific knowledge on the disease course and 
management is urgent. The use of basic cognitive measures combined with systematic 
behavioral observations is recommended and preferred over the use of questionnaires 
in this specific population. Systematic follow-up is necessary and special attention 
must be paid to transitional phases in development, such as puberty. The field should 
prepare by implementing specific multidisciplinary knowledge on the integration of 
clinical-molecular, psychiatric and neurocognitive expertise, ultimately forming the 
bridge with fundamental neuroscience research to understand aberrant bran devel-
opment.
There are a number of aspects that need to be evaluated regarding the studies of 
psychopathology and neurocognitive functioning in the monogenetic ID syndromes. 
In general, it is recommended to develop specific instruments for detection of fre-
quently occurring comorbidity, like ADHD and anxiety (more specifically: OCD and 
PTSD) in some syndromes. In addition, Cytochrome P450 polymorphisms (CYPs) 
are also common in this specific population, like they are in the general population 
where the estimated prevalence is about 10%, (Bradford, 2002). So far, there is a lack 
of prevalence rates for CYPs in the ID population. Of course, these are of importance 
for pharmacotherapy in this group, not only for the psychiatric disorders, as well as 
for other frequently occurring disorders in ID, e.g. regurgitation and epilepsy. Fur-
thermore, studies to objectively evaluate efficacy of specialist therapies, like music 
therapy and psychomotor therapy, are urgently needed(Haeyen, 2018). And finally, 
it is recommended that care should not only focus on the subjects but also on the 
parents. For example programs that promote acceptance (e.g. focused on the present 
monogenetic disorder, it’s course or associated medical problems, including psychi-
atric disorders) may relieve parental stress and contribute to the quality of life of the 
parents as well as the subjects. Patient groups and forums on social media may also 
have an important role in this.
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Specifically for KS, we recommend research at the following aspects: it is appropriate 
to perform prospective studies on the course and especially the origin of regressive 
episodes in KS. Melatonin metabolism should be evaluated because of the high prev-
alence of sleep problems. Randomized Clinical Trials (RCTs) to assess the drug of 
choice, during first and possible recurrent episodes, is also advisable. Besides, the 
microbiome is also interesting, since a lot of bowel problems occur already at young 
age or even seem to precede these regressive episodes. 
Finally, agents involved in essential metabolism balances are of interest. Vitamin D is 
an interesting agent, as well as endocrine factors, since hormonal dysbalances seem 
to provoke the regressive episodes in KS. For the latter, taking samples of corporal 
material is required. This will be a case of belt and braces, regarding medical-ethical 
permission to take these samples. Therefore, collection of clinical observations is of 
major importance before proceeding to such studies. 
Clinical and societal implications 
From a broader perspective, this thesis is also about the added value of multidis-
ciplinary approaches. During our studies a vast exchange of knowledge across the 
disciplines involved occurred, and to some extent this has improved the clinical care 
of our patients. Our integrated work on EMHT1 mutations, although partially still in 
pilot phase when it comes to pharmacological interventions, may serve as a blue print 
for future studies in genetic developmental disorders. It is expected that such studies 
will ultimately improve clinical care in a range of these disorders.
If true, how could the clinical care for those patients be best organized?
Ideally, health care should mimic the organization of research, which indeed would 
be a true form of translational research. From our center of expertise, we reached out 
to patients in many provinces of the Netherlands, Belgium and Luxembourg. Next, the 
combined perspective of the several medical specialists and neurocognitive psychol-
ogists helped to improve diagnostic fine-tuning, thereby facilitating the development 
of tailored interventions. As such, expertise centers could provide a platform or net-
work hub in (para)medical diagnosis and advice. However, it is important to note that 
treatment and guidance need to be provided in the home region of the subject, e.g. 
his or hers daily environment. 
This ideal model of combining expertise may provide a novel view on following clini-
cal guidelines and when to deviate from these. This is illustrated by pharmacological 
treatment of psychosis in Kleefstra Syndrome, which needs a firm dosage regime 
instead of a ‘ start low and go up slow’ approach (Chapter 7). In this way tailor-made 
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care can be provided, which relieves the burden to individual patients and their fam-
ilies due to inappropriate medical investigations and saves costs. 
Involvement of a (child)psychiatrist in such an expertise team is to our experience very 
often, of significant value. Annoying behaviors, which often occur in ID syndromes 
and may involve psychiatric symptoms, cause loss of quality of life in both subject 
and the parents/caregivers. Early genetic and psychiatric diagnosis enables to start 
appropriate (step-wise) treatment or training to relieve symptoms, may prevent the 
development of patterns in annoying behaviors, favorably influence on-going neurobi-
ological processes, help to identify physical causes underlying the problem behaviors 
and give direction to the other involved specialists, paramedical (e.g. special educa-
tors, speech therapists) as well as medical (pediatrician, neurologist, clinical geneticist 
etc.). Because of the interdependencies between physical and mental health, this is a 
job for psychiatrists par excellence. Bleuler already described in 1911 in his textbook, 
which has become one of the first reference books for general psychiatry, that there 
are physical substrates for psychiatric illnesses (Bleuler, 1911). During the 1970s, the 
antipsychiatric movement has questioned this (Foudraine, 1971) from the perspective 
of a human/decent treatment. However, about a century after the publication of Bleul-
er’s textbook, genetics are offering some of these substrates and combine this with 
tailor-made treatment, which does justice to the subject. Though this is an important 
step forward, there still there is much to gain in this area.
In the Netherlands, there is already expertise in various fields, such as ID, psychiatry 
and genetics. However, treating patients with problems that extend across multiple 
disciplines is still challenging. Bundling expertise and operate together in the bound-
aries of these disciplines is beneficial to the current approach. To this end, both 
interdisciplinary training (e.g. in educational programs including video training) and 
multidisciplinary intervision may contribute. 
Obstacles in achieving bundled expertise are the current health care organization and 
financing systems. These are motivated by politics, in which there is a tendency that all 
citizens should be (or made) self-reliant. This is not (fully) feasible for about 15% of the 
population (in the Netherlands this includes 2.6 million people in absolute numbers), 
who have a reduced cognitive and/or adaptive capacity. More societal and political 
awareness for this specific group will do justice to the individuals. For decades, or even 
centuries, vulnerable individuals have hold a mirror to show bottlenecks in society, 
also expressed in arts and literature (Kyaga et al., 2011). However, the current social 
position of vulnerable subjects in society is still ambivalent. Specific for ID, the life 
expectancy has increased as a result of medical-technological developments. On the 
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other hand, the possibilities for personal development have been reduced in the recent 
years: access to special services, like school and care providing institutions, is limited. 
This is a source of concern. 
In this thesis, I hope to contribute in turning the tide for patients with complex prob-
lems, across the boundaries of ID, psychiatry and genetics. In patients with KS, we 
have demonstrated that it pays to bundle expertise in diagnostics and treatment. But 
there are so many more patients. So many more patients with genetic developmental 
disorders, who suffer from mental health problems. And for these patients, a world 
of difference can still be made. 
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ADOS(-2)  Autism Diagnostic Observation Schedule (second version)
ASD Autism Spectrum Disorder(s)
CANTAB  Cambridge Neuropsychological Test Automated Battery
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CC Cumulative Control Group
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, fifth edition
EHMT1  Euchromatin histone methyltransferase 1
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GWAS Genome Wide Association Study
ICD-10  International Classification of Diseases-10
ID Intellectual Disability
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MDD Major depressive disorder
MG Mixed Group of controls
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PAS-ADD  Psychiatric Assessment Schedules for Adults with Developmental 
Disabilities
PRM  Pattern Recognition Memory
PZM Postzygotic mutations 
SSBP Society for the Study of Behavioural Phenotypes
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Nederlandse samenvatting
Verstandelijke beperking, genetica en psychiatrie
Een verstandelijke beperking (VB) is met een prevalentie van ongeveer 1% een veel-
voorkomende aandoening met een grote impact op het leven van de patiënt en diens 
naasten. Door recente ontwikkelingen in de genetica is het mogelijk om bij het me- 
rendeel van de patiënten een genetische oorzaak voor de VB vast te stellen. Bij een 
groot aantal patiënten (~40%) betreft dit een relatief onbekende genetische variant. 
Er is in de afgelopen jaren toenemend aandacht geweest voor de medische ken-
merken bij patiënten met relatief onbekende genetische varianten, met name voor 
de somatische kenmerken. Veel minder aandacht is er geweest voor het vóórkomen 
en kenschetsen van psychiatrische aandoeningen bij deze patiënten, anders gezegd: 
onderzoek naar de psychiatrische comorbiditeit is schaars. Een belangrijk aandacht-
spunt, want enerzijds komen psychiatrische stoornissen frequenter voor bij mensen 
met een VB – denk bijvoorbeeld aan autismespectrumstoornissen (ASS) – en ander-
zijds is er bij een groot deel van de patiënten binnen de reguliere psychiatrie sprake 
van een (lichte) VB of zwakbegaafdheid. Tevens weten we van de meer bekende 
syndromen, zoals bijvoorbeeld Down Syndroom en Prader-Willi Syndroom, dat zij 
specifieke psychiatrische comorbiditeit kennen gerelateerd aan de levensfase van de 
patiënt. Alzheimerdementie bij patiënten met Down Syndroom op middelbare leeftijd 
en cycloïde psychosen bij jongeren en jongvolwassenen met Prader-Willi Syndroom 
zijn daarvan voorbeelden. Ook is vaak per syndroom bekend of er specifieke aan-
passingen in behandeling nodig zijn. Dit alles maakt dat kennis over psychiatrische 
stoornissen bij specifieke genetische syndromen noodzakelijk is om goede zorg te 
kunnen leveren. 
Een moeilijkheid in het vaststellen van psychiatrische diagnosen bij verstandelijk 
beperkte personen bevindt zich met name in de vertroebeling van het klinische beeld 
door de beperking in zowel de verstandelijke vermogens als het vermogen tot zich aan-
passen aan de situatie. Symptomen van psychiatrische stoornissen kunnen zich anders 
uiten en de mogelijkheden van de patiënt om dit zelf te herkennen en communiceren 
zijn beperkt, waardoor sommige stoornissen bedekt raken door een rookgordijn van 
probleemgedragingen.
Daarnaast laat de organisatie van zorg voor mensen die lijden aan de combinatie 
van een VB én een psychiatrische stoornis te wensen over. In het verleden is de zorg 
voor mensen met een VB en/of psychiatrische stoornissen langere tijd samen gegaan, 
zoals bijvoorbeeld in dolhuysen. Halverwege de vorige eeuw is er onder invloed van 
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meerdere factoren een scheiding gekomen tussen psychiatrische zorg en zorg voor 
mensen met een VB. De groep die in de huidige tijd aan een combinatie van deze 
aandoeningen lijdt, valt daarmee (helaas) vaak tussen wal en schip. 
Voor de grote groep nieuwe genetische syndromen is veelal onbekend welke psychia- 
trische comorbiditeit gepaard gaat met het syndroom en hoe deze gediagnosticeerd, 
behandeld en vervolgd kan worden. De aantallen patiënten per genetische aandoe-
ning zijn, zelfs wereldwijd, vaak klein (het betreft immers zeldzame syndromen), wat 
kennisvergaring kan bemoeilijken. Daarbij is het vaak onbekend welke meetinstru-
menten kunnen worden ingezet bij welke (groep van) aandoeningen en bij welke ernst 
en intensiteit van de VB. Ook blijft daarmee onbelicht welke specifieke facetten van 
de aandoening extra aandacht behoeven in de behandeling.
 
Eén van de nieuwe, vooralsnog zeldzame, syndromen is het Kleefstra Syndroom 
(KS). Dit syndroom wordt veroorzaakt door ofwel een intragene mutatie ofwel een 
microdeletie van het EHMT1 gen, voluit het Euchromatine Histon Methyl Transferase 1 
gen. Dit bevindt zich aan het uiteinde van het 9e chromosoom. Beide vormen leiden 
tot disfunctie van één kopie van het gen (haploinsufficiëntie) en een klinisch feno-
type, dat gekenmerkt wordt door de trias: typische gelaatskenmerken, hypotonie op 
de kinderleeftijd en een VB.
In het voorliggende proefschrift hebben we dit syndroom als uitgangspunt genomen 
om de psychiatrische klinische kenmerken gericht in kaart te brengen. Dit is gedaan 
door middel van onderverdeling naar drie thema’s: 
1.  Het in kaart brengen van klinisch psychiatrische en neurocognitieve karak- 
teristieken bij personen met zowel het volledige fenotype door een mutatie in 
alle cellijnen ( kiembaanmutatie) als een fenotype veroorzaakt door een mutatie 
in een deel van de cellijnen (somatische mozaïekmutatie).
2.   Het onderzoeken van meetinstrumenten die geschikt zijn voor objectiverende 
diagnostiek binnen de populatie met een VB om het psychiatrische beeld te ver-
helderen of aan te scherpen 
3.  Specifieke aspecten in de zorg voor mensen met zeldzame aangeboren ontwik-
kelingsstoornissen.
 
Dit uitgebreide onderzoek naar Kleefstra Syndroom kan daarmee beschouwd worden 
als een blauwdruk voor de grote en groeiende groep van aangeboren ontwikkelings- 
stoornissen, waarvan de genetische oorzaak bekend is.
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Klinische kenmerken in de praktijk
In een eerste veldstudie (hoofdstuk 2) bij een viertal kinderen met KS hebben we 
gekeken naar klinisch relevante karakteristieken op het gebied van ontwikkeling en 
psychiatrie. Deze zijn vergeleken met de reeds bekende resultaten bij diermodellen 
met EHMT(1) disfunctie/ mutatie. 
Zo bleken uit onderzoek bij EHMT-mutante Drosophila (fruitvliegen) geheugenprob-
lemen kunnen worden aangetoond.  EHMT1-haploinsufficiënte muizen hadden naast 
leer- en geheugen problemen ook kenmerken van een autismespectrum stoornis, 
veelal in de vorm van verminderde exploratie, verminderde interesse in soortgenoten 
en een verhoogde angstreactie op onbekende stimuli. 
De onderhavige oriënterende studie bij kinderen bevestigde de aanwezigheid van een 
VB in combinatie met ASS problemen. Ook kwamen slaapproblemen veelvuldig voor 
en werden er angst- en stemmingsklachten gerapporteerd. Deze bevindingen komen 
grotendeels overeen met die bij volwassenen, die eerder werden beschreven in case 
reports. De resultaten suggereren dat het EHMT1 gen een belangrijke rol speelt bij 
cognitieve processen en dat verstoring van de genfunctie kan leiden tot een waaier 
aan psychiatrische symptomen.
In hoofdstuk 3 bespraken we de adaptieve en maladaptieve kenmerken van een 
groter cohort patiënten met het Kleefstra Syndroom (KS, n=24),  afgezet tegen een 
drietal groepen van patiënten met andere genetische aandoeningen: Koolen-deVries 
syndroom (n=13), GATAD2B-gerelateerd syndroom (n=6) en een gemengde groep 
bestaande uit verschillende extreem zeldzame genetische aandoeningen (n=15). Alle 
proefpersonen werden uitgebreid onderzocht op ontwikkelingsniveau en psychia-
trische kenmerken. Elk van de genetische syndromen toonde zijn eigen profiel met 
sterkten en zwakten in de ontwikkeling. Opvallend was dat de lifetime prevalentie 
van vrijwel alle psychiatrische aandoeningen veel hoger ligt bij KS in vergelijking met 
andere syndromen. Een andere opvallende bevinding is dat de prevalentie van ASS, 
gemeten met de ‘gouden standaard’, het Autism Diagnostic Observation Schedule 
(ADOS-2), bijna 100 procent bedroeg in dit KS-cohort.
Vanuit historisch perspectief is een VB vaak ingedeeld naar ernst en niet naar etio- 
logie, ook in wetenschappelijk onderzoek. Daarmee bleef de onderzochte populatie 
steeds heterogeen in origine. In de huidige studie werd juist gestreefd naar homo- 
genisering van de groepen en werden de resultaten van deze groepen tegen elkaar 
afgezet. Dit toonde een duidelijker onderscheidbaar profiel dan wanneer telkens één 
syndroom vergeleken werd met het totaal van de andere groepen samen. Deze bevin-
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dingen pleiten ervoor om in wetenschappelijk onderzoek niet alleen de ernst van de 
VB mee te nemen, maar juist ook de etiologie mee te nemen in de stratificatie. 
Naast patiënten met het volledige KS fenotype waren er bij ons ook enkele ouders 
bekend, die mozaïek drager zijn van een van een defect EHMT1 gen. Genetische 
mozaïcismen worden zelden gevonden als zij niet leiden tot ontwikkelingsproblemen 
of medische kwalen. In hoofdstuk 4 beschrijven we drie ogenschijnlijk gezonde 
ouders van kinderen, bij wie KS was vastgesteld. Op het eerste oog functioneerden 
deze ouders normaal. Omdat er bij hun kinderen met KS sprake is van een opvallend 
gedrags- en ontwikkelingsprofiel zijn deze ouders ook onderworpen aan een gede-
tailleerde meting van neuropsychiatrische parameters. In het functioneren van deze 
ouders was geen sprake van een VB, gemeten met de Vineland-Z. Zij scoorden allen 
boven het afkappunt voor ASS op de ADOS-2, module 4. Psychiatrische interviews 
leverden op dat zij kwetsbaar waren om depressieve klachten te ontwikkelen en neu-
ropsychologische testen toonden een verminderde cognitieve flexibiliteit bij alle drie. 
Recente studies laten zien dat dergelijke mozaïek varianten, die ontstaan na de ver- 
smelting van de geslachtscellen, in belangrijke mate bijdragen aan de ontwikkeling 
van ASS. Onze bevindingen ondersteunen dit. Tevens is de hypothese dat mozaïcismen 
van het EHMT1 gen kwetsbaar maken voor het ontwikkelen van psychopathologie in 
bredere zin, met inbegrip van stemmingsstoornissen. Hoewel deze ouders dus op het 
eerste gezicht niet aangedaan leken te zijn, gaat hun neuropsychiatrische profiel de 
richting op van dat van patiënten met een volledig KS- fenotype. Er is bij deze ouders 
daarmee sprake van een afwijkend functioneren ten opzichte van de algemene be- 
volking. Dit behoeft nadere aandacht in een groter cohort. 
Toepassing van meetinstrumenten voor aanvullende 
psychiatrische diagnostiek en beoordeling van neurocognitieve vermogens 
Een VB compliceert psychiatrische diagnostiek, doordat er overlap kan bestaan tussen 
de symptomen van de VB en psychiatrische aandoeningen (denk bijvoorbeeld aan 
prikkelgevoeligheid bij zowel VB als ASS), maar ook omdat symptomen zich anders 
uiten bij mensen mèt of zònder een VB. (bijv. prikkelbaarheid bij stemmingsproble-
men of  desorganisatie als belangrijkste symptoom van psychotische stoornissen in 
plaats van wanen en/of hallucinaties). Ook kunnen mensen met een VB hun sympto- 
men niet of minder goed verwoorden. Hierdoor bestaat er behoefte aan aanvullend 
onderzoek om symptomen te objectiveren.
In hoofdstuk 5 is daarom binnen een groep van 58 patiënten met monogenetische 
aandoeningen gekeken naar de inzet van reguliere instrumenten voor diagnostiek 
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naar autisme spectrum stoornissen. Hieruit komt naar voren dat de ADOS -2 uiter-
mate geschikt is voor ASS-diagnostiek in deze groep, vooral omdat het verschillende 
modules kent die op basis van taalniveau ingezet kunnen worden en omdat er verge- 
lijkingsscores per leeftijdsgroep beschikbaar zijn voor ieder van deze modules.  
Een tweetal veel gebruikte vragenlijsten om te screenen op ASS toonden in deze studie 
en sterke samenhang met de ontwikkelingsleeftijd. Het betreft de CBCL, subschaal 
voor pervasieve ontwikkelingsproblemen en de SCQ. In andere woorden: deze vragen-
lijsten zijn onvoldoende in staat om de kenmerken van ASS te onderscheiden van die 
de VB en  zijn daarom niet geschikt als screener voor ASS in deze populatie. 
Daarnaast werd een op de doelgroep aangepaste neuropsychologische testbatterij 
onderzocht in een groep van 56 patienten (hoofdstuk 6). Deze batterij was samen- 
gesteld uit een viertal bestaande testen op het gebied van (1) aandacht voor en be- 
diening van het touchscreen (Motor Screening Test, MOT), (2) patroonherkenning en 
geheugen (pattern recognition memory, PRM; deze test werd na 10 minuten herhaald), 
(3) flexibiliteit in wisselen van paradigma (intra-extradimensional testshift, IED) en 
(4) visuospatieel geheugen (paired associated learning, PAL; een soort geheugentaak). 
Deze testen zijn uitgebreid toegepast in de algemene bevolking en bij specifieke 
neuropsychiatrische ziektebeelden en werden vereenvoudigd voor toepassing in de 
populatie met een VB. Het voordeel van een dergelijke testbatterij is dat de sterkten 
en zwakten in het neurocognitief profiel kunnen worden blootgelegd, wat handvatten 
kan geven voor dagelijkse begeleiding, diagnostiek en behandeling. Daarnaast worden 
objectieve maten verkregen, die onderlinge vergelijking mogelijk maken. De testen 
kunnen voorts mondiaal afgenomen kunnen worden zonder interferentie van taal 
en/of cultuur, maar maken bijvoorbeeld ook evaluatie in de tijd bij eenzelfde persoon 
mogelijk. 
Veel (neuro)psychologische tests zijn voor het specifieke gebruik bij mensen met een 
VB niet voldoende valide, niet optimaal inzetbaar (wegens het stellen van te hoge 
eisen aan de verbale of motorische capaciteiten van de patiënt), of gewoonweg nog 
niet onderzocht. Het hoofdstuk richt zich dan ook op het ontrafelen vanaf welke 
ontwikkelingsleeftijd mensen met een VB in staat zijn, ‘testbekwaam’ zijn, voor deze 
aangepaste testbatterij die via een touchscreen tablet wordt afgenomen. Het bleek 
dat vanaf een ontwikkelingsleeftijd van 2,5 jaar het mogelijk is om deze aangepaste 
testen in te zetten om een indruk te verkrijgen van aandachtsfuncties, coördinatie, 
geheugen, cognitieve flexibiliteit en ruimtelijke oriëntatie. Er is daarbij gepoogd om 
te analyseren of er ook op deze functies syndroom-specifieke profielen onderscheiden 
konden worden, maar door de zeer hoge uitval in de groep met KS, was dit helaas niet 
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mogelijk. Deze uitval was overigens groter dan op basis van kansrekening verwacht 
zou mogen worden.  Deze uitkomst is mogelijk indicatief voor snelle overvraging en/
of overprikkeling in deze groep.
Uit de twee studies naar de rol en betekenis van diagnostisch instrumentarium in 
deze  bijzondere doelgroep blijkt dat, ofschoon niet zonder problemen, er al met al 
verschillende mogelijkheden zijn voor de inzet van meetinstrumenten bij mensen met 
monogenetische aandoeningen en psychiatrische en/of gedragsklachten. 
Specifieke aspecten in de zorg voor mensen 
met zeldzame aangeboren ontwikkelingsstoornissen:
Wanneer zich een psychiatrische stoornis voordoet bij een patiënt met een genetische 
aandoening en/of een VB is hiervoor net zo goed behandeling nodig als voor psy-
chiatrische stoornissen in de algemene bevolking.  In het geval van farmacotherapie 
wordt ten onrechte gedacht dat er bij mensen met een VB medicatie alleen volgens 
het algoritme “ start laag en verhoog langzaam ” (‘start low and go slow’) kan worden 
toegepast. Dit berust met name op de verwachting dat een dergelijke aanpak minder 
bijwerkingen geeft. Dit is echter niet altijd van toepassing , zoals in hoofdstuk 7 aan 
de hand van drie casus wordt beschreven. Bij KS komen perioden van functieverlies 
(regressie) voor die lijken te berusten op psychotische stoornissen; zij het met een 
uiting van desorganisatie en negatieve symptomen en niet zo zeer wanen of hallu-
cinaties. Deze worden voorafgegaan door het stoppen met slapen gedurende enkele 
nachten. Wanneer deze episoden niet medicamenteus behandeld worden, treedt ach-
teruitgang van het algehele functioneren op. Behandeling met olanzapine, snel ingezet 
en in een relatief hoge dosering, lijkt de regressie een halt toe te roepen zodra het 
slapen herstelt. Het advies luidt om bij deze groep te behandelen zoals in de algemene 
populatie en niet enkel terughoudend te zijn met doseren. Vanzelfsprekend dienen 
bijwerkingen en overdosering daarbij nauwgezet vervolgd te worden.  Medicatie uit 
de categorie benzodiazepinen gaf bij dit syndroom een paradoxaal effect en klassieke 
antipsychotica gaven forse extrapiramidale bijwerkingen zonder dat functieverlies 
werd tegengegaan of functieherstel optrad. Dit pleit voor olanzapine als eerste keus 
behandeling in de acute fase van een psychose bij dit syndroom.
Een aandachtspunt bij de doelgroep met een VB is dat farmacokinetische kenmerken 
vaak niet goed bekend is en monitoring behoeft. Medicamenteuze behandeling vormt 
overigens slechts een klein onderdeel van het zorgarsenaal en van de meer omvattende 
behandeling die patiënten met een monogenetisch syndroom nodig kunnen hebben. 
Naast farmacotherapie is ook voor andere vormen van therapie, zoals psychotherapie 
(bijv. gedragstherapie), maar bijv. ook muziektherapie en psychomotore therapie, nog 
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zeer schaarse evidentie. Dit komt mede doordat het moeilijk is om de effecten van deze 
therapieën te evalueren bij mensen met een VB.  
Naast patiëntgerichte interventies, moet ook goed gekeken worden naar de omgeving 
van de patiënt. In hoofdstuk 8 is geïnventariseerd hoe gestrest ouders zich voelen aan-
gaande de zorg voor hun kind met een monogenetische aandoening. Hierbij werden 
opvallend grote verschillen tussen de verschillende syndromen gevonden. Ouders 
van kinderen met KS ervaren in dit cohort meer stress vergeleken met ouders van 
kinderen met diabetes of ADHD (zonder VB). Bijna 1 op de 3 ouders (30,4%) scoor- 
de boven het afkappunt voor pathologische stress, tegenover bijvoorbeeld 1 op de 12 
ouders bij Koolen-deVries syndroom. In het totale cohort (n= 51) was bij 25,5% van 
de ouders sprake van een ziekmakende hoeveelheid stress. Dit is belangrijk om te 
weten voor zorgprofessionals. Zij kunnen daardoor stress bij ouders tijdig signaleren, 
bespreekbaar maken en mogelijk verwijzen voor eigen hulpverlening op dit vlak. Hier 
ligt overigens ook voor de maatschappij, waar in toenemende mate een beroep op 
zelfredzaamheid wordt gedaan, een nadrukkelijke rol. Zelfredzaamheid is lastig voor 
mensen met beperkingen in hun cognitieve en adaptieve functioneren (~15% van de 
bevolking). De zorgtaken verschuiven bij tekorten in zelfredzaamheid vaak naar de 
naasten van deze mensen. Slechts een gedeelte van deze mantelzorgers kan deze taak 
oppakken naast de eigen taken en die voor de overige gezinsleden (denk aan andere 
kinderen in het gezin). Wanneer een ouder naast de ouderrol tevens mantelzorger en 
vaak ook nog zorgcoördinator is, ligt overbelasting en/of stress op de loer. Het is voor 
zorgverleners belangrijk om zich te realiseren dat de stress die gepaard gaat met het 
grootbrengen van een kind met een aangeboren ontwikkelingsstoornis, hoger ligt dan 
die bij andere chronische aandoeningen, zoals suikerziekte of enkelvoudige ADHD. 
Screening op pathologische stress bij ouders, en het -op indicatie- in gang zetten van 
gerichte  verwijzing voor hulp, vormt daarmee een essentieel onderdeel in de medi- 
sche consultatie bij aangeboren ontwikkelingsstoornissen. 
In hoofdstuk 9 worden de conclusies en hun betekenis voor de wetenschappelijke en 
klinische praktijk besproken. Allereerst wordt uitgelicht dat het stratificeren op basis 
van de genetische origine van de VB recht doet aan de specifieke (neuropsychiatrische) 
kenmerken van een dergelijke groep. De groep patiënten met KS bleek in onze studies 
zeer gevoelig voor het ontwikkelen van psychiatrische stoornissen, met name autis-
mespectrumstoornissen en psychosen. 
Vervolgens wordt besproken dat diagnostiek bij de groep mensen met zowel een VB als 
psychiatrische klachten notoir ingewikkeld is. Objectieve maten zijn hierbij essentieel 
om stoornissen te identificeren, te evalueren en het beloop in kaart te brengen. De 
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ADOS-2 is een voorbeeld van een instrument dat zich hier goed voor leent, hoewel 
het aanbeveling verdient om in de handleiding specifieke aandachtspunten en tips te 
formuleren wanneer deze wordt afgenomen bij personen met een VB. De vereenvou- 
digde CANTAB-tests vormen een voorbeeld van hoe aanpassingen in een bestaande 
testbatterij de toepasbaarheid bij mensen met een VB vergroot en het verkrijgen van 
objectieve maten mogelijk maakt. 
Tot slot is het rondom ziekte-management belangrijk om psychiatrische stoornissen 
bij monogenetische aandoeningen te behandelen net zoals dit voor psychiatrische 
stoornissen in de algemene bevolking geldt.  Bij patiënten met KS is extra aandacht 
nodig voor farmacotherapie bij regressieve episoden, die optreden tijdens de puberteit 
en jong volwassenheid. Keuze voor het geneesmiddel en titratieschema lijken door- 
slaggevend te zijn voor het therapeutische effect. Naast zorg-op-maat voor de patiënt is 
het belangrijk om oog te hebben voor de naasten van de patiënt, want een belangrijk 
deel van de ouders – ruim een kwart – ervaart pathologische stress. 
Dit proefschrift geeft aanleiding om te reflecteren op klinische en maatschappelijke 
mogelijkheden om de zorg voor deze specifieke doelgroep te verbeteren. 
Toekomstig onderzoek naar specifieke genetische syndromen, die een VB veroorzaken, 
zou idealiter gebruik maken van meetinstrumenten die gevalideerd zijn voor de popu-
latie en directe metingen doen bij de patiënten zelf. Hierbij is het waardevol om aparte 
groepen voor de verschillende genetische defecten te maken, die vervolgd worden in 
de tijd en waarbij op meerdere momenten metingen gedaan worden. 
De organisatie van zorg rondom genetische syndromen, die een VB veroorzaken, 
zou bij voorkeur in multidisciplinaire teams vorm gegeven worden. Wanneer deze 
vanuit expertisecentra opereren, kunnen zij regionale zorgverleners ondersteunen 
en zorg-op-maat faciliteren. De aanwezigheid van een kinder- en jeugdpsychiater in 
een dergelijk team is van toegevoegde waarde vanwege de wisselwerking tussen soma-
tische en psychische factoren. 
Obstakel rondom het creëren van deze manier van zorg is dat de huidige zorgorgani-
satie en –financiering dit sterk bemoeilijken. Een VB is één van de duurste ziekten, die 
we kennen. De levenslange duur van de beperking draagt hier aan bij in combinatie 
met een veelheid aan comorbiditeit, die het volledige terrein van de somatische en psy-
chiatrische geneeskunde beslaan. Politieke overwegingen, waarbij de burger geacht 
wordt zo zelfredzaam mogelijk dient te zijn en zo min mogelijk beroep doet op de 
gezondheidszorg, staan hier haaks op. Voor ongeveer vijftien procent van de bevolking 
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met enige vorm van zwakbegaafdheid of een VB is zelfredzaamheid zeer moeilijk tot 
onmogelijk. Hun huidige maatschappelijke positie staat sterk onder druk, en daarmee 
de kwaliteit van leven, terwijl ook in deze groep de levensverwachting toeneemt. Dit 
onderwerp zou dan ook hoger op de politieke agenda mogen staan.
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Dankwoord
Veel mensen hebben bijgedragen aan het tot stand komen, de uitvoer en ook de afron-
ding van dit onderzoek. Ik wil het liefst iedereen persoonlijk bedanken, maar zal op 
de komende bladzijden naar een aantal mensen alvast bijzondere dank uitspreken.
Ik begin bij het begin. Speciale dank gaat uit naar de (oud-)bewoners van Opperank 
5 (St. Jozef, Heel) en Frodo (de Winckelsteegh, Nijmegen). Het jarenlang werken met 
jullie heeft mijn hart geopend voor een wereld die ik niet kende. Ik zal mijn bijzondere 
tijd met jullie niet vergeten en ik kan me niet voorstellen hoe ik me ontwikkeld zou 
hebben als ik jullie niet had leren kennen.
Dan de deelnemers en hun ouders/begeleiders. Wat was het fijn om met jullie te 
werken! Overal werden we hartelijk ontvangen en vertelden ouders én soms ook pa- 
tiënten openhartig over wat hen bezig hield. Jullie verhalen zijn het waard verteld te 
worden! Dat is mijn onderzoek ten goede gekomen. En dat niet alleen; het heeft me 
ook een betere dokter gemaakt en ik denk zelfs een beter mens.
Dit onderzoek zou nooit tot een boekje zijn gekomen, zonder mijn “promotie-team”! 
Voordat ik jullie, ieder afzonderlijk, bedank, wil ik noemen dat het fijn was om de 
synergie van het team te voelen: te samen kristalliseerden zoveel dingen uit. Dat gaf 
mij vaak een extra boost!
Mijn eerste promotor, Jos, dank voor je scherpe blik en feedback. Je weet de vragen 
altijd zo te stellen, dat ik toch nog even ging nadenken over het antwoord. Ik had graag 
meer willen leren van jouw taligheid, maar dat zit helaas niet zo in mij. Heel fijn dat 
je vaak de tijd en moeite hebt genomen om het dan weer te “vertalen”, zodat ook uit 
de verf kwam wat ik bedoelde.
Hans, jij bent vanaf het begin van dit project enthousiast en betrokken geweest (en 
gelukkig ook gebleven!). Je snelle en heldere commentaren op de stukken en je rake 
observaties bij de video’s brachten mij vooruit. Dank ook voor het vertrouwen dat ik 
onderwijs mocht geven; iets wat ik met veel plezier doe!
En dan mijn derde promotor, Wouter. Je maakte altijd tijd voor dit project en bleef 
immer positief, ook wanneer bij mijzelf de twijfels toesloegen. Die positiviteit gaf vaak 
de kracht, die ik nodig had om er toch weer nieuwe energie in te steken. Heel erg fijn! 
Daarnaast stimuleerde je me om deel te nemen in projecten, die in het verlengde lagen 
van dit onderzoek. Ook dat was heel waardevol, maar vooral ook ontzettend leuk en 
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dat deed groeien! Ik kijk met bewondering hoe jij alles weet te combineren in de volle 
breedte van ons mooie vak. 
Tjitske, ik heb geluk gehad met jou als copromotor. Altijd snel, stipt en ook nog eens 
supergezellig. De tripjes naar de familiedagen in Engeland waren altijd heel bijzonder 
en het is fijn om dat te kunnen delen. Het is een eer om onderzoek te doen naar een 
syndroom dat naar jou vernoemd is en ik ben blij dat we in de afgelopen jaren steeds 
meer hebben kunnen opzetten om psychiatrie bij KS te tackelen. Ik ben trots dat je 
een VIDI hebt binnengehaald, zodat we nog meer kunnen doen en ons team verder 
uit kunnen breiden. 
De opponenten wil ik bedanken dat zij tijd hebben kunnen maken om bij de 
verdediging te zijn en voor hun interesse in mijn werk. In het bijzonder de manu- 
scriptcommissie, die een cruciale rol speelt om het werk om te mogen zetten in het 
daadwerkelijke boekje. 
Joost Janzing en Jan Buitelaar, ook jullie wil ik bedanken voor jullie bijdragen. Jullie 
stonden aan de wieg van dit project en hebben mij geholpen om een weg te vinden 
naar dit grotere onderzoek. Jan, bij de pilot van dit onderzoek (hoofdstuk 2) heb je de 
moeite genomen om een groot aantal video-opnamen met mij te bekijken en door te 
spreken. Daar heb ik ontzettend veel van geleerd en ook aan gehad bij het vervolg van 
dit onderzoek. Joost, ik vind het fijn dat je altijd betrokken bent gebleven en ik hoop 
dat we de banden tussen kinder- en volwassenpsychiatrie voor de doelgroep met een 
verstandelijke beperking kunnen versterken in het Nijmeegse.
Zonder mijn student-assistenten had ik nog niet de helft van het werk gedaan gekre-
gen. Floor, Anneke, Femke, Marloes, Hirlande en Myriam, ontzettend bedankt! 
Productiviteit, gezelligheid en files bleken verrassend goed samen te gaan. Anneke, jou 
wil ik nog extra bedanken. Het is leuk om mensen op te leiden en nog leuker om jonge 
collega’s hard te zien groeien: van student-assistent naar AIOS en straks collega kjp. Ik 
verheug me op nog meer goede samenwerking. Heel fijn dat je mijn paranimf wil zijn!
Ook dank aan de collega’s van de verschillende instellingen met wie ik in de afge-
lopen jaren heb samengewerkt. In het bijzonder mijn “ oude” dreamteam in Horst: 
Petra, Callista, Véronique, Madieke en Marjolein, dankzij jullie kwam ik als jonge 
psychiater in een warm badje terecht en lukte het om klinisch werk en onderzoek 
te combineren. Gelukkig is er ook een nieuw dreamteam gekomen vanuit Karakter: 
Bram, Evelien, Annika, Elien, Frank, Lysanne, Marcel, Conny en Birgit, dank! En 
natuurlijk Madieke; zo fijn dat je bent gebleven! Ook Carin en Eddie wil ik bedanken 
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voor de geboden kansen, zoals deelname aan de ‘zeldzame poli’ in het Radboudumc. 
Vanuit het VVGI wil ik Linde en Wouter bedanken voor hun inzet en meedenken! En 
dan alle collega’s van het Expertisecentrum voor Zeldzame Aangeboren Ontwikke-
lingsstoornissen in het Radboudumc: top dat we dit samen kunnen doen!
Ook mijn voormalige kamergenootjes dr. Toni en dr. Rossi wil ik nog even extra in 
de schijnwerpers zetten: zonder jullie goede voorbeeld en de vele (hari)bo-momentjes 
had ik de eindstreep niet gehaald! 
De opleiding tot (kinder- en jeugd)psychiater was een bijzonder leerzaam traject. 
Ik zocht een weg naar de combinatie van psychiatrie, genetica en verstandelijke 
beperkingen. De steun en stimulans om in deze richting verder te gaan vanuit mijn 
supervisoren Hal Droogleever Fortuyn, Monica Pop en Edo Fennema zijn van grote 
waarde geweest. En dan de mensen met wie ik aan de opleiding begon: Niels, Inge, 
Hiske, Take en Dirk, wat ontzettend tof dat we elkaar nog steeds regelmatig zien! 
Altijd nieuwe inzichten, nieuwe ideeën en samen sterk. Onbetaalbaar! Jet, Michelle, 
Marloes, Odette en Marije, fijn om de kjp-perikelen samen te delen. En Jet, ook heel 
bijzonder dat onze zoons op hetzelfde moment en op dezelfde plek geboren zijn; dat 
schept nog een extra band!
Naast het onderzoekswerk en de dagelijkse patiëntenzorg was ik in de afgelopen jaren 
betrokken bij verschillende projecten en het Platform Psychiatrie en Verstandelijke 
Beperking bij de NVvP. Ik wil Sara en Arenda bedanken voor de fijne, maar vooral 
ook gezellige samenwerking! 
Ik zou mijn werk niet kunnen doen, als het op het thuisfront niet geregeld was. Rena 
en Habib, zo fijn dat jullie mij al jaren helpen! Zonder jullie zou ik verzanden in de 
chaos vrees ik. En ook de lieve juffen van Jasper; het feit dat hij groepje Rood ook mist 
als we op vakantie zijn, geeft maar aan hoe graag hij bij jullie komt spelen. Mijn dead-
lines zou ik niet gehaald hebben als er niet af en toe oppas in kon springen. Naast mijn 
ouders ben ik hiervoor Marenne zeer erkentelijk: weet dat je ook op de tekeningen 
van ons gezin staat die Jasper maakt! 
Dan veel dank voor mijn lieve vriend(inn)en en familie. Zonder deze mensen om mij 
heen, zou ik slechts een schim zijn van mezelf. Als ik iedereen apart zou noemen, dan 
zou het een boekwerk op zich worden. Een aantal mensen wil ik er daarom uitlichten.
Te beginnen bij de Marijnen in het Nijmeegse. Rijn, heel fijn om al zoveel jaren vrien-
dinnen te zijn en te weten dat ik je, voor wat dan ook, altijd kan bellen! Andere Arijn, 
samen met jou begon ik aan geneeskunde en andere avonturen, zoals de hellingproef 
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in Frankrijk en hardlopen. Het is fijn dat we zoveel kunnen delen. Speciale dank dat 
je ook even naar mijn stellingen hebt willen kijken voor ik ze inleverde! Janní, bij 
de introductie van bio is een goed fundament gelegd! Gezelligheid blijft en ondanks 
de reisafstand vinden we altijd wel momentjes, waarin de tijd weer is zoals altijd. 
Geweldig dat je m’n paranimf wil zijn! Wen, ik ben blij dat we afstanden altijd kunnen 
overbruggen, van Alkmaar tot Aruba. Je was in mijn studietijd mijn trouwe maatje 
om mee te koken en te oefenen voor examens, je werd mijn klusmaatje toen ik mijn 
eerste huis kocht (toen nog bij jou in de straat) en nu delen we het plezier van onze 
jongens. Geweldig! En op naar de volgende vakantie! Nicole, leuk dat we van collega’s 
vriendinnen werden en zoveel meer delen dan alleen onze Limburgse roots. In het 
bijzonder dank voor je steun in de moeilijke tijden toen Jasper nog klein was. Soof, 
het is zo gezellig dat we nu dichtbij elkaar wonen en elkaar wat vaker zien! En dat 
we samen kunnen genieten van de kleintjes. Rebs, het is al zolang geleden dat we 
eindexamen deden en in het lab stonden te prutsen met onze zebravisjes. Daar is wel 
een basis gelegd voor de “onderzoeksgeest”! Fijn dat we elkaar nog altijd zien en dat 
je nu in Amsterdam woont; toch iets dichterbij dan New York. En dan het Goudse 
duo Tjer & Rik: ooit huisgenoten en de herinneringen aan de klooster-avonturen 
(het “omarmen” van Albertinus, gangfeesten en Jacques-de-plaque) houden we warm 
tijdens de weekendjes; fijn dat Jasper en ik altijd mogen logeren aan de Vest! Coení. 
onze gesprekken brengen altijd lucht in mijn hoofd en dat is zóóó waardevol! Kim, veel 
dank dat we altijd welkom zijn bij jou en je familie! Fijn dat je altijd geïnteresseerd bent 
en ook bereid bent om mee te denken in zo ongeveer alles; van Engelse vertalingen tot 
de voorkant van mijn proefschrift! 
Dan mijn familie. Ik begin bij mijn oma’s: het voorbeeld van sterke vrouwen is ont-
zettend waardevol om mee op te groeien! Ik ben blij dat mijn ene oma dit bijzondere 
moment kan meemaken en dat mijn andere oma trots toekijkt ergens daar boven. 
Zonder mijn neven, nichten, ooms en tantes was het een stuk minder gezellig geweest. 
In het bijzonder wil ik mijn nichtje Frederike bedanken voor de relax-weekendjes die 
we tijdens de looptijd van mijn onderzoek regelmatig hebben ingelast. En tante Cathy, 
die ik altijd kon bellen om nog even wat onderzoeksdingetjes (en zoveel anders) te 
overleggen. Dan mijn broer Ruben, die altijd een realistische kijk op de zaken houdt 
en dat met droge humor over kan brengen. En natuurlijk mijn lieve ouders, Gerard 
& Marguerite, die inmiddels van alle markten thuis zijn: oppassen, data invoeren, 
klussen, stellingen verzinnen. Jullie onvoorwaardelijke steun doet groeien! Ik hoop 
dat er met het afronden van dit proefschrift niet alleen voor mij, maar ook voor jullie 
wat meer rust komt. Jullie zijn mij, en natuurlijk Jasper, zeer dierbaar. 
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overleggen. Dan mijn broer Ruben, die altijd een realistische kijk op de zaken houdt 
en dat met droge humor over kan brengen. En natuurlijk mijn lieve ouders, Gerard 
& Marguerite, die inmiddels van alle markten thuis zijn: oppassen, data invoeren, 
klussen, stellingen verzinnen. Jullie onvoorwaardelijke steun doet groeien! Ik hoop 
dat er met het afronden van dit proefschrift niet alleen voor mij, maar ook voor jullie 
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Tot slot Jasper, kleine man: wat is het geweldig om het leven met jou te beleven! Jou 
zien opgroeien, is op zo ontzettend veel vlakken waardevol en maakt me tot een leu-
kere en lievere versie van mezelf.
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Karlijn Vermeulen was born on Blue Monday (January 17th) 1983 
in Ittervoort, a small village in the municipality of Hunsel, which 
is situated in the southern part of the Netherlands. As a result of 
joining the local marching band ((jeugd)fanfare Concordia), she 
learned at a young age that the best outcomes result from playing 
together. She grew up close to two institutions for people with 
intellectual disabilities (ID), namely St. Joseph and St. Anna, both 
situated in the nearby village of Heel. Even as a young girl the residents fascinated her 
because they seemed to live in a different world. In 2001 she started to work as an assis-
tant sociotherapist at St. Anna and in the same year she graduated from high school 
(gymnasium at St. Ursula, Horn & Stebo, Utrecht). During her final year she performed 
a research project at the University of Utrecht on the effects of lithium in zebrafish 
offspring. Subsequently she enrolled in medical biology at the Catholic University of 
Nijmegen. In 2002 she was selected to study medicine and for a while she continued 
both studies. Meanwhile she kept working as a sociotherapist at first in Heel (Opper-
ank 5, St. Joseph) and later on in Nijmegen (Frodo, the Winckelsteegh). It was the 
combination of studies and work that got her interested in psychiatry in ID and also 
in genetic syndromes. During her studies she performed an internship in Sri Lanka 
at the Nagoda Hospital to study tropical infectious diseases in children (2007). She 
was able to combine her studies and work until she graduated in medicine in October 
2008. Shortly before she finished she obtained a training position in psychiatry at the 
Radboudumc Nijmegen, which she started in September 2008. During this training 
she focused on patients with ID and specialized in child and adolescent psychiatry. 
In 2013 she received a grant for further research in Kleefstra syndrome and related 
genetic disorders (AGIKO grant, Donders Institute, Radboud University Nijmegen). 
At the moment, Karlijn works as a (child and adolescent) psychiatrist at an outpatient 
clinic at Karakter, situated in Horst (south of the Netherlands, close to her roots). 
During her research project, she started to participate in a multidisciplinary team for 
Kleefstra syndrome and related genetic disorders at the Radboud University Medi-
cal Center (Radboudumc) Nijmegen as a consultant child psychiatrist. She is also a 
consultant psychiatrist for the Centre for Consultation and Expertise (CCE). Because 
of her affinity with educational programs, she has been involved in several national 
educational programs for medical students and psychiatrists (in training). She also 
supports mental health care for patients with ID within the Dutch Psychiatric Asso-
ciation by chairing the platform “ Psychiatry and ID”. 
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Karlijn lives in Cuijk with her son Jasper (2014). Besides her family and work she likes 
to write, and has published a few poems and stories. Also she loves music and swim-
ming, just like her patients.
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Donders Graduate 
School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young sci-
entists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), which 
was officially recognised as a national graduate school in 2009. The Graduate School 
covers training at both Master’s and PhD level and provides an excellent educational 
context fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine and 
related disciplines. Selective admission and assessment centers guarantee the enrol-
ment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, 
e.g. Stanford University, University of Oxford, University of Cambridge, UCL London, 
MPI Leipzig, Hanyang University in South Korea, NTNU Norway, University of Illinois, 
North Western University, Northeastern University in Boston, ETH Zürich, University 
of Vienna etc.
Positions outside academia spread among the following sectors: 
• specialists in a medical environment, mainly in genetics, geriatrics, psychiatry 
and neurology,
• specialists in a psychological environment, e.g. as specialist in neuropsychology, 
psychological diagnostics or therapy, 
• higher education as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of 
research and development. Fewer graduates stay in a research environment as lab 
coordinators, technical support or policy advisors. Upcoming possibilities are posi-
tions in the IT sector and management position in pharmaceutical industry. In general, 
the PhDs graduates almost invariably continue with high-quality positions that play 
an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit: http://www.ru.nl/donders/graduate-school/phd/
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I would be heard
uit: “My head” 
K’s Choice
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Uitnodiging
Graag nodig ik u uit voor het 
bijwonen van de openbare 
verdediging van mijn proefschrift
Psychiatry and Neurocognition 
in Genetic Developmental Disorders:
The Emblematic Case of  Kleefstra Syndrome
De verdediging vindt plaats 
op vrijdag 5 oktober 2018 
om 10.30 uur precies
 in de aula van de 
Radboud Universiteit, 
Comeniuslaan 2 te Nijmegen. 
Wij verzoeken u tijdig 
aanwezig te zijn. 
Aansluitend bent u van harte 
welkom op de receptie. 
Karlijn Vermeulen
karlijn.vermeulen@radboudumc.nl
Paranimfen:
Janneke Winterberg-Ravesloot
06- 18459614
Anneke de Boer
06- 18900700
Répondez, s’il vous plaît:
karlijn.promotie@gmail.com
